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Abstract 
Hepatitis C virus (HCV) readily establishes a chronic infection and it is currently thought to 
infect 2-3% of the global population. Treatment for HCV places a severe burden on patients, 
leading to a premature treatment termination in approximately 20% of individuals, and has 
poor efficacy against the predominant genotype. A greater understanding of the virus lifecycle 
and mechanisms of persistence will provide valuable information in the continuing 
development of direct-acting antiviral compounds.  
HCV encodes 10 proteins which are translated as a single polyprotein. Non-structural protein 2 
(NS2) is a small, hydrophobic, trans-membrane protein, yet the precise number and position of 
its trans-membrane domains remain unclear. NS2 is required for virion morphogenesis but it is 
not required for replication of the viral genome and it does not form part of the mature virion. 
NS2 has been shown to interact with other viral proteins, potentially via intra-membrane 
contacts. Determining the topology of NS2 is therefore vital to our understanding of how NS2 
interacts with the other viral proteins and functions within the virus lifecycle.  
The interactions between NS2 and membranes and the viral glycoprotein E2 were investigated 
by truncation analysis and fusion with reporter proteins. Glycosylation analysis demonstrated 
that the N- and C-termini of NS2 are oriented to the luminal and cytosolic faces of the ER 
membrane, respectively. Truncation of NS2 at residue 70 oriented a C-terminal reporter fusion 
to the ER lumen consistent with the formation of a luminal loop. This is the first biochemical 
evidence that NS2 assumes a 3 TMD topology. Co-immunoprecipitation studies with E2 and 
eGFP-tagged truncation of NS2 revealed that NS2 forms multiple interactions with E2 and that 
these interactions are dependent upon NS2 targeting to membranes but likely independent of 
NS2 topology. A model of NS2 topology is presented. 
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T Threonine 
T Thymine 
TAP 1/2 Antigen peptide transporter 1/2 
TBS Tris buffered saline 
 
 
xxi 
 
T-Cell Thyroid cell 
TEMED  N,N,N',N'-tetramethylethylenediamine 
TEV  Tobacco etch virus 
TFE Tetrafluoroethylene 
TGN  Trans-Golgi network 
TIR Toll/IL-1 receptor  
TMA Transcription-mediated amplification  
TMD Trans-membrane domain 
TMS Trans-membrane segment 
TNF-α  Tumour necrosis factor-α 
tNS2 Truncated NS2 
TNT Transcription and translation 
TRIFF TIR-domain-containing adapter-inducing interferon-β 
U Units 
U Uridine 
UC Uridine-Cytosine dimer 
UK United Kingdom 
Un Untreated 
UPR Unfolded protein response 
US United States of America 
UTR  Untranslated region 
V Valine 
v/v Volume per volume 
VLDL Very low density lipoprotein 
VLP Virus-like particule 
vNS2 Virus NS2 
VSK3 Vesicle surface kinase 3 
w/v Weight per volume 
WB Western blot 
WHO World Health Organisation 
wt Wild type 
X-gal 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
YFP Venus yellow fluorescent protein 
YFV  Yellow fever virus 
Chapter 1: Introduction 
 
1 
 
CHAPTER 1: INTRODUCTION
Chapter 1: Introduction 
 
2 
 
1.1 Viral hepatitis 
Viral hepatitis is a broad term referring to inflammation of the liver caused by infection with 
one of five human viruses:  hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus 
(HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV). A sixth virus known as hepatitis G 
virus (HGV) is synonymous with the name GB virus C (GBV-C) (Linnen et al., 1996). GBV-C is 
widespread throughout the population but it is not directly associated with hepatitis or any 
other disease pathology (Mohr et al., 2011; Stapleton, 2003). Although other viruses have 
been associated with hepatitis in humans, including yellow fever virus (YFV), human 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV); they are not commonly associated with 
the term viral hepatitis. It is thought that approximately 20% of viral hepatitis is not caused by 
hepatitis A-E viruses (Leary et al., 1996). It may be that newly identified viruses such as GB 
virus D (GBV-D), which has currently only been recovered from bats, are responsible for some 
of these infections (Epstein et al., 2010).    
HAV is the prototype member of the Hepatovirus genus within the Picornaviridae family. HAV 
is spread by the faecal-oral route and typically causes an acute, self-limiting disease. HAV 
causes roughly 1.5 million cases of clinical hepatitis annually. The majority of cases occur in 
areas of high endemicity where people are infected in early childhood and infection is often 
asymptomatic. There are several inactivated-virus vaccines available for HAV but their use is 
recommended for those in high risk groups, such as those travelling from developed countries 
to areas where the virus is endemic (WHO, 2011a). 
HBV is a member of the Orthohepadnavirus genus, within the Hepadnaviridae family. HBV 
causes both acute and chronic diseases and is spread parenterally. The symptoms of acute 
infection tend to be mild but chronic infection can cause severe liver disease and 
hepatocellular carcinoma (HCC). HBV particles were identified in 1970 (Dane et al., 1970) 
following the description of a viral antigen in the blood of an Australian aborigine (Blumberg et 
al., 1965) which led to the development of highly effective blood screening programs. Despite 
the development of a vaccine for hepatitis B in the early 1980s, over 350 million people world-
wide are thought to be chronically infected with HBV (WHO, 2011b). 
HDV requires HBV surface antigen for infectivity and as such infection only occurs as a co-
infection with HBV (Rizzetto et al., 1980). Consequently, transmission and host specificity of 
HDV are assumed to be the same as HBV. As HDV is unrelated to HBV it is not considered a 
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defective-interfering particle, rather a satellite virus of HBV. HDV co-infection increases the 
severity and progression of hepatitis B disease (Gerin et al., 2001).  
A non-HAV, non-HBV agent causing acute, water-borne hepatitis was first suspected in the 
1980s but it was not until 1991 that the first full-length HEV genome was cloned (Tam et al., 
1991). HEV has a higher rate of mortality than HAV, especially among pregnant women (Purcell 
& Emerson, 2008). Pigs and other animals act as animal reservoirs for HEV and zoonosis is 
thought to be responsible for some of sporadic HEV infections of unknown source in 
developed countries (Pavio et al., 2010). 
One of the closest related viruses to HCV is GB virus B (GBV-B). This virus has been shown to 
cause an acute, self-limiting hepatitis in tamarins (Karayiannis et al., 1989; Schaluder et al., 
1995) prompting its use as an animal model for HCV. The pathogenicity in humans is unknown 
as is the natural host of GBV-B although a host range study concluded that it is likely to be a 
virus of New World monkeys (Bukh et al., 2001). 
1.2 Hepatitis C Virus 
1.2.1 Discovery of HCV 
After the generation of diagnostic tests for HAV and HBV in 1975 it became apparent that the 
vast majority of transfusion-associated hepatitis was not caused by either of these agents. 
Although associated with transfusions, this agent was prevalent in the general population and 
in particular among haemophiliacs and intravenous drug users. Initially termed non-A, non-B 
hepatitis (NANB or NANBH) the disease was thought to be caused by more than one agent 
(Bradley et al., 1983; Shimizu et al., 1979). Liver biopsies from experimentally infected 
chimpanzees revealed the presence of membranous tubules. This ‘tubule-forming’ NANBH 
agent was thought to be a small, enveloped virus due to its sensitivity to organic solvents 
(Bradley et al., 1983) and ability to pass through an 80 nm filter (Bradley et al., 1985).  
Due to the low titre of this agent, 102-103 chimpanzee infectious doses per ml (CID/ml), the 
pooling of plasma from several chronically infected chimpanzees enabled the generation of a 
cDNA library using random primers. The cDNA molecules were cloned into an expression 
vector and screened for the expression of pathogen-specific peptides using sera from infected 
individuals. This technique identified 1 clone that was used as a specific hybridisation probe 
that hybridised with an approximately 10,000 nucleotide (nt) RNA molecule. Sequencing of this 
molecule revealed that it generated a single polyprotein of approximately 3,000 amino acids 
(aa) with homology to the non-structural proteins of members of the Flaviviridae family. This 
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new virus was renamed hepatitis C virus and speculatively named as a member of the 
Flaviviridae (Choo et al., 1989; Choo et al., 1990). 
1.2.2 Epidemiology and transmission of HCV 
Hepatitis C virus (HCV) can cause either an acute or chronic infection. Estimates of the number 
of people chronically infected with HCV have varied from 100-170 million people, or 2-3% of 
the global population (Lavanchy, 2009; Perz et al., 2004). It is thought that a further 4 million 
new incidences of HCV infection are diagnosed every year (Mast et al., 1999); however this 
figure may be out of date. HCV prevalence is determined from sero-conversion data but 
accurate quantification is hampered due to the often asymptomatic nature of acute HCV 
infections, poor screening and surveillance in many countries and sero-reversion, where 
chronically infected individuals can lose HCV-specific antibodies over time (Lavanchy, 2009). 
The global distribution of HCV varies greatly with areas of northern Africa, South America and 
the Far East showing significantly higher prevalence than Europe and North America (WHO, 
2002) (Figure 1.1).  
The most common route of HCV infection is parenteral, either by injection drug use or 
transfusion of infected blood products. The latter route is on the decline in most countries 
since screening of blood products for HCV became routine. Other rare routes have been 
identified such as sexual transmission; religious rites and body piercings; although often the 
route of transmission is not identified. While breast feeding does not appear to be a route of 
transmission; the spread of HCV perinatally has been demonstrated (Ohto et al., 1994) and 
there is no conclusive evidence that caesarean section avoids infection of the neonate. There 
are seven genotypes of HCV that also vary in their global distribution but also the route of 
transmission. Sub-types 1b and 2a are associated with blood transfusion while 1a and 3a are 
associated with intravenous drug use.  
1.2.3 Acute HCV infection 
It is thought that the majority of acute HCV infections go undetected and the natural course of 
acute infection is highly variable. Acute infection is characterised by an increase in serum levels 
of liver-produced aminotransferases to 20-30 times in excess of the normal range between 6 
and 12 weeks after exposure. HCV genomic material – ribonucleic acid (RNA) - can be detected 
by polymerase chain reaction (PCR) several days after infection but it can take weeks 
(Hoofnagle, 1997). Sero-positivity is often achieved 8 weeks after initial exposure but it may 
occur after several months or not at all. Symptoms of acute HCV infection include malaise, 
nausea, vomiting and jaundice. 
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Figure 1.1 Global prevalence of hepatitis C virus.  
HCV is most prevalent in less developed regions: South America, central and northern Africa 
and South East Asia. Reproduced from (WHO, 2002). 
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1.2.4 Chronic HCV infection 
A key clinical feature of HCV is its ability to establish a persistent chronic infection. Clearance 
of the virus is thought to be achieved in as few as 20% of individuals and spontaneous 
clearance of chronic HCV is thought to be very rare (Yokosuka et al., 1999). Chronic hepatitis C 
is defined as infection with HCV for more than 6 months as determined by detection of viral 
RNA. In the absence of liver cirrhosis most chronically infected individuals are asymptomatic or 
experience only mild symptoms such as fatigue (Merican et al., 1993). Chronic hepatitis C can 
lead to liver damage but disease progression usually requires decades and the causes are not 
clear. Disease complications are almost entirely restricted to those with cirrhosis, as is the 
development of hepatocellular carcinoma (HCC). The risk of developing cirrhosis within 20 
years of infection is estimated at 10-20% (Seeff, 2002). Numerous factors are known to 
influence disease progression such as age, gender, ethnicity, HBV co-infection and alcohol 
abuse. Viral load and genotype do not appear to be significant in the natural course of 
infection but are major factors in treatment outcome. However, a recent analysis of patient 
histories and disease progression identified infection with genotype 3 as an independent risk 
factor for the development of HCC (Nkontchou et al., 2011). 
1.2.5 Diagnosis 
HCV infection is diagnosed either by serologic assay or nucleic acid testing. Serological 
diagnosis is determined by enzyme-linked immuno-sorbent assays (ELISA) that detect the 
presence of anti-HCV antibodies using regions of NS5A and NS3 as the bait. Detection of anti-
HCV immunoglobulin M (IgM) may precede detection by other methods, however this is 
uncommon and it does not allow disease characterisation as an acute, chronic or cleared 
infection. False-positives are more common in patients with rheumatoid conditions and 
patients from low-prevalence groups such as blood or organ donors. False-negatives can occur 
more frequently in immuno-compromised patients. Core antigen-based ELISAs exist that are as 
effective and accurate as RNA-based detection methods at distinguishing between acute or 
chronic infections but their significantly reduced sensitivity compared to RNA-based detection 
methods preclude the use of core ELISAs as diagnostic tools (Morota et al., 2009). The most 
powerful qualitative technique for detecting HCV infection is transcription-mediated 
amplification (TMA)-based RNA detection. TMA uses a combination of two primers and two 
enzymes (Figure 1.2). From the positive sense RNA genome of HCV a region is amplified as a 
double stranded (ds) DNA molecule by reverse transcriptase. The primer used to generate the 
positive strand of this DNA duplex contains a promoter region for RNA polymerase which  
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Figure 1.2 Schematic diagram of transcription-mediated amplification (TMA) polymerase 
chain reaction (PCR) used as a clinical test for HCV infection.  
The diagnostic kit comprises two enzymes; reverse transcriptase (RT) and DNA-dependent 
RNA-polymerase (RNA Pol), and two primers; the 5’ overhang of Primer 1 contains an RNA Pol 
promoter region. 
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generates further mRNA copies of the amplified region and the process is repeated. Attempts 
to standardise treatment of HCV led to treatment protocols based upon the monitoring of viral 
load. Viral load is measured in international units (IU), which equate to 1 IU = ~2.5 viral 
genome copies/ml, and is monitored using highly sensitive quantitative real-time reverse-
transcriptase polymerase chain reaction (real-time RT-PCR) assays. Cross-centre and genotype 
variation is a major issue in diagnosis and treatment of HCV, despite calibration of assays to a 
World Health Organisation (WHO) standard (Chevaliez et al., 2007). 
1.2.6 Disease pathology  
HCV is not thought to be cytopathic as virus load has no bearing on the severity of liver disease 
or prognosis. Therefore, similar to HBV, the disease pathophysiology of HCV infection, 
particularly cirrhosis, is thought to be resultant of the host immune-response or anti-viral 
therapy. The only cytotoxic effect attributed to HCV is steotosis (accumulation of lipid in 
hepatocytes) and while patients infected with all genotypes can develop steotosis it is only 
thought be virus-induced in genotype 3 infections (Kumar et al., 2002). The particular 
mechanism by which genotype 3 viruses induce steotosis is not known, nor is it clear whether 
the virus benefits from this pathology or not.  
Extra-hepatic manifestations (EHMs), such as rheumatic, dermatologic, endocrine and 
haematologic disorders or chronic fatigue, are often the only clinical signs of HCV infection. 
Hepatitis as a result of the immune response to viral infection leads to fibrosis. In the case of 
chronic infection fibrosis in turn leads to cirrhosis of the liver. While fibrosis is reversible, 
cirrhosis is rarely reversible even after viral clearance. Cirrhosis does not confer liver failure, 
rather it can be classified as compensated, when liver function is retained, or decompensated, 
when liver function is impaired. The development of HCC as a result of liver cirrhosis is a rare 
but significant complication associated with HCV infection (Saito et al., 1990). HCV is the 
leading indication for liver transplantation in the UK and US and transplant is the only effective 
treatment once liver decompensation or HCC have developed (Hoofnagle, 1997).  
1.2.7 Immune response to HCV 
Effective clearance of HCV requires rapid responses from both the innate and adaptive arms of 
the immune response. Clearance of the virus does not confer immunity upon re-exposure but 
does reduce the risk of viral persistence upon re-infection (Bowen & Walker, 2005). The role of 
antibodies in viral clearance is unclear as neutralising antibodies have been identified yet sero-
conversion does not prevent re-infection (Farci et al., 1992; Lai et al., 1994) and viral clearance 
has been observed without sero-conversion (Post et al., 2004). Viraemia is used as a marker 
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for HCV infection and levels usually peak 6-10 weeks after infection, regardless of outcome 
(Abe et al., 1992). Clearance is associated with rapid and persistent activation of CD4+ (helper) 
and CD8+ (cytotoxic) T-cells (Cooper et al., 1999; Grakoui et al., 2003). HCV-specific T-cells and 
expression of IFN-gamma within the liver of experimentally infected chimpanzees coincided 
with a reduction in HCV RNA levels (Cooper et al., 1999; Major et al., 2004). The innate 
immune response to viral infection is based upon interferons which are cytokines produced by 
cells in response to recognition of intracellular pathogens. HCV replicates via a ds RNA 
intermediate which is a stimulus for interferon production via the toll-like receptor (TLR) 3. It is 
hypothesised that upon infection of a cell HCV undergoes initial rounds of translation from its 
positive stranded RNA genome to produce sufficient protein prior to initiation of viral 
replication. This enables HCV to disrupt the interferon signalling pathway before it generates 
immunogenic ds RNA and thus avoid detection by the innate immune response (Li et al., 
2005a). Levels of IFN-β (Yang et al., 2011) and IFN-λ (Marukian et al., 2011) have been shown 
to be stimulated during HCV infection in model systems. However, it is not clear how these 
correlate with clearance of the virus and to what extent they are representative of natural 
infections in humans. 
1.2.8 Treatment  
Current treatment for Hepatitis C is combination anti-viral therapy using interferon-α (IFN-α) 2 
and Ribavirin. There is no consistent difference in efficacy between IFN-α 2a or 2b 
(McHutchison et al., 2007), although IFN-α 2b is cleared by the kidneys so is inappropriate for 
patients suffering renal complications. Achievement of a sustained virological response (SVR) is 
the goal of therapy as 99.9% of those attaining SVR remain negative for HCV RNA 5 years after 
treatment end (Swain et al., 2007). The addition of polyethylene glycol to IFN-α 2a increased 
the half-life of the drug, permitting less frequent administration, and improved the rate of SVR 
(Wedemeyer et al., 2002). 80/80/80 treatment adherence is a major factor in achieving SVR 
and non-adherence is an indicator for discontinuation (McHutchison et al., 2002). Adherent 
patients are those who receive 80% of IFN-α, 80% of Ribavirin and are treated for more than 
80% of the prescribed treatment period. 
Treatment efficacy varies depending upon the virus genotype. This is reflected in the therapy 
durations which are 24 weeks for genotype 2 and 3 infections and typically 48 weeks for 
genotype 1 infections. The rate of SVR in genotype 2 and 3 infections is around 80% 
(Hadziyannis et al., 2004) and treatment can be reduced to 12 or 16 weeks if a rapid virological 
response (RVR) is achieved. RVR is defined as the loss of detection of HCV RNA 4 weeks after 
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treatment initiation and correlates strongly with SVR. If HCV RNA has not decreased by 2 logs 
by week 12 treatment is discontinued.  
The rate of SVR in genotype 1 infections is around 45% (Hadziyannis et al., 2004) and efficacy is 
evaluated at weeks 4, 12 and 24. Undetectable HCV RNA at 4 weeks can justify a 24 week 
treatment program whereas a poor response at 4 weeks is an indicator for discontinuation. If a 
patient is negative for HCV RNA at 12 weeks a 48 week regimen is taken and if the patient 
becomes negative for HCV RNA between week 12 and 24 treatment can be extended to 72 
weeks.  
The production of interferon stimulates antiviral processes within the cell as well as shutting 
down protein synthesis and cellular proliferation and inducing a similar environment in 
neighbouring cells reducing the ability of the virus to spread. The mechanism of action of 
Ribavirin is unclear although it is has been speculated to be a competitive inhibitor of RNA 
replication (Crotty et al., 2000) as it is a nucleoside analogue (Oxford, 1975), or as a modulator 
of cellular adenosine monophosphate (AMP)-activated protein kinase (AMPK) (Mankouri et al., 
2010). Ribavirin monotherapy is ineffective at reducing viral load. 
Numerous side-effects are associated with combination therapy which lead to termination of 
treatment in up to ~20% of patients and interferon is contraindicated in a significant 
proportion of individuals, such as people with auto-immune diseases, as IFN-α is a potent 
stimulator of the immune system and has numerous side effects. The development of ‘direct-
acting antiviral agents’ (DAA) or ‘specifically targeted antiviral therapies for hepatitis C’ (STAT-
C) have predominantly focused on the viral polymerase and protease with an aim to producing 
better tolerated treatment with less side effects and thus increase treatment adherence. 
Clinical trials are underway examining the use of the protease inhibitors Boceprivir and 
Telaprevir, the nucleoside-analogue inhibitor Mericitabine and an inhibitor of the primary viral 
protein involved in host-cell modulation, non-structural protein 5A (NS5A). Work is also being 
carried out to develop novel interferons with less side-effects (Muir et al., 2010) and inhibitors 
of cellular proteins that facilitate HCV replication (Flisiak et al., 2009). Furthermore, 
combination therapy lacking IFN is also under investigation and a recent study examining the 
efficacy of triple therapy using a protease inhibitor, a polymerase inhibitor and Ribavirin in 
genotype 1-infected individuals showed high levels of SVR and none of the patients 
discontinued therapy prematurely (Zeuzem et al., 2011). 
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1.2.9 HCV/human immunodeficiency virus (HIV) co-infection 
Co-infection prevalence is linked to blood-borne transmission of human immunodeficiency 
virus (HIV) and in 2006 it was estimated that 4-5 million of the 33.4 million people infected 
worldwide with HIV were co-infected with HCV (Alter, 2006). Levels of HCV viraemia increase 8 
times faster due to the lack of CD4+ T-cells however it has been suggested that up to 20-30% 
of newly infected people are still able to spontaneously resolve HCV infections despite 
underlying HIV infection (Vogel & Rockstroh, 2010). The chance of developing cirrhosis 
increases in co-infection, from 2-6% to 15-25% (Soto et al., 1997), as does that of developing 
HCC (Giordano et al., 2004). Highly active anti-retroviral therapy (HAART) seems to have 
positive effect on treatment of HCV however this is thought to be due to immune system 
recovery rather than direct anti-viral effects. Liver transplantation requires undetectable levels 
of HIV DNA or the assurance of effective control post-transplant. 
1.2.10 HBV/HCV co-infection 
Due to the lack of large scale population data the exact number of HBV/HCV co-infected 
individuals in unknown but as they share the same routes of transmission, co-infection is most 
common in populations where HBV infection is endemic. The viral interactions are complex 
and inconsistent but the basic trend appears to be that HCV is suppressive of HBV (Liaw, 2001). 
HCV super-infection is most common in HBV endemic populations but HBV super-infection 
remains largely unstudied. The incidences of cirrhosis and decompensated liver disease are 
more likely in co-infection (Mohamed Ael et al., 1997) and HCC is twice as likely in co-infected 
patients as HCV mono-infected individuals (Chiaramonte et al., 1999). There is currently no 
standardised treatment for HCV/HBV co-infection. 
1.3 Molecular virology of HCV 
1.3.1 Classification 
HCV is a member of the Flaviviridae family which includes the Flavivirus, Hepacivirus and 
Pestivirus genera. A recent report called for the formation of a forth genus – Pegivirus – to 
include GBV-A, C and D (Stapleton et al., 2011). HCV is the prototype member of the 
Hepacivirus genus. It shares greatest sequence homology with GB virus B (GBV-B), tentatively 
classed in the genus Hepacivus, bovine viral diarrhoea virus (BVDV), a Pestivirus, and the as yet 
unclassified canine hepacivirus (CHV) (Kapoor et al., 2011). The Flaviviruses are vector borne 
pathogens. 
Chapter 1: Introduction 
 
12 
 
1.3.2 Genetic heterogeneity 
There are six recognised genotypes of HCV (1-6), with proposals for the formation of a seventh 
genotype in progress (Murphy et al., 2007), which vary by ~25-35% at the nucleotide level, and 
numerous subtypes (a, b, c, etc) which vary by ~15-25%. The high level of sequence divergence 
in HCV is due to the high levels of RNA replication and the low fidelity of the virus encoded 
polymerase which has been estimated to be 10-4 mutations per nucleotide per year 
(Bartenschlager & Lohmann, 2000).  
Within an infected individual subtype quasi-species, which differ by 1-5% at the nucleotide 
level (Davis, 1999; Honda et al., 1994), often occur with the predominant quasi-species 
fluctuating over time. This ‘sequence drift’ is thought to aid in viral escape as the major areas 
of non-synonymous mutations occur in the ecto-domains of the glycoproteins. Patients 
infected with multiple subtypes also see shifts in the dominant subtype. 
The global distribution of the genotypes is uneven (Figure 1.3), with genotype 1 the dominant 
global genotype worldwide. Genotypes 2 and 3 are dominant in eastern Africa and the Asian 
sub-continent respectively. Genotype 4 is localised to northern Africa, particularly Egypt, 
where it is the dominant genotype, and genotype 5 appears largely confined to and dominant 
in southern Africa.  Genotype 6 is mainly restricted to the Far East (WHO, 2009).  
1.3.3 Genome organisation 
The genome of HCV is a single positive stranded RNA molecule acting as the transcription 
template for the viral proteome (Choo et al., 1989). The genome comprises the protein coding 
region which is flanked by 5' and 3' non-translated regions (NTR) containing conserved RNA 
secondary structures (Figure 1.4A). The virus encodes 10 proteins (Grakoui et al., 1993a; Lin et 
al., 1994) expressed as a 3010 aa polyprotein from a single open reading frame (ORF) (Choo et 
al., 1990). The N-terminal region of the polyprotein contains the structural proteins: core and 
the glycoproteins E1 and E2. The non-structural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A and 
NS5B make up the C-terminal region of the polyprotein. The NS proteins are involved in 
replication of the viral genome and are assumed to play varying roles in the assembly and 
secretion of virus particles. The p7 protein is encoded between the structural and non-
structural proteins and its presence or absence within virions has yet to be confirmed. 
Translation is carried out by a cap-independent mechanism whereby the 40S ribosomal 
subunit is recruited, along with other cellular proteins, to the highly ordered RNA structures 
within the 5’ UTR which forms an internal ribosomal entry site (IRES) (Fukushi et al., 1994; 
Tsukiyama-Kohara et al., 1992). The structural proteins are released by host signal peptidases 
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Figure 1.3 Global distribution of HCV genotypes. 
Genotype 1 is the most prevalent genotype. Genotypes 2 and 3 are found to varying levels 
across the globe, but Genotypes 4, 5 and 6 are largely confined to northern Africa (particularly 
Egypt), South Africa and the Far East respectively. Reproduced from the Global Distribution of 
HCV Genotypes (WHO, 2009). 
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Figure 1.4 Genome organisation of HCV. 
(A) Full length HCV genome depicting 5’UTR (HCV IRES), 3’ UTR and core-NS5B coding region. 
(B) Structure of autonomously replicating sub-genomic RNA molecules. The HCV 5’UTR (HCV 
IRES) and 3’ UTR are maintained. Translation of the reporter gene (neomycin or luciferase) is 
mediated by the HCV IRES. Translation of the truncated HCV genome is mediated by an 
encephalomyocarditis virus (EMCV) IRES. The EMCV IRES was used in favour of using a 
duplicate HCV IRES as translation driven by this IRES is more efficient. Arrow heads denote 
cleavage of the polyprotein by signal peptide peptidase (purple), signal peptidase (red), the 
NS2/3 cysteine protease (green) and the NS3/4A serine protease (black). SP represents the p7-
cognate signal peptide encoded by the carboxyl (C)-terminal 23 residues of E2. 
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 (Grakoui et al., 1993a; Hijikata et al., 1991) and the non-structural proteins by two viral 
proteases: a cysteine auto-protease; NS2 (Grakoui, 1993b; Lorenz et al., 2006b; Schregel et al., 
2009) that catalyses cleavage of the NS2/NS3 junction, and a serine protease; NS3/4A (Tomei 
et al., 1993) that cleaves to release the other NS proteins. 
1.3.4 Virus Lifecycle 
1.3.4.1 Virus Entry 
The hepatropic nature of HCV was established early on in HCV history and more recently HCV 
has been identified in brain macrophages from infected individuals (Wilkinson et al., 2009). 
Virus entry is mediated by the E1 and E2 glycoprotein hetero dimer (Figure 1.5). The cellular 
entry factors required for entry are cluster of differentiation 81 (CD81) (Pileri et al., 1998), 
scavenger receptor B type I (SR-BI) (Scarselli et al., 2002) and two tight junction-associated 
ligands, claudin-I (CLDN-I) (Evans et al., 2007) and occludin (OCLN) (Ploss et al., 2009). The 
virus is thought to encounter the baso-lateral membrane of hepatocytes in the liver where 
CD81 and CLDN-I are localised (Reynolds et al., 2008). Polarisation of cell mono-layers in tissue 
culture systems is not required for entry but other factors such as glucosaminoglycans (GAG), 
the low density lipoprotein (LDL) receptor (LDL-R) and C-type lectins are important. Entry can 
be inhibited by mannan binding lectin (MBL), a component of the innate immune response 
(Brown et al., 2010). 
CD81 is a tetraspanin with a large, extracellular loop (LEL) that is bound by E2. CD81 is 
expressed on the surface of a wide variety of cell types and is associated with activation of the 
immune response by co-stimulation of T-cells. Antibodies specific for CD81 impair virus entry, 
although CD81 may be involved after initial virus binding (Koutsoudakis et al., 2006). SR-BI is 
highly expressed on liver cells and is responsible for uptake and efflux of cholesterol from cells 
to high density lipoprotein (HDL) and LDL particles. The SR-BI ligand HDL also appears to play a 
role in HCV entry post-binding (Voisset et al., 2005). The role of LDL-R is to internalise 
circulating LDL as part of the cholesterol homeostasis pathway. LDL-R complexes are 
internalised by clathrin-mediated endocytosis and traffic via endosomes (Sabahi, 2009) in a 
similar mechanism to that predicted for HCV (Thorley et al., 2010). Antibodies against LDL-R 
inhibit HCV entry as do exogenous LDL and peptide inhibitors of LDL-R. GAG chains are 
important for the binding of numerous viruses. HCV E2 has been shown to bind the GAG 
heparan sulphate and pre-incubation of cells with a heparan sulphate homologue, heparin, or 
a heparinase, which cleaves heparin sulphate, impairs entry of HCV (Morikawa et al., 2007).  
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Figure 1.5 HCV particle entry is associated with lipoproteins. 
Lipid droplet-associated HCV particles attach to cells via the LDL receptor and GAG molecules. 
The E2 glycoprotein then specifically binds to SR‐B1 CD81. The virion is laterally trafficked to 
the tight-junctions where interactions with CLDN‐1 and OCLN facilitate clathrin-mediated 
endocytosis. Endosome acidification induces fusion of the virion envelop resulting in genome 
release. Reproduced from (Eyre et al., 2009).  
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Heparan sulphate appears to be involved in initial binding as incubation of cells with heparin 
after addition of virus did not significantly inhibit HCV entry (Koutsoudakis et al., 2006). 
The current model for HCV entry is outlined in Figure 1.5. Initial cell binding is thought to be 
mediated by interactions with surface GAGs, on the baso-lateral membrane of hepatocytes, 
followed by secondary interactions with SR-BI and CD81. The cell-associated particle is thought 
to traverse to tight junctions and associate with CLDN1 and OCLN prior to internalisation by 
clatharin-mediated endocytosis. Internal trafficking is thought to arrest at early endosomes 
where acidification results in fusion of the virus membrane with the endosome membrane 
allowing release of the viral RNA into the cytoplasm. 
1.3.4.2 Genome Replication 
After entry and uncoating the HCV genome is released into the cytoplasm and undergoes 
initial rounds of translation. The HCV proteins are expressed as a single polyprotein: core, E1, 
E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B (Grakoui et al., 1993a). An additional initiation site 
in the +1 reading frame, within the core coding region, produces a species known as frame-
shift (F) protein, or alternate reading frame protein (ARFP). Initial translation of the viral 
polyprotein is thought to allow the accumulation of viral proteins to sufficiently disable the 
innate immune response and the formation of a membranous web structure called the 
replication complex (Egger et al., 2002; Gosert et al., 2003). Replication of the HCV genome is 
carried out by the virus-encoded RNA-dependent RNA-polymerase (RdRp) NS5B, via a dsRNA 
intermediate. Newly synthesised genomes are either packaged into virions or used as the 
template for protein synthesis or further rounds of replication. RNA levels, protein levels and 
infectivity do not directly correlate leading to the hypothesis that each process could be 
differentially prioritised throughout the life cycle, although the mechanisms involved remain 
unclear. 
RNA structure is important to the pathogenesis of the virus and HCV RNA structure has been 
shown to be maintained as a survival factor. Slow growing, persistent RNA viruses like HCV and 
GBV-C correlate with high levels of genomic structure whereas acute viruses like BVDV have 
lower levels of RNA secondary structure. RNA secondary structure is thought to prevent the 
binding of host RNAs and thus allow the genomes to remain autonomous and less detectable 
to ds RNA sensing antiviral pathways (Davis et al., 2008).  
1.3.4.3 Particle Assembly and Egress 
HCV has poor assembly efficiency in tissue culture and as a result it has been difficult to 
discern the mechanism by which infectious particles are produced. Core association with lipid 
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droplets is a key early step (Boulant et al., 2006) but the site of assembly has not been 
identified. Core is able to bind RNA (Boulant et al., 2005), but whether it dissociates from lipid 
droplets to begin packaging of the genome at sites of replication or whether NS5A, which also 
contains RNA binding domains (Huang et al., 2005), recruits the genome to LDs is also unclear 
(Bartenschlager et al., 2011). Numerous studies have provided evidence that HCV utilises the 
very low density lipoprotein (VLDL) biosynthesis pathway, however the evidence is conflicting 
as to the involvement of apolipoprotein (Apo) B, Apo E and microsomal transfer protein (MTP). 
Recruitment of the virus envelope likely occurs with the addition of E1/E2 hetero-dimers at the 
ER or an ER-derived membrane. Other viral proteins are vital for the production of infectious 
virus particles. NS2 and p7 were shown to act at an early stage in virus assembly (Jones et al., 
2007) possibly through the co-ordination of the replication complex with the glycoproteins 
(Jirasko et al., 2010; Ma et al., 2011; Stapleford & Lindenbach, 2011). The co-localisation of E2, 
NS2, NS3 and NS5A to cytosolic lipid droplets at 72 hours post-transfection with full-length 
virus suggested that assembly may be occurring at these sites (Jirasko et al., 2010). The 
mechanism of virus egress from these sites is therefore unlikely be that of VLDL, which is 
synthesised at the ER membrane and secreted from the cell via the Golgi (Bamberger & Lane, 
1990), rather it may utilise the endosomal trafficking pathway, aspects of which have been 
shown to be essential for virus release (Corless et al., 2009). 
1.4 Systems for studying HCV  
1.4.1 Chimpanzees  
Chimpanzees are the only animal other than humans that can be infected with HCV and their 
use enabled the demonstration of an infectious agent as the cause NANBH (Alter et al., 1978; 
Tabor et al., 1978). Indeed, ultra-structural studies on livers from infected chimpanzees led to 
the suggestion that two agents were responsible for NANBH (Shimizu et al., 1979). The use of 
chimpanzees were also instrumental in the isolation and cloning of HCV (Choo et al., 1989) and 
confirmation of the in vivo infectivity of culture derived virus produced by the JFH-1 isolate 
(Wakita et al., 2005). Chimpanzees infected with the JFH-1 isolate were positive for viral RNA 3 
days post-infection, however they presented no signs of hepatitis and viraemia was limited; 
approximately 103 copies/ml (Kato et al., 2008; Wakita et al., 2005).  
There are differences in the disease course in chimpanzees and humans as disease is generally 
milder in chimpanzees (Boonstra et al., 2009) and one longitudinal study found that the rate of 
chronic infection was much lower in chimpanzees (33%) than in humans (~80%) (Bassett et al., 
1998). As GBV-B and HCV share a relatively high degree of sequence homology it is hoped that 
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by studying both infections in animal systems that it will become apparent why one causes an 
acute infection and the other is so effective at achieving a persistent infection (Beames et al., 
2001). Despite the exploration of GBV-B infection of tamarins as a surrogate for HCV, 
chimpanzees are currently used for testing of anti-HCV compounds and potential vaccines 
(Carroll et al., 2009; Chen et al., 2007; Verstrepen et al., 2011) and examination of the immune 
response and viral persistence (Kato et al., 2008). Draw-backs of the use of chimpanzees 
include experimental cost, limited sample numbers, absence of disease-induced liver fibrosis 
and ethical concerns. 
1.4.2 Non-primate animal models 
As HCV does not infect any non-primates, attempts have been made to genetically engineer or 
humanise a strain of mice permissive to HCV infection. Progress has been made recently in the 
development of two such models (Dorner et al., 2011; Washburn et al., 2011). Earlier mouse 
models relied upon the engraftment of human hepatocytes into animals with severely 
depleted immune systems in order to achieve infection but as a result no liver damage was 
observed (Bissig et al., 2010; Mercer et al., 2001). It was shown that expression of human 
orthologues of CD81 and occludin in murine cells (Ploss et al., 2009) and mice (Dorner et al., 
2011) was sufficient to render them permissive to HCV infection. However, viral proteins could 
not be detected in HCV infected mice expressing human CD81 and occludin, suggesting that 
virus replication, and possibly also translation, is inefficient in mouse hepatocytes (Dorner et 
al., 2011). Mice engrafted with human liver and immune cells were permissive to HCV 
infection (Washburn et al., 2011). These mice generated an HCV-specific immune response of 
preferentially expanded human T-cells; they developed hepatitis and fibrosis in response to 
HCV-derived peptide and could be re-stimulated upon re-challenge suggesting the 
establishment of memory T-cells (Washburn et al., 2011). In combination these models could 
dramatically increase our understanding of virus entry, replication, host tropism and immune 
response/evasion. 
1.4.3 Replicons  
The development of the HCV sub-genomic replicon (SGR) in 1999 enabled dissection of HCV 
replication and the roles of the non-structural proteins in replication and host cell modulation 
(Lohmann et al., 1999) (Figure 1.4B). The original SGR was a bi-cistronic RNA molecule and was 
first developed from the genotype 1b isolate Con1. Expression of a 5’ neomycin 
phosphotransferase (NPT) gene is controlled by the viral IRES and translation the non-
structural proteins NS3-5B is mediated by an EMCV IRES (Lohmann et al., 1999). The SGR 
originally included NS2 but it was found to be detrimental to replication (Lohmann et al., 
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1999). Culture adaptations in the original SGR were noted and upon introduction into the wild-
type SGR they increased replication by 105 (Blight et al., 2000; Krieger et al., 2001; Lohmann et 
al., 1999). The most commonly used laboratory adapted SGR is termed FK5.1 which contains 2 
mutations in NS3, one in NS4B and four in NS5A (Krieger et al., 2001). Replication of the SGRs 
was initially restricted to the human hepatocellular carcinoma cell line Huh7. Treatment of 
Huh7 cells stably harbouring a genotype 1b replicon with IFN-α led to the removal of HCV RNA; 
however these cured cells, Huh7.5 cells, were then more permissive to replication upon re-
introduction of HCV RNA (Blight et al., 2002). Full-length replicons were generated but they 
failed to produce infectious virus and replicated less efficiently (Blight et al., 2002; 
Pietschmann et al., 2002). Replacement of the resistance gene with a Firefly luciferase reporter 
gene created a system for analysis of transient replication (Lohmann et al., 2001) enabling the 
high-throughput analysis of anti-viral compounds. Other replicon systems include NS3-5B, NS2-
5B and SPp7-5B replicons based on the genotype 1b isolate Con1, corresponding replicons 
made using the genotype 2a isolate JFH-1 (Tedbury et al., 2011), which doesn’t require culture 
adaptations (Kato et al., 2003), and a mono-cistronic NS3-5B replicon employing a green 
fluorescence protein-tagged NS5A (Schaller et al., 2007). 
1.4.4 Infectious HCV culture systems  
A major step forward in the study of HCV came with the identification of the fully infectious 
JFH-1 isolate which is capable of producing infectious virus in cell culture and chimpanzees 
(Wakita et al., 2005; Zhong et al., 2005). Further analysis revealed that chimeric viruses based 
on the JFH-1 isolate were capable of causing infection both in cell culture and in vivo 
(Lindenbach et al., 2005; Lindenbach et al., 2006; Pietschmann et al., 2006). Infectivity of cell 
culture-derived HCV can be neutralised with E2 and CD81-specific antibodies as well as patient 
sera (Lindenbach et al., 2005; Wakita et al., 2005; Yi et al., 2006; Zhong et al., 2005). 
Although the majority of infectious clones have been generated in the JFH-1 background, a 
fully infectious genotype 1a clone, derived from the Hutchinson isolate H77, has been 
developed although it is significantly less infectious than JFH-1 based viruses (Yi et al., 2006). 
Chimeric viruses involving the structural proteins from non-genotype 2a isolates can require 
compensatory mutations for efficient infectivity (Yi et al., 2007). Chimeric viruses, particularly 
those including the structural proteins from the most prevalent genotype 1a and 1b isolates,  
could play a central role in the development of cross-genotype therapies targeting virus entry 
and uncoating (Pietschmann et al., 2006). The unique ability of the JFH-1 isolate to replicate in 
cell culture has recently been proposed to centre on the replication efficiency of the viral 
polymerase (Simister et al., 2009). Comparative analysis of the polymerase encoded by the 
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JFH-1 isolate and the closely related J6 isolate demonstrated that the JFH-1 polymerase 
initiates replication more efficiently resulting in increased replication in vitro. Mutations within 
the polymerase were shown to result in a more closed conformation which may improve de 
novo initiation kinetics (Simister et al., 2009). Whether the increased replication efficiency of 
the polymerase is solely responsible for enabling detectable replication of JFH-1 in cell culture 
is not clear. 
1.5 Untranslated regions (UTRs) 
1.5.1 5’ UTR 
The HCV 5’ UTR contains a highly conserved internal ribosomal entry site (IRES) (Tsukiyama-
Kohara et al., 1992). The 5’ UTR is 341 nucleotides in length and the IRES encompasses 
nucleotides 40-341 of the genome (Honda et al., 1999) (Figure 1.6A). The 5’ UTR forms 4 stem 
loop structures (I, II, III, IV), the first of which, along with stem loop II, is essential for 
replication (Kim et al., 2002). A predicted structure for loop II was proposed from sequence 
comparison with the GBV-B 5’ UTR structure (Brown et al., 1992; Honda et al., 1996) and was 
refined to one containing more base-pairing following application of folding constraints based 
on the GBV-B structure (Honda et al., 1999). HCV RNA replication is enhanced by a liver 
specific micro RNA 122 (miR-122) which has two seed-matches between nts 22 and 43 of the 
HCV 5’ UTR (Jopling et al., 2005), both of which are required for optimal HCV replication 
(Jopling et al., 2008). The tissue specificity of miR-122 could be a crucial determinant in the 
tissue and host tropism of HCV. A recent report where miR-122 was exogenously expressed in 
the non-permissive HepG2 cell-line rendered cells permissive to HCV replication (Narbus et al., 
2011). 
Loops II, III and IV form the IRES and, under physiological conditions, form two recognition 
domains for eukaryote initiation factor 3 (eIF3) and the 40S ribosomal subunit (Kieft et al., 
1999) to facilitate cap-independent translation of the HCV polyprotein. The first ~40 nts of the 
5’ UTR, which contain stem loop I, are not required for initiation of translation (Fukushi et al., 
1994) but translation does benefit from the 5’ 30 nts of the core coding sequence (Reynolds et 
al., 1995). 
A long-range, protein independent interaction between the 5’ and 3’ UTRs has been implicated 
as the switching mechanism between RNA replication and polyprotein translation (Romero-
Lopez & Berzal-Herranz, 2009). 
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Figure 1.6 The predicted structures of the HCV UTRs. 
 (A) The 5’UTR forms 4 stem-loop structures. Loops I and II are required for RNA replication, 
loops II, III and IV are required for recruitment of the 35S ribosome and eIF3. The start codon 
for translation of the primary HCV ORF is highlighted in black. Reproduced from (Honda et al., 
1996). (B) Structure of the 3’ UTR. The three major structural components are marked and the 
stop codon is highlighted. Reproduced from (Kolykhalov et al., 1996). 
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Two chimeric viruses encoding the core-NS2 and 5’ UTR-NS2 from the J6 isolate in the JFH-1 
background had comparable replication and translation, but the J6 5’ UTR-NS2 virus produced 
10-fold more infectious virus (Mateu et al., 2008). The JFH-1 and J6 5’ UTRs differ by three nts 
and it was found that increased infectivity required the mutation of all three bases (Mateu et 
al., 2008). This was suggestive that the 5’ UTR plays a role in particle assembly, as well as 
replication and translation, making it a viable target for antiviral compounds (Guerniou et al., 
2007). 
1.5.2 3’ UTR 
The 3’ UTR extends for 236 nts following the translation termination site at the 3’ end of the 
NS5B coding sequence (Figure 1.6B). It comprises a variable region of ~40 nts; a polyuridine 
and polypyrimidine [poly (U/UC)] tract of variable length; and a highly conserved region called 
the 3’ X‐tail which is 98 nts in length (Kolykhalov et al., 1996; Tanaka et al., 1995; Tanaka et al., 
1996). The X-tail forms three stem loops of conserved structure (Blight & Rice, 1997; Ito & Lai, 
1997) and has been shown to enhance translation in cis but not in trans (Ito et al., 1998). 
Numerous proteins, such as polypyrimidine tract-binding protein (PTB) which can bind both 
the 5’ and 3’ UTR, have been shown to interact with the 3’UTR of HCV and enhance translation 
(Ito & Lai, 1999; Spangberg et al., 1999; Tsuchihara et al., 1997). However, a contradictory 
report demonstrated that replication was independent of PTB and that deletion of the X-tail or 
the poly (U/UC) tract enhanced replication (Murakami et al., 2001). 
The 3’ terminus is thought to end in a dsRNA stem loop (Tanaka et al., 1996), but one cDNA 
clone was found to extend for a further two uridine (U) bases forming a single stranded 
terminus (Yamada et al., 1996). 
1.6 Structural proteins  
1.6.1 Core  
The nucleocapsid or core protein is the amino (N)-terminal protein on the nascent polyprotein 
(Figure 1.7). An internal signal sequence encoded between core and E1 is responsible for 
directing translation of the developing polyprotein to the ER membrane. Cleavage at the N-
terminus of E1 by signal peptidase releases an immature core protein of 191 aa and 
subsequent intra-membrane cleavage by signal peptide peptidase (SPP) releases the mature 
core protein of 179 aa (McLauchlan et al., 2002). Production of the mature core and its 
association with lipid droplets are essential for virus particle assembly (Boulant et al., 2007; 
Targett-Adams et al., 2008). Core remains membrane associated by virtue of 2 amphipathic  
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Figure 1.7 Cartoon depicting the membrane interactions of the HCV proteins about the ER 
membrane. 
NS2 is shown in green and the membrane-spanning domain is undefined. Following release 
from E2 by signal peptidase, the C-terminal domain of core is further processed within the 
membrane to enable flipping of the C-terminus to the cytosol. The trans-membrane domains 
(TMDs) of E1 and E2 initially form short hairpin structures to act as signal peptides for E2 and 
p7 respectively. Following cleavage by signal peptidase the E1 and E2 TMDs re-orient their C-
termini to the cytosol to generate single pass, tail-anchored membrane topologies. NS5B also 
forms a tail-anchored protein topology. Core and NS5A remain membrane-associated by virtue 
of their amphipathic helices. The N- and C-terminal amphipathic helices of NS4B are shown.  
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α-helices (AH) between residues 119-136 and 148-164 (Boulant et al., 2006). Core is also able 
to target to the outer membrane of mitochondria via a 10 aa stretch within the C-terminal AH 
(Schwer et al., 2004). Biochemical analysis suggested that this 10 aa sequence in isolation 
acted like an AH as GFP expressed as a fusion to this domain could be extracted from purified 
mitochondria with alkaline carbonate along with the amphitropic mitochondrial heat-shock 
protein 70 (mtHSP70) (Schwer et al., 2004). 
Core has two distinct domains; an N-terminal RNA-binding domain (Boulant et al., 2005; 
Santolini et al., 1994) and a C-terminal domain responsible for targeting core to lipid droplets 
(Boulant et al., 2006; Hope & McLauchlan, 2000). Core protein is thought to homo-oligomerise 
to form the virus nucleocapsid encapsulating the viral genome. It has been proposed that the 
nucleocapsid is enveloped in a host endoplasmic reticulum (ER)-derived lipid bi-layer, the 
surface of which is believed to be punctuated by the virally encoded glycoproteins E1 and E2 
(Moradpour et al., 2007) although the extent to which they are exposed is the subject of 
controversy. Core is localised predominantly to the cytosolic face of the ER and it remains ER-
associated if cleavage by SPP is prevented (McLauchlan et al., 2002). Core localises to lipid 
droplets (Hope & McLauchlan, 2000; Santolini et al., 1994) which are increased in abundance 
in HCV-infected cells. This is thought to be caused by core protein as over-expression studies 
found that core induced lipid droplet accumulation in tissue culture (Abid et al., 2005). 
Genotype 3a core had the greatest effect prompting speculation that core could be 
responsible for the observed virus-induced steotosis in genotype 3a infections (Abid et al., 
2005). Core is thought to alter the cellular localisation of lipid droplets to a perinuclear 
distribution as it disrupts the association of adipocyte differentiation-related protein (ADRP), 
the major protein content of lipids, with lipid droplets (Boulant et al., 2008). More recently the 
host proteins hnRNPH1, NF45, and C14orf166 have been identified as interacting partners of 
core protein (Lee et al., 2011) and core has also been shown to form an interaction with both 
UTRs in cells (Yu et al., 2009). 
1.6.2 Frameshift protein (F) 
Translation of the HCV polyprotein occurs from a single ORF, although it had previously been 
noted that mutation of the primary AUG resulted in translation initiation from a downstream 
AUG (Reynolds et al., 1995). Subsequently, several reports noted the translation of a second 
ORF within the core coding region in the +1/-2 frame (Walewski et al., 2001; Xu et al., 2001). 
Expression of frame-shift (F) protein or alternate reading frame protein (ARFP) is independent 
of cellular and viral proteases and the gene product varies in length between 126 aa and 162 
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aa depending upon the genotype. This variation has led to speculation of the authenticity of 
this gene product during natural infection. 
Antibodies to F protein have been detected in sera from chronically (Shesheer Kumar et al., 
2008; Walewski et al., 2001) and acutely infected HCV patients (Morice et al., 2009). A cell-
mediated immune response to F protein was not observed in a selection of acutely infected 
individuals (Drouin et al., 2009) but F protein-specific CD4+ T-cell responses were detected in 
transgenic mice (Gao et al., 2010). F protein appears to be unnecessary for virus infection in 
cell culture but a recent study found high levels antibodies to F protein in patients with HCC 
suggesting a role of F protein in HCV-related pathogenesis (Dalagiorgou et al., 2011). 
1.6.3 E1 and E2 
E1 and E2 are the viral envelop glycoproteins each consisting of a single C-terminal TMD, that 
anchors them to the ER membrane (Cocquerel et al., 1999; Cocquerel et al., 1998; Selby et al., 
1994), and an N-terminal ectodomain which is oriented to the ER lumen (Cocquerel et al., 
2000; Santolini et al., 1994). E1 and E2 contain 6 and 11 predicted N-linked glycosylation sites 
and have observable masses of 31 kDa and 70 kDa by electrophoresis, respectively (Grakoui et 
al., 1993a; Stapleford & Lindenbach, 2011). The correct folding of both E1 and E2 requires the 
formation of numerous di-sulphide bonds and the ER chaperones calreticulin and calnexin 
(Choukhi et al., 1998; Dubuisson & Rice, 1996). The folded glycoproteins form non-covalent 
hetero-dimers via interactions of their TMDs (Deleersnyder et al., 1997; Op De Beeck et al., 
2000; Selby et al., 1994).   
The TMDs comprise two hydrophobic sections separated by at least one charged residue 
(Ciczora et al., 2007; Cocquerel et al., 2002; Cocquerel et al., 2000) and dimerisation is severely 
reduced following mutation of these residues (Ciczora et al., 2007; Stapleford & Lindenbach, 
2011). These charged residues are also essential for correct polyprotein processing as the C-
terminal portion of each TMD forms a signal sequence for the downstream protein and 
enables cleavage by signal peptidase (Cocquerel et al., 2002) (Figure 1.6). Both TMDs are 
understood to form intra-membrane hairpins, with the charged residues acting as the pivot 
point, with the C-terminus oriented to the ER lumen prior to signal peptidase cleavage. Once 
released from the downstream protein the signal sequence then inverts to form a single α–
helical membrane-spanning domain (Op De Beeck et al., 2000; Penin et al., 2004). 
The glycoproteins are thought to be exposed on the surface of the virus particle (Wakita et al., 
2005) to facilitate binding and fusion of the virus to cell surface membranes. Experiments using 
the soluble ectodomain of E2 have shown that it interacts with CD81 (Pileri et al., 1998), SR-BI 
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(Scarselli et al., 2002) and claudin I (Evans et al., 2007) while E1 coordinates the interaction 
with the LDL-R (Mazumdar et al., 2011). E1 has also been shown to interact with core, 
presumably within the ER membrane (Lo et al., 1996), but it has not been determined whether 
this interaction is required for particle assembly and maintained within mature virions. 
Antibodies targeting the E2 glycoprotein or the cellular entry factors prevent virus entry. 
1.6.4 p7 
The p7 protein is an integral membrane protein (Carrere-Kremer et al., 2002) and comprises 
two TMDs and a conserved charged basic-loop, with both termini oriented to the ER lumen 
(Carrere-Kremer et al., 2002; Lin et al., 1994) (Figure 1.7). A dual topology of p7 has been 
proposed whereby the C-terminal helix does not span the membrane, instead it lies parallel to 
the membrane on the cytosolic face (Isherwood & Patel, 2005). The C-terminal helix of p7 is 
capable of acting like a signal peptide (SP) and so appears to form the SP sequence for NS2 
(Carrere-Kremer et al., 2002). p7 is released from the viral polyprotein by cleavage at both 
termini by signal peptidase and mutation of the C-terminal alanine to arginine abrogates p7-
NS2 cleavage (Cocquerel et al., 2002; Mizushima, 1994).  
p7 is 63 residues in length and it has been shown to homo-oligomerise to form a hexameric or 
heptomeric ion channel, leading to its classification as a viroporin (Clarke et al., 2006; Luik et 
al., 2009). The inclusion of p7 within virus particles has not been established but it is vital for 
infection in vitro (Jones et al., 2007) and in chimpanzees (Sakai et al., 2003). The expression of 
core, E1, E2 and p7 in cis in insect cells led to the formation of virus-like particles (VLPs) with 
uncleaved E2-p7 detectable on the surface of these particles (Isherwood & Patel, 2005). 
However, cleavage of the E2-p7 junction is severely impaired in insect cells compared to 
mammalian cells (Isherwood & Patel, 2005).  
p7 ion channel activity can be chemically inhibited by amantadine but this is genotype 
dependent (Griffin et al., 2008; StGelais et al., 2007). Ion-channel activity can also be inhibited 
in a genotype-independent manner by rimantadine and iminosugars such as N-
nonyldeoxynojirimycin (NN-DNJ) (Gottwein et al., 2011; Griffin et al., 2008; Pavlovic et al., 
2003; StGelais et al., 2007; Wozniak et al., 2010).  
Compounds that inhibit ion channel activity also block virion release, implicating ion-channel 
function in virion morphogenesis (Griffin, 2010; Griffin et al., 2008; Luik et al., 2009). Mutation 
of the two basic residues in the cytoplasmic loop, termed the p7 basic-loop, block ion-channel 
function (Griffin et al., 2004; StGelais et al., 2007) and severely reduce infectivity (Jones et al., 
2007; Ma et al., 2011; Steinmann et al., 2007). Deletion of p7 from the full-length JFH-1 virus 
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(Jones et al., 2007; Steinmann et al., 2007) or chimeric viruses rendered them uninfectious 
(Popescu et al., 2011). p7 basic-loop mutants could be rescued by the vATPase inhibitor 
bafilomycin A or exogenous expression of influenza M2 but this wasn’t the case for p7 deletion 
viruses, further implicating a channel-dependent function of p7 in the virus life cycle (Brohm et 
al., 2009; Wozniak et al., 2010). The inclusion of p7 within the virus particle remains an area of 
investigation. 
Analysis of p7 function using liposomes revealed that the basic-loop mutant was less efficient 
at inserting into membranes (StGelais et al., 2007). The additional mutant histidine (H) 17 
alanine (A) and glycine (G) 39A both reduced ion-channel function but did not alter membrane 
insertion. The effect of G39A on ion-channel function was more profound than the H17A 
mutant and the G39A. The H17A mutation could be compensated for by increased 
concentrations of p7 but the G39A mutant could not. This was suggestive of a more significant 
effect on channel structure (StGelais et al., 2007). 
1.7 Non-structural proteins  
1.7.1 NS2 
NS2 is discussed in detail in section 1.8. 
1.7.2 NS3 
NS3 is a multi-functional protein and is the only viral protein whose maturation is independent 
of membranes (Errington et al., 1999; Svitkin et al., 2005). The N-terminal 189 residues of NS3 
form a chymotrypsin-like serine protease. Histidine 57, aspartic acid (D) 81 and serine (S) 139 
form the catalytic triad. A zinc ion is co-ordinated by 3 cysteine (C) residues and a histidine 
(C97, C99, C145 and H149) which is thought to be of structural, not catalytic, importance (De 
Francesco et al., 1996; Stempniak et al., 1997). The NS3 protease cis-cleaves at the NS3/4A 
junction and, in association with NS4A, trans-cleaves the subsequent downstream viral protein 
junctions (Eckart et al., 1993; Failla et al., 1994; Grakoui et al., 1993a; Hijikata et al., 1993a; 
Hijikata et al., 1993b; Tomei et al., 1993). As mentioned earlier, there are numerous antiviral 
compounds targeting NS3/4A protease activity currently in clinical trials. The serine protease 
domain is also required for efficient cleavage of the NS2/3 junction (Thibeault et al., 2001) and 
zinc co-ordination by NS3 is thought to play a structural role here as well (Tedbury & Harris, 
2007). NS2/3 cleavage is discussed in greater detail in section 1.8.2. 
The C-terminal two thirds of NS3 possess helicase and NTPase activities (Kim et al., 1995) but 
there is no dependence between the helicase and protease activities (Gallinari et al., 1998). 
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Helicase activity progresses in a 3’ to 5’ direction (Tai et al., 1996) and it has been shown to 
unwind dsRNA and RNA‐DNA hetero‐duplexes. Helicase activity is dependent upon 
dimerisation of NS3 (Serebrov & Pyle, 2004) and activity is ATP and divalent cation-dependent 
(Frick et al., 2007; Suzich et al., 1993; Wardell et al., 1999). NS3 helicase and ATPase activities 
are unaffected by the presence of uncleaved NS2 (Welbourn et al., 2005). 
NS4A forms a β-strand in complex within the NS3 β-barrel which is essential to induce a 
conformational change in NS3 (Kim et al., 1995; Yan et al., 1998). The NS3/4A protease has 
also been shown to inhibit antiviral response pathways by specifically cleaving the cellular 
proteins mitochondrial antiviral signalling protein (MAVS) (Li et al., 2005b) and Toll/IL-1 
receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF) (Li et al., 2005b).  
The enhancing mutation of glutamine (Q) 221 to leucine (L) (Q221L) within the helicase 
domain was originally described in the H77S/JFH-1 chimeric virus and confers high levels of 
infectivity to the wt chimeric virus (Ma et al., 2008; Yi et al., 2006) as well as increasing 
infectivity of the wt JFH-1 virus (Ma et al., 2008). It was subsequently found to rescue 
deleterious mutations within NS2 in other chimeric viruses (Jirasko et al., 2010; Phan et al., 
2009). Introduction of the Q221L mutation into the Jc1 chimeric virus, which achieves 
improved titres over full-length JFH-1, did not produce and additive effect on virus titres (Phan 
et al., 2009). The role of this residue is unlikely to be a direct interaction with specific regions 
of NS2 as a large number of widely distributed NS2 mutations were suppressed by this NS3 
mutation. The mechanism by which this residue confers enhanced infectivity is unclear as two 
other mutations in NS3 (Isoleucine (I) 286 valine (V) and I399V) were able to functionally 
replace the Q221L mutation in the H77S/JFH-1 virus (Ma et al., 2008). Comprehensive analysis 
of the NS3 enzyme functions found little difference between wt and the Q221L mutant except 
that the mutant showed a decrease in functional RNA binding and a minor decrease in RNA 
unwinding (Phan et al., 2009). Unfortunately, the phenotypes of the I286V and I399V mutants 
were not examined in this study. 
1.7.3 NS4A  
NS4A is an 8 kDa (Grakoui et al., 1993a) integral membrane protein that interacts non-
covalently with NS3 to anchor it to membranes via its C-terminal TMD (Brass et al., 2008; 
Hijikata et al., 1993b; Kim et al., 1999; Wolk et al., 2000) (Figure 1.7). NS4A associates with NS3 
forming an integral β-strand as part of the N-terminal protease domain of NS3 and acts a co-
factor for the NS3 serine protease (Failla et al., 1994; Kim et al., 1999; Kim et al., 1996). 
Truncation analysis identified residues 21-35 of NS4A as the minimum required to stimulate 
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the release of NS4B, NS5A and NS5B in vitro and in tissue culture (Lin et al., 1995; Tomei et al., 
1996). Binding of NS4A was initially thought be unnecessary for NS3 helicase activity (Gallinari 
et al., 1999), however a more recent report suggested that it may also be a co-factor for 
helicase activity as it enhanced the RNA binding capacity of the helicase in the presence of ATP 
(Beran et al., 2009). Mutation analysis implicated a conserved stretch of acidic residues in the 
C-terminal domain of NS4A as the regulatory domain of the helicase (Shiryaev et al., 2010).  
Whether NS4A has any functions independent of NS3 is not known. If NS4A acts solely in trans 
with NS3 it may be that one of the functions of NS3 requires it to dissociate from the 
membrane. As part of the NS3/4A protease; NS4A is linked with mitochondrial dysfunction and 
over expression studies suggested it functions as a transcription /translation regulator (Florese 
et al., 2002; Kadoya et al., 2005), but these require validation in more physiological systems. 
1.7.4 NS4B  
NS4B is a 27 kDa integral membrane protein capable of targeting independently to ER 
membranes, indicating the presence of an internal signal sequence (Grakoui et al., 1993a; 
Hugle et al., 2001). NS4B has been shown to alter membrane formation and has therefore 
been implicated as the architect of the 'membranous web' associated with the HCV replication 
complex and is essential for replication (Egger et al., 2002). Both termini are processed by the 
NS3/4A protease and it is predicted to form a 4 TMD protein with both termini oriented to the 
cytosol (Lundin et al., 2006; Lundin et al., 2003) (Figure 1.7). As the result of an assumed post-
translational event, a minor proportion of the NS4B population has been proposed to assume 
a different topology whereby the N- terminus is oriented to the ER lumen, giving it a topology 
common to the NS4B protein of other viruses of the Flaviviridae (Lundin et al., 2003). 
However, this phenomenon is of limited occurrence when NS4B is co-expressed with NS5A 
(Lundin et al., 2006). The C-terminal domain of NS4B has been reported to modulate NS3/4A 
activity, NS5A hyper-phosphorylation and genome replication (Lindenbach et al., 2007). 
In addition to the four characterised TMDs of NS4B, two N-terminal amphipathic helices have 
been described between residues 6-29 (Elazar et al., 2004) and 42-66 (Gouttenoire et al., 
2009a). Residues 42-66 displayed α-helical structure in membrane mimetic detergents by 
solution nuclear magnetic resonance (NMR) and was speculated to be capable of traversing 
the membrane upon NS4B oligomerisation (Gouttenoire et al., 2009a). Both domains were 
sufficient to target GFP to membranes but targeting was abrogated following mutagenesis 
(Elazar et al., 2004; Gouttenoire et al., 2009a). Furthermore, residues 227-254 within the C-
terminal domain of NS4B have also been solved by NMR and proposed to form an amphipathic 
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helix (Gouttenoire et al., 2009b). Disruption of the membrane targeting of any of these three 
domains prevented replication complex formation (Elazar et al., 2004; Gouttenoire et al., 
2009a; Gouttenoire et al., 2009b). Residues 40-69 and 227-254 fused to GFP were fully or 
partially extracted from membranes, respectively, following alkaline carbonate treatment 
implying that they were superficially associated with membranes (Gouttenoire et al., 2009a; 
Gouttenoire et al., 2009b). 
1.7.5 NS5A  
NS5A is essential for replication of the viral genome and is a component of the replication 
complex (Macdonald et al., 2005). It exists in two phosphorylation states: the basally-
phosphorylated p56 (56 kDa) and the hyper-phosphorylated p58 (58 kDa) forms (Huang et al., 
2005). Limited proteolysis by tryptic digest confirmed computational prediction of a three 
domain organisation of NS5A separated by two low complexity sequences (LCS) (Tellinghuisen 
et al., 2004). NS5A associates with membranes via a membrane-targeting sequence within 
domain 1 (Figure 1.7). Expression of the N-terminal 30 residues of NS5A as a fusion to eGFP 
altered the sub-cellular localisation of eGFP to a pattern comparable to NS5A (Brass et al., 
2002; Elazar et al., 2003). These residues are well conserved, particularly for hydropathy, and 
helical wheel projection analysis found that aa 4-26 resemble an amphipathic helix (Brass et 
al., 2002; Elazar et al., 2003). The solution NMR structure of this domain showed it to be α-
helical in nature with a flexible helical loop in the middle (Penin et al., 2004). Further NMR 
characterisation suggested that it formed an in-plane amphipathic helix that embedded deeply 
into the membrane bi-layer (Penin et al., 2004). The ability of NS5A to associate with 
membranes is vital for its role in replication (Elazar et al., 2003). 
A similar domain was also found in the NS5A protein of other related viruses (Brass et al., 
2007; Sapay et al., 2006) and an 18-mer synthetic peptide of the NS5A AH that was potently 
virocidal against HCV and numerous other enveloped, ss RNA viruses was hypothesised to 
function by disrupting the virion envelops (Cheng et al., 2008). Whether NS5A functions in vivo 
to limit the viral load via it’s AH and thus aid in immune-evasion is not known. 
Co-ordination of a zinc ion by a zinc binding finger within domain I is essential for replication 
(Tellinghuisen et al., 2004). Structural characterisation of domain I showed that it may form 
two distinct dimer conformations that may play unique roles within the life cycle (Love et al., 
2009; Tellinghuisen et al., 2005). Domains II and III appear to be mostly unstructured (Hanoulle 
et al., 2010; Hanoulle et al., 2009; Liang et al., 2007; Verdegem et al., 2011) or flexible which is 
thought to enable the formation of numerous protein:protein interactions. NS5A is thought to 
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modulate replication by interacting with HCV RNA (Huang et al., 2005) and NS5B (Shirota et al., 
2002). NS5A RNA-binding involves all three protein domains and it preferentially binds the poly 
(U/UC) tract of the HCV 3’ UTR, whereas NS5B preferentially binds the 3’ UTR X-tail region 
(Foster et al., 2010a). 
NS5A is a proline-rich protein that has been shown to interact with numerous cellular proteins 
in order to modulate the cellular environment and the virus life cycle (Macdonald et al., 2004). 
NS5A contains two poly-proline motifs within the low-complexity sequence separating 
domains 2 and 3 (LCSII) which bind cellular proteins containing Src-homology 3 (SH3) domains. 
Domain 2 contains the interferon sensitivity determining region (ISDR) which was identified by 
comparative analysis of samples from sensitive and insensitive patients and confirmed by 
mutagenesis (Enomoto et al., 1995; Enomoto et al., 1996). However, other studies have 
questioned the correlation between this domain and indeed NS5A in determining virus 
sensitivity to IFN-α (Aizaki et al., 2000; Brillet et al., 2007). 
While domain III of NS5A is not required for RNA replication (Appel et al., 2008; Tellinghuisen 
et al., 2008b), deletion mapping (Appel et al., 2008; Hughes et al., 2009b) and domain 
swapping (Kim et al., 2011) identified that it plays an essential role in virion morphogenesis. 
Subsequently specific residues within domain III and LCSII have been shown to regulate the 
assembly function of NS5A (Hughes et al., 2009a; Masaki et al., 2008; Tellinghuisen et al., 
2008a).  
1.7.6 NS5B  
NS5B is the C-terminal protein of the HCV polyprotein and is a 65 kDa RNA dependant RNA 
polymerase (RdRp) (Behrens et al., 1996; Grakoui et al., 1993a). NS5B is a so-called ‘tail-
anchored’ protein as it is targeted to the ER or ER-derived membranes via the hydrophobic 
C‐terminal 21 residues which form a TMD (Ivashkina et al., 2002; Schmidt-Mende et al., 2001) 
(Figure 1.7). NS5B is capable of post-translationally associating with membranes and inserts to 
orientate its N-terminal enzyme domain to the cytosol (Schmidt-Mende et al., 2001). 
Membrane association is essential for enzyme activity (Lee et al., 2004; Moradpour et al., 
2004). 
The C-terminal trans-membrane domain can be replaced with that of poliovirus 3A protein 
(Lee et al., 2006) and the TMD from the GBV-B polymerase (Brass et al., 2010). Maintenance of 
the 3A anchor region-containing replicon under prolonged selection pressure recovered 
replication but no mutations were found in the 3A domain, suggesting that its role is purely 
that of a membrane anchor (Lee et al., 2006). Subsequently, a more detailed structural analysis 
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of chimeric replicons identified a conserved structural feature present within the 3A anchor 
domain and the NS5B TMD from HCV and GBV-B that conferred viability, possibly through 
enabling intra-membrane interactions (Brass et al., 2010). 
Solution of the X-ray crystal structure of NS5B showed that it forms a ‘right-hand’ structure 
with thumb, finger and palm domains (Lesburg et al., 1999). The three domains completely 
encircle the active site, in contrast to other similar polymerases which form an open-circle, or 
‘U’ shape. The global structure was found to be relatively inflexible and is believed to remain 
largely unchanged throughout the catalytic cycle (Lesburg et al., 1999). 
The RdRp enzyme contains a highly conserved GDD motif that is flanked by hydrophobic 
sequences. This motif is a common feature of the RdRp of RNA viruses (Kamer & Argos, 1984; 
Poch et al., 1989) and mutation of this motif completely blocks genome replication (Yamashita 
et al., 1998). 
Using the positive sense genome as the template, the RdRp binds the 3’ X-tail within the 3’ 
UTR (Foster et al., 2010a; Zhong et al., 2000) and initiates synthesis of a negative-strand copy 
in a primer-independent manner (Behrens et al., 1996). NS5B is capable of synthesising RNA 
duplexes by de novo and ‘copy–back’ mechanisms (Ferrari et al., 1999); although de novo 
synthesis is thought to be the mechanism employed in vivo (Zhong et al., 2000). The 
replication intermediate is then used by the RdRp to replicate the genome. RdRp activity was 
found to require the presence of Mn2+ ions, preferentially, or Mg2+ ions in vitro (Behrens et al., 
1996; Ferrari et al., 1999). Glutamic acid 18 and histidine 502 were found to be essential for 
catalytic activity (Qin et al., 2001), and subsequently also for oligomerisation, implying that 
RdRp activity may be dependent upon multimerisation (Qin et al., 2002).  
The RdRp does not contain any proof-reading activity which leads to the high sequence 
variability of the major genotypes and of the quasi-species within infected individuals and is 
central to the virus’ ability to escape the immune response and become resistant to specific 
antivirals (Lindenbach & Rice, 2003). Two forms of drugs targeting NS5B RdRp function are 
currently under development: nucleoside-analogue inhibitors (NIs) and non-nucleoside-
analogue inhibitors (NNIs). Because NIs target the highly conserved active site they confer 
better genotype cross-reactivity and a greater barrier to resistance. 
NS5B forms part of the replication complex and is able to function without any co-factors in 
vitro. NS3, NS4B and NS5A have been shown to modulate activity of NS5B (Behrens et al., 
1996; Piccininni et al., 2002; Shirota et al., 2002) and the interaction between NS5A and NS5B 
Chapter 1: Introduction 
 
34 
 
is essential for genome replication (Shimakami et al., 2004). The cellular protein c-Src has been 
shown to interact with NS5A and NS5B via its SH2 and SH3 domains, respectively, thus 
mediating the NS5A:NS5B interaction and promoting replication (Pfannkuche et al., 2011). The 
cellular protein cyclophilin B (CyPB) was shown to stimulate NS5B RNA binding activity 
(Watashi et al., 2005), although cyclophilin A (CyPA) was later shown to be the only cyclophilin 
with a pivotal role in replication (Yang et al., 2008). Other cellular interacting partners of NS5B 
include two helicases, both of which enhance replication (Goh et al., 2004; Kyono et al., 2002). 
1.8 NS2 
1.8.1 Topology and structure  
NS2 is a 217 amino acid trans-membrane protein comprising residues 814 to 1030 of the JFH-1 
polyprotein (Grakoui, 1993b; Mizushima et al., 1994; Selby et al., 1994). Release of NS2 from 
the polyprotein requires cleavage at the N-terminus by signal peptidase (Mizushima et al., 
1994), and processing at the C-terminus by the NS2/3 cysteine autoprotease (Grakoui, 1993b). 
NS2 has two domains: an N-terminal trans-membrane domain comprising residues 1-92 and a 
soluble C-terminal catalytic domain comprising residues 93-217, although the exact definitions 
of these domains vary. NS2 localises to the ER membrane (Santolini et al., 1995), and can co-
translationally target to membranes independently from the other viral proteins  (Yamaga & 
Ou, 2002). Truncation analysis demonstrated that NS2 contains two distinct internal 
membrane-targeting sequences, between residues 30-74 and 119-151 (Yamaga & Ou, 2002).  
The catalytic domain was originally defined as the minimum sequence required for cleavage of 
the NS2/3 junction (Thibeault et al., 2001) and more recently the X-ray crystal structure of the 
catalytic domain in a post-cleavage state was solved (Lorenz et al., 2006b) (Figure 1.8).  
Mutational analysis had shown that histidine 143, glutamic acid 163 and cysteine 184 were 
involved in catalysis of NS2/3 cleavage (Grakoui, 1993b; Hijikata et al., 1993a; Welbourn et al., 
2005). Elucidation of the 3D structure of the NS2 catalytic domain (aa 94-217), post-cleavage, 
by X-ray crystallography confirmed that these three residues form the enzyme catalytic triad 
(Figure 1.8). Interestingly, the NS2 catalytic domain, post-cleavage, was shown to form a 
chimeric active-site dimer, comprising H143 and E163 residues from one monomer and the 
C184 residue from another monomer (Lorenz et al., 2006b). Dimerisation of the mature full-
length protein has not been directly addressed, although Stapleford et al., reported an NS2-
specific protein species of approximately 40 kDa following blue-native polyacrylamide gel 
electrophoresis (BN-PAGE) analysis of NS2-containing complexes which they speculated to be 
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Figure 1.8 3D crystal structure of the NS2 catalytic domain (aa 94-217) in the post-cleavage 
state. 
The domain crystallised as an active-site dimer and the two monomers are shown in blue and 
green (Lorenz et al., 2006b). The active-site is highlighted. Two of the catalytic residues, H143 
and E163, are provided by one monomer, the third catalytic residue, C184, and the substrate 
sequence is provided by the other monomer. Post-cleavage, the C-terminal leucine, L217, is 
coordinated into the activate site.  
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NS2 dimers (Stapleford & Lindenbach, 2011). Using site directed mutagenesis to disrupt the 
putative dimer interface, Dentzer and colleagues (Dentzer et al., 2009) concluded that 
dimerisation was essential for infectivity; however they did not confirm that the NS2 mutants 
disrupted dimer formation.  
The catalytic domain can be further divided into two sub-domains; the N-terminal domain that 
contains two α-helixes and the C-terminal domain that consists of four anti-parallel β sheets. 
The two sub-domains are connected by an extended linker (Lorenz et al., 2006b). In relation to 
the active site residues; H143 and E163 are in the N-terminal sub-domain and C184 is in the C-
terminal sub-domain. Another notable feature of the crystal structure was that proline 164 
assumed an unusual cis conformation which heavily contributed to the active site architecture 
(Lorenz et al., 2006b). Mutation of this residue in a mono-cistronic J6/H77/JFH virus blocked 
replication and mutation in the bi-cistronic virus reduced infectivity by 10 fold but did not alter 
replication (Phan et al., 2009). This suggests that correct active site architecture is required for 
efficient virus assembly, as well as NS2/3 cleavage. 
Glycosylation analysis of in vitro expressed NS2 was combined with hydropathy scoring to 
generate a 4 TMD topology prediction for NS2 (Yamaga & Ou, 2002) (Figure 1.9A). In this 
model the N-terminal ~140 aa were described as forming the membrane-spanning domain and 
both termini were predicted to be orientated to the ER lumen (Yamaga & Ou, 2002), in 
agreement with previous findings (Santolini et al., 1995). In this model the fourth TMD was 
predicted to be within the catalytic domain (aa 119-147), yet the crystal structure of the 
catalytic domain provided no evidence of a TMD (Lorenz et al., 2006b).  
By analysing the outputs of 6 topology prediction programs, and taking into account the 
localisation of the cleavage events that release the mature protein and the 3D structure of the 
catalytic domain, Jirasko et al., (Jirasko et al., 2008) produced a 3 TMD model that omitted the 
fourth putative TMD defined by Yamaga and Ou (Yamaga & Ou, 2002) (Figure 1.9B).  
Subsequently the 3D structure of the N-terminal 27 residues of NS2 from the Con1 isolate 
were solved by solution NMR and were found to assume an α-helical conformation in 50% 
tetrafluoroethylene (TFE) (Jirasko et al., 2008). The structure of this domain was incorporated 
into a refined model of NS2 topology based on the output from a single topology prediction 
program (Phan et al., 2009) (Figure 1.9C). This model estimated the 3 TMDs to be positioned 
between aa 4-24, aa 30-50 and aa 63-84. More recently 3D structures of peptides encoding 
residues 27-59 and 60-99 from the Con1 isolate have also been solved by solution NMR and  
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Figure 1.9 Topology models for NS2. 
Model A represents the complete NS2 protein; the catalytic domain is not shown for models B-
D. Sites of artificial glycan acceptor sites that were glycosylated are shown (green circles). Key 
residues are shown. No information was given regarding the position of the luminal loop in 
model C. All topology models predicted the N-terminus to be luminal oriented. 
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shown to form stretches of α-helical structure in 50% TFE (Jirasko et al., 2010). This has led to 
the proposal of a refined model of NS2 topology, generated from domain reconstruction of the 
three peptide sequences (Jirasko et al., 2010; Popescu et al., 2011) (Figure 1.9D). In this latest 
model the three TMDs are shown to span residues 8-24, 29-48 and 74-97. A three TMD 
topology is in agreement with recent observations of NS2 topology in virus expressing cells 
following partial permeabilisation of the plasma membrane. Under these conditions the 
catalytic domain was detected in the cytosol and sensitive to protease treatment (Ma et al., 
2011). 
Residue 10 of NS2 is a highly conserved glycine and in the NMR structure of the aa 1-27 
peptide it was shown to disrupt the α-helical structure of the putative first TMD. Mutation of 
G10 to alanine was lethal in the Con1/C3 virus (Figure 1.10), leading to the proposal that this 
residue and the role it performs as a flexible joint in the first putative TMD of NS2 were vital 
for virus assembly (Jirasko et al., 2008). However, mutation of this residue in the Jc1 virus and 
JFH-1 virus (Figure 1.10) resulted in an attenuated phenotype with extracellular infectivity 
reduced by 1 log (Phan et al., 2009). While different viruses may be the root cause of the 
differences it is also important to note that while Jirasko and colleagues observed that p7-NS2 
cleavage was impaired in this mutant, Phan et al., employed foot and mouse disease virus 
(FMDV) 2A autoprotease to artificially mediate p7-NS2 cleavage (Phan et al., 2009). So the 
more impaired phenotype observed by Jirasko et al may have been a direct result of impaired 
p7/NS2 cleavage (Jirasko et al., 2008), at least in the Jc1 virus. 
Conservation of specific residues and small amino acids along one face of the helix formed by 
aa 1-27 led to the speculation that the first putative TMD may form stabilising inter or intra-
molecular interactions with other helices (Jirasko et al., 2008). The residues of this helix are 
well conserved within genotypes but show significant variability between genotypes 
suggesting co-adaptation of this domain with corresponding domains of NS2 or other viral 
proteins. 
The second peptide (aa 27-59) formed a single, unbroken α-helical structure between aa 27-
49, with polar residues populating one face of the helix (Jirasko et al., 2010). This structure was 
reminiscent of an amphipathic helix and it was noted that in order for this domain to stably 
span the membrane it would require neutralisation of the charged residues, potentially by 
interacting with another membrane-spanning domain (Jirasko et al., 2010).  
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Figure 1.10 Schematic representation of the genome organisation of some of the viruses 
used to study NS2. 
Genome segments provided by each isolate are coloured. The genotypes of donor isolates are 
noted. The 5’ and 3’ UTRs were JFH-1 in origin. The point of recombination in the Jc1 and 
Con1/C3 viruses is after residue 33 of NS2. 
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The third peptide (aa 60-99) formed three α-helical structures; designated trans-membrane 
segment (TMS) 3.1 (aa 61-70), TMS3.2 (aa 73-86) and TMS3.3 (aa 89-95). TMS3.1 was 
predicted to orientate in-plane with membrane bi-layers and at right angles to TMS3.2 and 
TMS3.3 because of a proline at position 73. A glycine and proline at residues 88 and 89 were 
responsible for a loss of secondary structure between TMS3.2 and TMS3.3. 
1.8.2 NS2/3 processing  
NS2/3 processing is essential for infection in chimpanzees (Kolykhalov et al., 2000) and in cell 
culture using wild type (wt) virus (Jones et al., 2007). The insertion of a second IRES between 
NS2 and NS3 clearly demonstrated that NS2/3 cleavage was only necessary to correctly release 
NS3 in cell culture as mutation of the active residue C184 to alanine in the bi-cistronic virus 
had no effect on RNA replication or infectivity of the virus at 72 hours post-transfection, 
although it displayed delayed kinetics (Jones et al., 2007). This also demonstrated that while 
uncleaved NS2/3 precursor is essential for infectious particle production in BVDV and other 
Pestiviruses, this was not the case for HCV (Jones et al., 2007). As no other target of the NS2/3 
protease has been identified and catalysis of cleavage of the NS2/3 junction appears to be 
required solely to correctly release NS3; the NS2/3 protease has been described as a positive 
strand RNA virus accessory protease (Thibeault et al., 2001). 
Proteolytic cleavage of NS2/3 precursor molecules can occur in the absence of microsomal 
membranes (Santolini et al., 1995; Thibeault et al., 2001) and independently of cellular co-
factors (Hijikata et al., 1993a; Thibeault et al., 2001); however it does require membrane 
mimetic detergents (Pieroni et al., 1997; Thibeault et al., 2001) highlighting the necessity of a 
hydrophobic environment to facilitate folding and/or functionality of the protease. The NS2/3 
precursor, identified by truncation analysis as the minimal region required for efficient auto-
cleavage, encompasses the C-terminal domain of NS2 (aa 95-217) and the serine protease 
domain of NS3 (aa 1-181) (Thibeault et al., 2001). Although this construct expressed well in E. 
Coli and was cleavage-competent it was insoluble so required denaturing, purifying and re-
folding before it could be analysed (Thibeault et al., 2001).  
The inhibition of NS2/3 processing by EDTA and 1, 10 phenanthroline (Grakoui, 1993b; Hijikata 
et al., 1993a; Thibeault et al., 2001), but not by specific NS3 inhibitors (Thibeault et al., 2001), 
and stimulation of processing by ZnCl2 implied that NS2/3 cleavage was carried out by a zinc 
metalloprotease and independent of NS3 protease activity (Hijikata et al., 1993a). It was later 
found that the protease domain of NS3 contains three cysteine residues and a histidine residue 
which co-ordinate a zinc ion and that loss of zinc-co-ordination following mutation of these 
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residues inhibited auto-cleavage of the NS2/3 pre-cursor (Tedbury & Harris, 2007). NS3 serine 
protease activity also requires zinc coordination but NS2/3 auto-cleavage activity is more 
sensitive to zinc chelation than NS3 protease activity (Tedbury & Harris, 2007). 
NS2/3 processing was efficiently inhibited by expression of the C-terminal 10 aa of NS2 as a 
peptide (Thibeault et al., 2001). A mechanism of competitive inhibition is consistent with the 
X-ray crystal structure of the NS2 catalytic domain, post-cleavage, in which the C-terminus of 
NS2 was co-ordinated within the active site (Lorenz et al., 2006b). Peptides of NS4A have also 
been shown to inhibit in vitro translated and bacterially expressed NS2/3 while enhancing NS3 
protease activity (Darke et al., 1999; Thibeault et al., 2001). 
Recent work demonstrating that inefficient cleavage was possible with as few as 2 aa of NS3 
provided the first evidence that NS2 is an independent protease (Schregel et al., 2009). The 
role of NS3 is therefore likely one of a structurally important co-factor involving co-ordination 
of a zinc ion (Dentzer et al., 2009; Schregel et al., 2009) as protein re-folding of the NS2/3 
precursor was blocked upon the addition of EDTA to the re-folding buffer (Foster et al., 
2010b). 
Mutations to residues proximal to the cleavage site were well tolerated by NS2/3 pre-cursor 
expressed in vitro. Mutation of the C-terminal residue of NS2, L217, to alanine, arginine and 
phenylalanine had no effect on processing in vitro. L217E caused a moderate inhibition of 
cleavage and mutation to proline prevented cleavage entirely (Hirowatari et al., 1993; Reed et 
al., 1995). When similar mutations were analysed in the context of a fully infectious bi-cistronic 
virus, with an IRES separating NS2 and NS3 (Figure 1.10), they were found to be largely 
ineffectual towards replication but severely inhibited infectious virus production (Dentzer et 
al., 2009). Even the relatively subtle mutation of L217I produced a 10-fold decrease in virus 
infectivity. 
Similar to the findings of Jones et al., (Jones et al., 2007), mutation of the active-site residue 
C184 to alanine in a bi-cistronic Jc1 virus, but encoding NS2 from the H77 isolate (Figure 1.10), 
had no effect on replication, intra- and extracellular core and intra- and extracellular infectivity 
(Dentzer et al., 2009). However, mutation of H143, also part of the catalytic triad, to alanine in 
a similar bi-cistronic virus caused a minor decrease in released core but a 1.5-2 log decrease in 
intra- and extracellular infectivity (Jirasko et al., 2008). Examination of the 3D structure of the 
catalytic domain suggested that H143 interacts with the two C-terminal leucines and serine 
194 from the other monomer and forms a salt bridge with E163 of the same molecule (Lorenz 
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et al., 2006b). It was speculated that mutation of H143 to alanine would disrupt these 
interactions, whereas the C184A mutation was expected to have little impact (Jirasko et al., 
2008). Analysis of these two mutations in the NS2/3 precursor showed that while both 
mutations impaired protein re-folding; H143A was significantly less folded than C184A and 
lacked the α-helical secondary structure characteristics observed in the wt and C184A pre-
cursors (Foster et al., 2010b). Together this demonstrates that, while catalytic activity of the 
NS2 protease is not required, correct structural conformation of the catalytic domain and the 
C-terminal leucine, governed in part by interactions formed by the active-site residue H143, 
are required for infectivity. 
As mentioned previously, the post-cleavage NS2 catalytic domain crystallised as an active-site 
dimer. The potential for trans cleavage of the NS2/3 junction was initially identified by co-
expression of cleavage-deficient (C184A and H143A) truncated NS2/3 precursor molecules 
with full-length polyprotein and monitoring for the formation of truncated NS2 (Grakoui, 
1993b). This was explored in more detail by characterising the cleavage in trans of a precursor 
molecule lacking the P1 and P1’ residues of the NS2/3 cleavage site (ΔP1-P1’) (Reed et al., 
1995). In isolation the ΔP1-P1’ precursor was not able to catalyse auto-cleavage; however co-
expression with a C184A mutant precursor resulted in cleavage, albeit highly attenuated by 
comparison to wt precursor molecules. Interestingly, co-expression of ΔP1-P1’ with a H143A 
mutant precursor produced no cleavage products (Reed et al., 1995). These experiments were 
reproduced by Lorenz et al., and demonstrate the potential for NS2/3 cleavage in trans (Lorenz 
et al., 2006b). These experiments corroborate the crystal structure data showing that the 
active site cysteine residue and the prospective C-terminus are co-ordinated by one molecule, 
while the other two active site residues, H143 and E163, are provided by the other molecule 
(Lorenz et al., 2006b; Reed et al., 1995).  
Controversy still surrounds the notion of bi-molecular cleavage at the NS2/NS3 junction as if it 
is an obligatory factor for NS2/3 cleavage it would require the coordination of at least one 
nascent polyprotein at the membrane surface and therefore could impose a rate limiting step 
on protein expression and replication. It is interesting to note therefore that separation of NS2 
and NS3 with a second IRES, thereby negating this potential rate-limiting step, did not result in 
an increase in virus replication kinetics (Jones et al., 2007). Furthermore, the highly attenuated 
cleavage observed in trans suggests that this mechanism is very inefficient. It is possible that 
the conformation shown in the catalytic domain structure produced by Lorenz et al., (Lorenz et 
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al., 2006b) represents a less abundent, but more stable, conformation that was more 
amenable to crystallisation techniques. 
1.8.3 tNS2 
Several groups have reported the generation of a truncated form of NS2, termed tNS2 (Jirasko 
et al., 2008), in experiments involving full-length virus. tNS2 appears to be the results of an N-
terminal cleavage event as it has been observed with anti-NS2 antiserum (Boson et al., 2011; 
Jirasko et al., 2010; Stapleford & Lindenbach, 2011) but not N-terminal tag epitopes (Jirasko et 
al., 2010; Stapleford & Lindenbach, 2011). tNS2 was detectable in whole-cell lysates but not in 
high molecular weight, NS2-containing complexes (described in detail in section 1.8.6) purified 
from the same samples (Stapleford & Lindenbach, 2011). Ma et al., (Ma et al., 2011) observed 
tNS2 only when an IRES was inserted between p7 and NS2 leading the authors to suggest that 
is an aberrant initiation product.  
The NS2A of YFV plays an essential role in virus assembly which is mediated by a cleavage 
event carried out by the viral protease (Nestorowicz et al., 1994). Stapleford et al., (Stapleford 
& Lindenbach, 2011) speculated that the generation of tNS2 may operate as a means to 
prevent premature particle assembly or a mechanism to dissociate the NS2 complexes prior to 
particle formation. It is unlikely to be as straight forward as this however, as point mutations 
that altered the amount of tNS2 did not correlate with observed decreases in infectivity 
(Jirasko et al., 2010). 
The role and indeed the relevance of tNS2 in the virus cycle remains to be confirmed. 
Truncated forms of NS2 have not been reported using in vitro translation systems (Hijikata et 
al., 1993a; Santolini et al., 1995; Yamaga & Ou, 2002) as well as some cellular systems 
(Tedbury et al., 2011; Yi et al., 2009). This could be for several reasons; the absence of the 
specific protease from the systems studied, experimental constraints such as protein 
resolution and detection or that this cleavage event is not ubiquitous among HCV isolates. 
1.8.4 S168 
NS2 is a short lived protein with a reported half-life of <30 minutes for DNA-expressed (Franck 
et al., 2005) and between 3-6 hours for RNA-expressed protein (Welbourn et al., 2009). Serine 
168 was originally described as being critical for the degradation of NS2 in the genotype 1a 
isolate HCV-H via the proteasome as levels of genotype 1a NS2 could be rescued following 
treatment with the proteasome inhibitors MG132 and clasto-lactocystin-β-lactone (Franck et 
al., 2005; Yi et al., 2009). Sequence analysis revealed that serine 168 was part of a consensus 
casein kinase II (CKII) phosphorylation site S/TXXE, where X is any residue. Mutation of S168 to 
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alanine in an over-expression system stabilised NS2 to the same extent as MG132 treatment. 
Furthermore treatment of cells expressing a full-length replicon with either the CKII inhibitor 
curcumin or MG132 both resulted in NS2 stabilisation (Franck et al., 2005). Similarly NS2/3 
precursor levels could be stabilised using MG132 in NS2/3 cleavage-deficient replicons based 
on a genotype 1b isolate, Con 1, suggesting proteasome-mediated degradation (Welbourn et 
al., 2005; Welbourn et al., 2009). However, mature Con1 NS2 was insensitive to MG132 
treatment (Welbourn et al., 2009). Furthermore, mutation of the 6 lysine residues within Con1 
NS2 to arginine had no effect on mature protein stability, suggesting that degradation of NS2 
and NS2/3 may be different and may vary between genotypes (Welbourn et al., 2009).  
Tedbury et al., generated two replicons encoding NS2 through to NS5B (NS2-5B) and signal-
peptide p7 through to NS5B (SPp7-5B) (Tedbury et al., 2011) (Figure 1.4B). Using these 
constructs it was found that NS2 partitioned to a detergent-insoluble fraction in the presence 
of p7 and co-localised with NS3 and NS5A. While the S168A mutation did not alter NS2 
partitioning, it did disrupt co-localisation with NS5A (Tedbury et al., 2011). NS2 expressed from 
SPp7-5B replicons was able to bind NS5A and co-localise to discrete punctae with NS3 and 
NS5A, both of which were blocked by the S168A mutation (Tedbury et al., 2011). Although this 
data implicated S168 as vital for the NS2:NS5A interaction, it was inconsistent with full-length 
virus experiments where the S168A/G mutations were lethal but did not disrupt NS2 
subcellular localisation (Ma et al., 2011). The mechanism of action of the S168 mutations is 
further confused by the speculation that their lethal phenotype in full-length virus was a result 
of a disrupting co-localisation between NS5A and E2 (Ma et al., 2011). 
Interestingly the S168A mutation resulted in attenuation of the HJ3-5 virus but the NS2:NS3 
interaction was unaffected (Ma et al., 2011). Rescue experiments found that second site 
mutations in NS2 (L174V) and NS5A (V464L) could recover infectivity from the HJ3-5 S168G 
virus suggesting that the C-terminal catalytic domain of NS2 interacts with NS5A (Yi et al., 
2009). The X-ray crystal structure of the NS2 catalytic domain shows S168 and V174 to be 
positioned on the same solvent-exposed surface (Lorenz et al., 2006b). By supplying NS2 in 
trans, it was shown that wt NS2 could trans-complement mutations to S168, in a genotype-
specific, or possibly strain-specific, manner (Yi et al., 2009).  
Mutation of S168 to alanine or glycine in the HJ3-5 virus (Yi et al., 2009) or to the phospho-
mimetic residues aspartic acid or glutamic acid in the Jc1 virus severely attenuated infectious 
virus formation and extracellular RNA levels (Phan et al., 2009). CKII phosphorylation of S457 
of NS5A is essential for virus infectivity, but mutation to the phospho-mimicking aspartic acid 
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enables infectivity while conferring resistance to CKII inhibitors (Tellinghuisen et al., 2008a). 
Treatment of infectious virus clones, containing the S457D mutation in NS5A, with the CKII 
inhibitor DMAT (2-Dimethylamino-4, 5, 6, 7-tetrabromo-1H-benzimidazole) had no effect on 
intra- or extracellular infectivity (Tellinghuisen et al., 2008a; Yi et al., 2009), implying that the 
role of S168 is phospho-independent. 
Analysis of released core demonstrated that infectious particles produced by the HJ3-5 virus 
were ‘fast sedimenting’ while the majority of core released from the uninfectious progenitor 
virus, HJ3 (which lacks culture adapted mutations that confer viability), was ‘slow sedimenting’ 
(Yi et al., 2009). Surprisingly, the majority of extracellular core produced by the uninfectious 
HJ3-5 (S168G) mutant virus was also ‘fast-sedimenting’ (Yi et al., 2009). Consistent with the 
findings using the Jc1 virus (Jirasko et al., 2008), the levels of intracellular core for HJ3-5 
(S168G) virus were comparable to the wt HJ3-5 virus, but extracellular core was dramatically 
decreased (Yi et al., 2009). This fits with the hypothesis that S168 is involved in a maturation 
step is required to confer infectivity and facilitate virus particle release, which, if not 
completed, results in degradation of the uninfectious particles, via the proteasome 
(Gastaminza et al., 2008).  
Together these data advocate the hypothesis that S168 plays a role in virus morphogenesis 
prior to release, and that final maturation of virions likely requires the formation of 
protein:protein interactions between NS2 and NS5A.  
S168 is highly conserved in all genotypes except genotype 4a where it is a threonine. 
Interestingly, NS2 T168S was identified as a culture adaptive mutation in a genotype 4a/2a 
chimeric virus encoding core-NS2 from the genotype 4a sequence (Scheel et al., 2008). It is 
possible that the interacting domain of NS5A in genotype 4a viruses may vary from other 
genotypes such that it favours a threonine at this site. 
1.8.5 Interactions between NS2 and other HCV proteins 
Numerous reports have demonstrated physical interactions between NS2 and other viral 
proteins (Figure 1.11). Stapleford and Lindenbach generated several clones of the Jc1 virus 
with inserted biotin-acceptor sites and expressed them in a modified Huh7.5 cell line 
expressing a codon optimised, secreted form of the biotin ligase BirA – Huh7.5 (BirA) 
(Stapleford & Lindenbach, 2011).  Using this system it was found that biotin-tagged E2 in the 
context of full-length virus was able to interact with NS2 and NS3 while biotin-tagged NS2 
interacted with E2 and NS3 (Stapleford & Lindenbach, 2011). Mutagenesis whereby an alanine 
was inserted following aa 16, aa 41 and aa 82 in order disrupt the helical face of the 3 putative  
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Figure 1.11 Cartoon of the interactions between NS2 and the other viral proteins. 
NS2 (green) forms interactions with the other viral proteins. Arrows denoted whether the 
interaction was shown to be disrupted by the p7 basic loop mutation (purple) or not (pink). 
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TMDs (defined by Jirasko et al., 2010) was combined with deletion mapping to suggest that the 
E2 interacting domain of NS2 was between aa 32-62 i.e. within the putative second TMD 
(Popescu et al., 2011). 
Interactions between NS2 and NS3 have been reported in a wide range of other systems 
(Dimitrova et al., 2003; Jirasko et al., 2008; Kiiver et al., 2006). Several mutations within the 
NS2 trans-membrane that reduced infectivity also impaired the NS2:NS3 interaction. The 
interaction could be partially recovered by compensatory mutations in other proteins that also 
recovered infectivity (Jirasko et al., 2010). A loss of the NS2:NS3 interaction was noted in the 
Δp7 virus but not the ΔE1/E2 virus, suggesting the NS2:NS3 interaction is dependent upon p7 
and perhaps independent of the glycoproteins (Stapleford & Lindenbach, 2011). Interestingly 
the interaction was also reduced when NS2 and NS3 were separated by a second IRES 
(Stapleford & Lindenbach, 2011). NS2 and p7 have been shown to interact directly by 
immunoprecipitation studies (Ma et al., 2011; Popescu et al., 2011) and FRET-FLIM 
(fluorescence resonance energy transfer with fluorescence lifetime imaging microscopy) 
(Popescu et al., 2011). The interaction appears to be genotype-independent and it is the trans-
membrane domain of NS2, not the catalytic domain, that interacts with p7 (Boson et al., 2011; 
Popescu et al., 2011). Replacement of the coding sequence for aa 1-27 of NS2 in the JFH-1 
virus with that of the Con 1 sequence reduced infectivity and impaired the ability of NS2 to co-
immunoprecipitate E2, NS3 and NS5A (Jirasko et al., 2010). However, addition of the E3D 
rescue-mutation within p7 recovered infectivity and the NS2 interactions providing further 
evidence that NS2 and p7 interact via their respective N-terminal domains. This also suggested 
that the NS2:p7 interaction is important for the interaction between NS2 and the other virus 
proteins (Jirasko et al., 2010). However, the role of p7 in determining the interactions between 
NS2 and other virus proteins is inconsistent as experiments using full-length JFH-1 virus found 
the NS2:E2 interaction to be independent of p7 (Popescu et al., 2011).  Mutation of the p7 
basic loop dramatically disrupts normal protein function as it blocks p7 membrane insertion, 
abolishes p7 ion-channel function (StGelais et al., 2007) and increases the degradation of NS2 
and p7 (Tedbury et al., 2011). Introduction of the p7 basic loop mutation into full length HJ3-5 
virus was lethal and abrogated the NS2:E2, NS2:NS3 and NS2:NS5A interactions (Ma et al., 
2011), suggesting p7 maybe stabilise or facilitate the NS2:protein interactions.  
NS2 has been shown to interact with E1 from virus expressing cells (Ma et al., 2011; Popescu et 
al., 2011). Long-term culturing of a triple chimeric virus, where the NS2 coding sequence was 
transposed with that of the H77 isolate in the Jc1 background (J6/H77/JFH – Figure 1.10), 
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produced an adaptive mutation in E1 (A269T), suggesting direct interaction between E1 and 
NS2 (Dentzer et al., 2009). However, disruption of E1:E2 hetero-dimerisation (Ciczora et al., 
2007) abolished the E1:NS2 interaction which is consistent with E1 interacting with NS2 via its 
association with E2 (Stapleford & Lindenbach, 2011). An interaction between NS2 and NS4A 
has been reported and truncation mapping revealed that aa 74-134 of NS2 were sufficient to 
immunoprecipitate NS4A (Flajolet et al., 2000).  
NS2 has also been shown to interact with NS5A, although the interaction is weak compared to 
other NS2 interactions (Jirasko et al., 2010). Interestingly, it was reported that NS2 
preferentially binds the p56 form of NS5A (Jirasko et al., 2010). Confirmation of the NS2:NS5A 
interaction is lacking though as one study found that NS2 was able to IP NS5A but that this is 
not reciprocal (Ma et al., 2011), while another group observed no physical interaction between 
the two proteins (Stapleford & Lindenbach, 2011). This may be a reflection of a weak 
interaction between NS2 and NS5A or that the tagging methods used produced steric clashes 
(Stapleford & Lindenbach, 2011). The latter may be less likely as NS2 interactions with E2 and 
NS3 were consistent across studies using a variety of tagging methods. It has been reported 
that the NS2:NS5A interaction is dependent upon p7 (Ma et al., 2011; Tedbury et al., 2011).  
Despite the inference of a core:NS2 interaction from an NS2-based rescue mutant of a non-
infectious core mutation (Murray et al., 2007), no physical interaction has been observed 
between core and NS2 by numerous co-immunoprecipitation studies.  
1.8.6 High molecular weight NS2-containing complexes 
High molecular weight complexes were obtained from virus-infected cells and, following blue-
native polyacrylamide gel electrophoresis (BN-PAGE), they were found to contain a proportion 
of E1, E2, NS2 and NS3 (Stapleford & Lindenbach, 2011). The formation of high molecular 
weight complexes containing both E1 and E2 have been reported previously, although the 
presence of NS2 was not addressed (Vieyres et al., 2010). The glycoproteins present within the 
NS2-containing complexes were sensitive to Endo H glycosidase suggesting that they contained 
unmodified, high-mannose glycans indicative of retention in a pre-Golgi compartment 
(Stapleford & Lindenbach, 2011). This was consistent with the identification of ER-retention 
signals within the glycoproteins (Cocquerel et al., 1999; Cocquerel et al., 1998). The presence 
of p7 and NS4A within high molecular weight NS2-containing complexes was not determined. 
E1 has been shown to interact with core (Lo et al., 1996) but core was absent from NS2-
containing complexes, as was NS5A (Stapleford & Lindenbach, 2011). As not all of the protein 
species were incorporated into these complexes the core:E1 interaction may well involve a 
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different sub-population of E1, such as E1 that is not dimerised with E2, or perhaps the core:E1 
interaction occurs at a later stage in virion assembly following dissociation from the NS2-
containing complexes. 
Formation of NS2-containing complexes was impaired by the insertion of a second IRES 
between E2/p7, p7/NS2 and NS2/NS3 and, although replication was not affected by the 
introduction of a second IRES, TCID50 was reduced by 2 logs (Stapleford & Lindenbach, 2011). 
IRES insertion between p7 and NS2 disrupted the protein:protein interaction of these two 
proteins, similarly a reduction in the NS2:NS3 interaction was observed when NS2 and NS3 
were separated by an IRES (Stapleford & Lindenbach, 2011). Mutation of residues key to E1/E2 
hetero-dimerisation demonstrated that E1 is incorporated into the complexes via interaction 
with E2 (Stapleford & Lindenbach, 2011). It was reported that these complexes did not form in 
the uninfectious Δp7 virus suggesting p7 plays a key role in complex formation, however no 
data was presented to substantiate this (Stapleford & Lindenbach, 2011).  
Analysis of previously characterised NS2 mutations that caused a reduction in virus infectivity 
(Phan et al., 2009) revealed that K27A, W35A, Y39A and E45K severely reduced or abrogated 
the NS2:NS3 interaction, while the mutations K81A and P89A disrupted the interactions 
between NS2 and the glycoproteins (Stapleford & Lindenbach, 2011). The Q221L mutation in 
NS3 and the A78T mutation in E1, which rescued the NS2 K27A and the NS2 K81A mutations 
respectively, failed to restore the impaired protein interactions, indeed the A78T mutation in 
E1 appeared to further impair the ability of NS2 to interact with the glycoproteins (Stapleford 
& Lindenbach, 2011). As this implied that not all of the NS2 interactions were essential for 
virion assembly it was hypothesised that NS2 may ordinarily alter the function of the 
glycoproteins and protease complexes, but that these compensatory mutations bring about 
these alterations in an NS2-independent manner (Stapleford & Lindenbach, 2011). 
1.8.7 Role in Replication 
NS2 is not required for replication of the viral genome and its inclusion in SGRs had a negative 
effect on HCV RNA replication in comparison to NS3-5B replicons (Lohmann et al., 1999; 
Tedbury et al., 2011). Mutation of 27 highly conserved NS2 residues in a mono-cistronic Jc1 
virus (Phan et al., 2009) and 14 residues in both a mono and a bi-cistronic J6/H77/JFH virus 
(Dentzer et al., 2009) found that replication was only inhibited when NS2/3 cleavage was 
impaired, providing further evidence that that NS2 is unlikely to play a role in genome 
replication. The apparent negative regulation of RNA replication by NS2 observed in the 
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replicon systems may be resultant of NS2 interacting with the other non-structural proteins 
and directing them to prospective sites of virus assembly. 
1.8.8 Role in Assembly 
NS2 has been shown to play a vital role in virus assembly (Jones et al., 2007) and was 
hypothesised to form a link between replication complexes and virus factories (Dimitrova et 
al., 2003; Pietschmann et al., 2006). Naturally occurring inter-genotypic chimeric viruses have 
been isolated from patients where recombination has taken place within NS2 (Kalinina et al., 
2002; Noppornpanth et al., 2006). Numerous groups have generated viable chimera in the lab, 
based upon the JFH-1 isolate (Lindenbach et al., 2005; Lindenbach et al., 2006; Mateu et al., 
2008; Pietschmann et al., 2006; Scheel et al., 2008; Yi et al., 2007). A study generating and 
characterising chimeric viruses, where the JFH-1 structural proteins were replaced with those 
of another isolate, found that all but one virus (a genotype 3a/2a chimera) produced highest 
titres when the point of recombination was after residue 33 in NS2 (Pietschmann et al., 2006). 
These phenomena have led some to speculate that the N-terminal domain of NS2 forms 
interactions with the structural proteins, while the catalytic domain may form interactions 
with the non-structural proteins. 
The exact mechanism by which NS2 contributes to infectivity is poorly understood. It has been 
demonstrated that both the trans-membrane and catalytic domains are essential, although 
catalytic activity is dispensable (Jirasko et al., 2008; Jones et al., 2007). Indeed, many of the 
conserved residues within NS2 appear to have roles in efficient virus production independent 
of NS2 protease activity, such as S168. Yet, viruses encoding lethal NS2 deletions (aa 10-62, 
aa32-96 and aa 97-217) can be trans-complemented by SGRs encoding wt NS2 (Jirasko et al., 
2008). 
As mentioned in section 1.8.5; the role of NS2 protein interactions remains unclear. The 
delayed virus kinetics observed when NS2 and NS3 were separated by an IRES (Jones et al., 
2007; Stapleford & Lindenbach, 2011) could be resultant of impaired interactions between the 
two proteins (Stapleford & Lindenbach, 2011). No compensatory mutation is known of that 
rescues an attenuated NS2 mutant with an impaired NS2:NS3 interaction, without 
concomitantly partially recovering the NS2:NS3 interaction. Therefore this interaction may be 
pivotal to infectious virus production. 
NS2 expressed in isolation has a diffuse cellular distribution and co-localises with ER markers 
(Franck et al., 2005; Kim et al., 1995; Yamaga & Ou, 2002; Yang et al., 2006). In virus-expressing 
cells NS2 and E2 co-localise early on with diffuse, cytosolic distributions (Jirasko et al., 2010; Yi 
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et al., 2009) with the formation of more punctate structures between 48h and 72h (Ma et al., 
2011; Popescu et al., 2011; Tedbury et al., 2011). A similar pattern, but with a lower degree of 
co-localisation, was also observed between NS2 and NS3 (Jirasko et al., 2010). NS2 in these 
punctate structures co-localises with lipid droplets (LD) and NS5A, although NS5A associates 
with LD independently of NS2 (Jirasko et al., 2010; Ma et al., 2011; Popescu et al., 2011). No 
co-localisation has been observed between core and NS2 around LD (Jirasko et al., 2010; 
Popescu et al., 2011; Yi et al., 2009). As core has been shown to accumulate on lipid droplets 
(Barba et al., 1997) it was hypothesised that NS2 facilitates assembly by conveying the 
glycoproteins and aspects of the replication complex to sites of virion assembly on lipids 
droplets. 
Exchanging of the putative first TMD of NS2 within the full length JFH-1 isolate with that of 
another isolate reduced infectivity and resulted in the recruitment of E2 and NS3 to LD being 
blocked and severely impaired, respectively (Jirasko et al., 2010). The ability of NS5A to co-
localise with LD was unaffected. Introduction of rescue mutations restored the association of 
E2 and NS3 with LD, suggesting that NS2 mediates the association of these proteins with LDs 
(Jirasko et al., 2010). Furthermore, deletion of the TMD of E2, deletion of p7 and mutation of 
the p7 basic-loop all abolished the localisation of NS2 and E2 to punctate structures, 
suggesting a complex interaction between E2, p7 and NS2 (Ma et al., 2011; Popescu et al., 
2011).  
It has been proposed that while nucleocapsid assembly may take place on lipid droplets in the 
absence of NS2 (Miyanari et al., 2007), addition of the glycoproteins and particle maturation 
may occur at the ER or ER-derived sites in proximity to NS2 (Jirasko et al., 2010; Stapleford & 
Lindenbach, 2011). Assembly defective mutants had markedly less NS2 associated with lipid 
droplets, but this association was partially recovered by rescue mutations (Jirasko et al., 2010).  
A recent report observed that core is predominantly localised to lipid droplets in the JFH-1 
virus, but it co-localises to the ER with the virus glycoproteins and calnexin in the more 
infectious Jc1 virus (Boson et al., 2011). It was discovered that this differential localisation 
influences the infectivity of the HCV as long-term culturing of the wt JFH-1 virus identified 
higher titre mutants in which core was re-distributed to ER membranes. Co-expression of core 
protein from each isolate with core-NS2 from the opposing isolate inverted the core 
localisation phenotypes, and further co-expression studies identified NS2 and p7 to be 
responsible for core localisation. This role was shown to be dependent upon interactions 
between the C-terminal helix of p7 and aa 5-43 of NS2. Mutation of the p7 basic-loop blocked 
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the influence of p7 and NS2 on core re-distribution (Boson et al., 2011). This evidence favours 
the hypothesis that while lipid droplets may be a reservoir for core and other virus proteins, 
assembly takes place at the ER (McLauchlan, 2009). The mechanism by which NS2 and p7 are 
able to modulate core localisation is confused by the reports that NS2 and p7 do not co-
localise with or immunoprecipitate core and that core was not detected in high molecular 
weight NS2-containing complexes (Jirasko et al., 2010; Ma et al., 2011; Popescu et al., 2011; 
Stapleford & Lindenbach, 2011).  
1.8.9 Cellular interactions 
NS2 appears to impose a generally suppressive effect on promoter-controlled gene expression 
(Kaukinen et al., 2006). Reporter gene expression controlled by hCMV, HBV and simian virus – 
40 (SV-40) promoters, as well as the cellular tumour necrosis factor-α (TNF-α), ferrochelatase 
and nuclear factor κB (NF-κB) regions promoter/enhancer sequences, was inhibited by NS2 
expression. Over-expression of core, E1 and p7 did not inhibit reporter expression (Dumoulin 
et al., 2003). General inhibition of cellular promoters and suppression of gene expression 
controlled by the NF-κB promoter by NS2 compared to empty vector has also been described 
by Yang et al., (Yang et al., 2006). Yang and colleagues also found that NS2 expression reduced 
cell proliferation and this was attributed to NS2-mediated down regulation of cyclin A (Yang et 
al., 2006). However, conflicting data describing NS2-mediated stimulation of interleukin - 8 (IL-
8) production, through activation of the NF-κB promoter (Oem et al., 2008a), and fatty acid 
synthase (FAS) gene expression, as a result of up regulation of the transcription factor sterol 
regulatory element-binding protein 1c (SREBP-1c) by NS2 (Oem et al., 2008b), have been 
reported. As all of these studies were conducted using over-expressed NS2 in isolation from 
the other viral proteins the validity of these observations in the context of a natural infection 
remains to be demonstrated.  
Residues 99-139 of NS2 were shown to interact with the cellular pro-apoptotic protein cell 
death-inducing DNA fragmentation factor (DFF) 45-like effector (CIDE)-B using a yeast two-
hybrid system (Erdtmann et al., 2003). NS2 co-localised with CIDE-B by confocal 
immunofluorescence (IF) microscopy and it was shown that NS2 interacts specifically with the 
liver-associated CIDE-B protein and not the non-hepatic homologue CIDE-A. NS2 was shown to 
prevent CIDE-B-induced cytochrome c release from mitochondria, and thus inhibit apoptosis 
(Erdtmann et al., 2003). Unfortunately, an attempt to verify this interaction in virus-infected 
cells by immunoprecipitation of tagged-NS2 was unsuccessful (Stapleford & Lindenbach, 2011). 
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1.9 NS2 in related viruses  
HCV NS2 does not appear to have a homologue within the Flaviviruses. The sequence 
upstream of NS3 in the Flaviviruses encodes two proteins termed NS2A and NS2B. Catalysis of 
the NS2A/NS2B and NS2B/NS3 junctions is carried out by the NS3 protease. NS2B is thought to 
span the membrane twice and acts as the protease co-factor (Falgout et al., 1991). NS2A is 
thought to span the membrane three times and is a vital component of the replicase 
(Khromykh et al., 2000). NS2A has been shown to undergo an additional cryptic cleavage 
event, mediated by NS3, to produce the NS2Aα protein (Nestorowicz et al., 1994).  
The Pestiviruses, of which BVDV is the prototype species, are more closely related to the 
Hepaciviruses and BVDV NS2 shares common features with HCV NS2. The N-terminus of BVDV 
NS2 is cleaved by signal peptidase and NS2 catalyses auto-cleavage of the NS2/3 junction 
(Lackner et al., 2004); however this event requires the coordination of the cellular factor J-
domain protein interacting with viral protein (Jiv) at two distinct sites (Lackner et al., 2005; 
Lackner et al., 2006; Rinck et al., 2001). Efficient cleavage of the NS2/3 junction correlates with 
replication and is essential for the cytopathogenicity of BVDV (Rinck et al., 2001). The 
dependence of NS2/3 cleavage on cellular Jiv is pivotal to the establishment of a persistent 
infection by BVDV (Lackner et al., 2005). 
In contrast to HCV the NS2 protein in Pestiviruses contains the zinc coordination motif rather 
than NS3 (Lackner et al., 2004). A further difference between the genera is that although 
Pestivirus NS2 functions in virus assembly, it does so only as part of an uncleaved NS2/3 
precursor which is essential for infectious virus production (Agapov et al., 2004). 
In common with HCV NS2, expression of classical swine fever virus (CSFV) NS2 in isolation was 
found to induce ER-stress, activate transcription via NF-κB and induce an S-phase cell-cycle 
arrest by inducing cyclin A degradation (Tang et al., 2010). A recent report proposed that CSFV 
NS2 contains four TMDs and contains two signal sequences using a combination of 
computational prediction and deletion mapping (Guo et al., 2011).  
1.10 Mechanisms for protein targeting to membranes 
Nascent mammalian membrane proteins destined for cellular organelles or the cell surface are 
translated at the ER membrane. The growing peptide encodes an N-terminal signal peptide 
that is recognised by the signal recognition particle (SRP) that temporarily stalls translation and 
targets the ribosome to the ER membrane. This complex then joins with the translocon to 
insert the signal peptide into the membrane and reinitiate translation of the peptide into the 
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translocon, into the ER lumen or the membrane bi-layer (Grudnik et al., 2009; Saraogi & Shan, 
1111). The translocon in mammalian cells consists of three or four copies of the sec61 
heterotrimer, which form an aqueous pore within the ER membrane (Hanein et al., 1996), and 
the ATPase and pore-gating protein BiP (Hamman et al., 1998). 
Targeting of nascent polypeptides to membranes independently of a signal peptide has been 
reported in E. coli (Bornemann et al., 2008), although this was speculated to be a 
compensatory mechanism for the lack of elongation arrest function which is provided by the 
Alu domain of the mammalian SRP (Saraogi & Shan, 2011).  
The manner in which trans-membrane proteins are inserted into the ER membrane is thought 
to occur by one of two routes. The ‘en masse’ hypothesis asserts that all of the TMD of a 
nascent polytopic membrane protein are translated and held in the lumen of the translocon 
and released into the membrane as a mature protein (Borel & Simon, 1996). The spatial 
constraints of the translocon pore has led some to exclude the en masse model in the case of 
large polytopic proteins; in favour of another model that where TMDs exit the translocon 
‘sequentially’ upon formation or perhaps upon reaching a limit of the translocon pore size 
(Mothes et al., 1997).  
1.11 Systems for studying protein topology 
Determining the topology of trans-membrane proteins is fundamental to our understanding of 
their function. Attempts to resolve the structure of trans-membrane proteins are hampered 
due to their inherent hydrophobic nature, making it difficult to achieve the solubility that is 
required for crystallisation. Consequently, numerous different biochemical techniques have 
been developed to study the topology of membrane proteins. A selection of cell-based and in 
vitro topology investigation techniques are described below. 
1.11.1 Topology prediction 
Numerous computational programs are available and produce varying forms of topology 
prediction based upon database information, relative hydropathy values assigned to each 
amino acid (Kyte & Doolittle, 1982)(Appendix 2), sequence alignment with topologically 
defined homologues and more global traits like the ‘positive inside rule’ (Hartmann et al., 
1989; Heijne, 1986) whereby positively charged residues are four times more likely to reside 
on the cytosolic face of a membrane. More complex modelling algorithms have been 
generated using hidden Markov models (HMM) with Bayesian networks and statistically 
averaging the outputs of numerous individual programs. These programs do not take into 
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account intra-protein interactions, such as salt bridges, or lipid-protein interactions, such as 
dynamic membrane domains or amphipathic helices (Ott & Lingappa, 2002). Prediction of 
prokaryote membrane proteins is most accurate due to the number of proteins on which to 
base, confirm and refine predictions. Eukaryote proteins have an added diversity in that the 
lipid composition of membranes of different cellular compartments varies, affecting the pKa of 
local protein side-chains (van Klompenburg et al., 1997), and this can significantly influence the 
topology and targeting of trans-membranes proteins (Bogdanov et al., 2005).  
The membrane-spanning domains of viral proteins provide an additional challenge to topology 
prediction as they may not follow exactly the same rules as host membrane proteins such as 
helix length. They may also be intentionally different in order to manipulate the cellular 
environment such as in generating the ‘membranous web’ characteristic of many positive-
sense RNA virus families (den Boon & Ahlquist, 2010). As result, these programs are used as a 
basis for further biochemical analysis.  
1.11.2 Fusion with reporter proteins 
Reporter proteins such as alkaline phosphatase (PhoA), β-galactosidase (β-gal) and β lactamase 
(β-lac) are commonly used for the determination of integral membrane-protein topology 
(Bogdanov et al., 2005). Reporter molecules are expressed as fusions to the C-terminus of a 
series of C-terminal truncations of the protein of interest. C-terminal truncations are typically 
used as the orientation of the N-terminal TMD was proposed to directly influence the 
orientation of subsequence TMDs within the protein (Hartmann et al., 1989). Enzyme activity 
can be monitored by colourimetric or chemiluminescent assay. 
Dual reporter systems involve fusions of two reporters with complementary activity such that 
they are active on opposing sides of the target membrane. Alkaline phosphatase requires 
oxidation in the periplasm in order to become active, while β-gal appears to become trapped 
in the periplasmic membrane upon translocation as a fusion to a transmembrane domain 
(Georgiou et al., 1988). More recently PhoA and β-gal have been used as combined fusion 
where the PhoA gene is in frame with the β-galactosidase α-subunit of (LacZα). It this system 
the LacZα fragment is not toxic to bacteria but is still inactive if it is localised to the periplasm 
as its activity requires complementation with Ѡ-fragment localised exclusively to the cytosol 
(Alexeyev & Winkler, 1999; Alexeyev & Winkler, 2002; Korres & Verma, 2004). 
Antibiotics can be used as reporter fusion partners. The gene product of bla - β lactamase, is 
active in the periplasm but not in the cytoplasm. Conversely the product of the cat gene, 
chloramphenicol acetyltransferase, confers resistance when it is expressed in the cytoplasm 
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where there is a source of acetyl co-enzyme A (CoA) which is required for inactivation of the 
antibiotic. 
The main limitation of C-terminal reporter fusions is that they do not accommodate the 
possibility of long range or inter-helix interactions which may be required for correct topology. 
The ‘sandwich’ reporter system whereby the reporter is inserted into the full length protein 
has been found to give a more accurate topology (Ehrmann et al., 1990). This approach still 
suffers limitations as insertion of a non-native protein within the protein sequence may alter 
protein folding (of both the protein of study and the reporter which could lead to false results) 
and membrane insertion.  
1.11.3 Glycosylation site insertion  
Introducing glycosylation sites is a commonly used method whereby the coding sequence is 
altered to introduce the conserved glycosylation sequence Asn-X-Ser/Thr, where X is any 
residue except proline, or a peptide loop domain containing a known glycan acceptor site. N-
linked glycosylation is highly dependent upon the size of the luminal loop as 
oligosaccharyltransferase (OST) requires 12 residues upstream and 14 residues downstream 
between the Asn-acceptor residue and the reticular membrane in order to catalyse the 
reaction (Nilsson & von Heijne, 1993). If the asparagine (Asn) residue is suitably exposed within 
the lumen of the ER it will be N-glycosylated by the addition of a polysaccharide 
(Glc3Man9GlcNAc2) to its amine group by OST. The addition of this oligosaccharide results in a 
molecular weight increase that is detectable by SDS PAGE. The two N-acetylglucosamine 
molecules (GlcNAc) form the chitobiose core and are fused directly to the Asn-acceptor 
residue. The glycan moiety of a protein trafficked via the Golgi can undergo maturation where 
the high-mannose chain is removed and replaced with complex or hybrid oligosaccharide 
chains. Endoglycosidase H (Endo H) only cleaves within the chitobiose core of high mannose 
and some hybrid oligosaccharides (Maley et al., 1989). Peptide: N-Glycosidase F (PNGase F) 
cleaves nearly all types of N-linked glycan chains except those containing core α1-3 fucose 
(Tretter et al., 1991) and cleaves between the Asn-acceptor residue and the chitobiose core 
(Maley et al., 1989). As glycosylation occurs exclusively in the ER, this can be used to 
determine the orientation of a protein domain about the ER membrane.  
1.11.4 Partial membrane permeabilisation 
Partial or selective membrane permeabilisation can be achieved using a number of 
compounds. Digitonin is a detergent produced by Digitalis purpurea while streptolysin-O (SLO), 
a toxin obtained from Streptococci and Escherishia coli (E. coli). Both digitonin and SLO are 
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selective for cholesterol-rich membranes and produce pores of variable sizes. At the right 
concentration these toxins are specific for the plasma membrane (Bhakdi et al., 1993; Dunn & 
Holz, 1983) so optimisation is required to achieve pores large enough for antibody infiltration 
into cells without compromising cellular integrity or intracellular compartments. 
Other methods of partial permeabilisation of the plasma membrane include dilute 
concentrations of detergents such as Tween20 or saponin, repeated cycles of freeze thaw 
action or other toxins such E. coli haemolysin and Staphylococcus aureus α-toxin.  
Digitonin and SLO treatment has recently been combined with confocal IF microscopy to 
examine the topology of human papilloma virus (HPV) early protein 5 (E5) which localises to ER 
membranes and shown to form a three TMD topology using this method (Krawczyk et al., 
2010). 
1.11.5 Protease protection studies 
Protease protection studies can be performed using trypsin or proteinase K treatment of 
labelled protein expressed in vitro in the presence of microsomal membranes (MM) and with 
or without membrane solubilisation. Any remaining protein can be visualised by SDS PAGE gel. 
This system can be used in combination with N and C-terminal truncations to identify the 
protected domain. Protease protection was used in a yeast expression system in combination 
with glycosidase treatment and reporter fusion activity to characterise the unstable nature of 
TMD 6 of the cystic fibrosis transmembrane conductance regulator (CFTR) (Tector & Hartl, 
1999). 
Protease protection method has twice been applied to the study of NS2 topology in vitro and 
on both occasions the majority of the protein, including the C-terminus, was determined to be 
oriented to the ER lumen (Santolini et al., 1995; Yamaga & Ou, 2002). This method can also be 
applied, in combination with selective permeabilisation of the plasma membrane, to cell-
expressed proteins resident on intracellular membranes. Interestingly it has recently been 
used to investigate the topology of NS2 expressed from the viral polyprotein and it was found 
that in this system the majority of the protein, including the C-terminus, was localised to the 
cytosol (Ma et al., 2011).  
1.11.6 Fluorescence protease protection (FFP) 
FFP is in combination with partial permeabilisation and protease digestion; GFP, or 
fluorophore derivatives, are expressed as terminal fusions to the protein of interest and 
viewed by microscopy (Lorenz et al., 2006a). Cell plasma membranes are selectively 
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permeabilised with digitonin following fixation and then trypsin is added. Cells are viewed with 
and without trypsin treatment and if fluorescence remains then the fluorophore is inferred to 
be luminal oriented. This can be confirmed by immunofluorescence labelling of control 
proteins and fully permeabilising cells with detergent, followed by addition of trypsin, which 
should abolish any fluorescence. FFP has been used in the topology investigation of vesicle 
surface kinase 3 (VSK3) (Fang et al., 2007). 
1.11.7 Antibody Epitope insertion 
Epitope insertion involves the systematic insertion of an antibody recognition sequence 
throughout the protein avoiding potential disruption caused by C-terminal deletions and 
reducing the potential impact caused by insertion of large reporter enzymes. In a polytopic 
membrane protein the orientation of the epitope about the membrane will determine its 
accessibility to antibody detection following selectively permeabilising cells for IF microscopy. 
Using a small epitope that is unlikely to disrupt topology is best. Similar to FFP this technique 
requires the selective permeabilisation of the plasma membrane followed by indirect IF 
detection of the epitope tag which can be blocked by proximity of the epitope to the 
membrane bi-layer or by protein structure.  
1.11.8 Specific cleavage motif insertion 
A consensus cleavage motif for a specific proteinase, such as tobacco etch virus (TEV) 
protease, is systematically inserted throughout the protein. This system is typically used in 
vitro where the protein is translated in the presence of MM and the enzyme is added either 
with or without membrane permeabilisation in order that the orientation of the cleavage site 
can be determined. This method has met with limited success as access to the cleavage site 
can suffer the same impedances as epitope insertion analysis (Henderson et al., 2004).  
1.11.9 Trans-Membrane Domain Trapping 
Sugano et al., (Sugano et al., 1998) described a method of screening cDNAs for the presence of 
trans-membrane domains that they termed ‘trans-membrane domain trapping’. This method 
involves the expression of cDNA from a single ORF in frame with a signal peptide and the IL-2 
receptor alpha-chain as a detection epitope. If the cDNA encodes a TMD it presents the IL-2 
domain to the extracellular face of the plasma membrane, if not the epitope domain is 
secreted into the extracellular media or retained within the cell. Surface expression of the IL-2 
epitope is determined by indirect immunofluorescence microscopy.  
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1.11.10 SCAMTM 
Another technique is substituted cysteine accessibility method for trans-membrane topology 
(SCAMTM), which involves replacing single amino acids with cysteine residues (Bogdanov et al., 
2005). Maleimides react with the thiol groups to form a stable thioester bond that is non-
reducible by β-mercaptoethanol or dithiothreitol (DTT). Identification of modified cysteine 
containing proteins can be done by various methods based on the principle of fusion of the 
maleimide with a radiolabel, a biotin-tag, a fluorophore or as an appreciable size increase 
following SDS PAGE analysis. Cytoplasmic cysteine residues can be determined by partially-
permeabilising the cell membrane and introducing a membrane impermeable thiol-specific 
reagent. Direct identification of luminal regions can be achieved by quenching thiol reactive 
groups (with a thiol reagent that is transparent in the detection phase) in partially 
permeabilised cells followed by complete permeabilisation and addition of a detectable thiol 
reagent.  
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1.12 Aims 
At the undertaking of this work little was known of the membrane topology of NS2 in cells and 
that which had been reported was contradictory to known localisation of the cleavage events 
that release mature NS2 from the HCV polyprotein. It had recently been demonstrated that 
deletion of NS2 from the virus prevented infectious virion production. However, the manner in 
which NS2 facilitates virus particle assembly, and the significance of NS2 membrane topology 
has in this role, was similarly unknown.  
In this study a series of C-terminal truncations of NS2 were generated to investigate the 
membrane topology of NS2. In response to these findings, and those reported within the field, 
a further set of truncations were generated to investigate the membrane targeting, subcellular 
localisation and protein interactions of NS2, specifically the NS2:E2 interaction and NS2 
oligomerisation. These studies were carried out in a mammalian cell expression system to 
validate and expand upon previously published in vitro data regarding NS2 topology and to 
further explore the role of the NS2 trans-membrane domain in forming protein:protein 
interactions with the other viral proteins. 
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2.1 Materials  
2.1.1 Bacterial strains and culture conditions 
Escherichia coli (E. coli) DH5α genotype: F- φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17(r
k
-
, m
k
+
) phoA supE44 thi-1 gyrA96 relA1 λ
- 
(Invitrogen) were used for cloning.  
Bacteria were cultured in Luria-Bertani (LB) liquid medium (1% w/v bacto-tryptone, 0.5% w/v 
Bacto-yeast extract, 171 mM NaCl, pH7.0) or isolated as single clones on solidified LB 
containing 1.5% w/v bactoagar, at 37°C with sufficient aeration. Cultures were supplemented 
with 100 g/ml ampicillin or 50 g/ml kanamycin where appropriate. 
Chemically competent bacteria were produced by the Inoue method (Sambrook, 2001)(section 
2.2.1.12). 
2.1.2 Mammalian cell lines and culture conditions  
Protein expression was carried out in Huh7 cells, a human hepatocellular carcinoma cell line 
susceptible to propagation of HCV subgenomic replicons and full-length virus; and COS7 cells, a 
simian cell line endogenously expressing the SV40 large T antigen which increases plasmid DNA 
copy number by episomal plasmid replication. 
Huh7.5 cells, a derivative of the Huh7 cell line shown to support higher levels of replication of 
replicons (Lohmann et al., 1999), stably harbouring the SGR NS3-5B and SPp7-B (Tedbury et al., 
2011) were maintained in 250 ng/ml G418. 
Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) supplemented 
with 10% v/v foetal bovine serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin and 2 
mM L-glutamine and incubated at 37°C in a humidified incubator with  5% CO2. Culture 
medium for Huh7 cells was additionally supplemented with 1% v/v non-essential amino acids 
(Cambrex). Huh7 cells used to culture virus were supplemented with 10 mM HEPES. 
Cells were passaged by washing in phosphate buffered saline (PBS) pH 6.8 prior to incubating 
with trypsin-EDTA solution pH 8 (Sigma Aldrich) to disassociate cells from growth surface. Cells 
were mechanically resuspended in culture medium, quantified using a haemocytometer and 
seeded into fresh culture medium at the desired density. 
2.1.3 Virus sequences 
HCV sequences: 
EUHK2 -  genotype 6a, accession number: Y12083 
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EUH1480 -  genotype 5a, accession number: Y13184 
ED43 -  genotype 4a, accession number: GU814265 
NZL1 -  genotype 3a, accession number: D17763 
JFH-1 -  genotype 2a, accession number: AB047639 
HC-J6 -  genotype 2a, accession number: D00944 
J4L6S -  genotype 1b, accession number: AF054247 
H77 -  genotype 1a, accession number: AF011753 
Con1- genotype 1b, accession number: AJ238799 
QC69 -  genotype 7a, accession number: EF108306 
Canine hepacivirus (CHV), accession number: JF744991 
GB virus B (GBV-B), accession number: AF179612 
2.1.4 Plasmids 
pSEAP2-control (Clontech) was used as the source of the secreted alkaline phosphatase (SEAP) 
gene and as a control in SEAP expression assays in mammalian cells. It carries an ampicillin 
resistance gene. 
pEBBLacZ and pcDNA3.1LacZ were kind gifts from Dr T. Tuthill and Dr A. MacDonald and were 
used as controls in β-galactosidase (β-Gal) expression assays. pEBBLacZ was used as the source 
of the LacZ gene. They both carry an ampicillin and a neomycin resistance gene. 
pJFH-1 was kindly provided by Dr T. Wakita. It carries an ampicillin resistance gene and was the 
source of HCV genotype 2a sequence segments. Culturing of bacteria containing pJFH-1 was 
carried out at 30°C. 
pCRBlunt (Invitrogen) was used as a cloning intermediate for polymerase chain reaction (PCR) 
products. It carries a kanamycin resistance gene. 
pcDNA3.1(+) (Invitrogen) was used for protein expression in mammalian cells. It carries an 
ampicillin and a neomycin resistance gene. 
peGFP-N1 and peGFP-C2 (Clontech) were used for the expression of GFP fusion proteins. Both 
encode resistance to kanamycin and neomycin. 
The following previously characterised plasmids were used: pSG5-NS5A-Flag (GB virus - B) 
(Mankouri et al., 2008b), peGFPC1Eps15, pSG5-NS5A (JFH-1) and pSG5-NS5A-eGFP (JFH-1) 
(Mankouri et al., 2008a), pFBM(JFH-1)core-p7 (Adair et al., 2009), peGFPC1(IBV)N-protein 
(Emmott et al., 2008) 
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pFBM(Con1)core-p7 was a kind gift from Dr C. McCormick and peGFPC1(HCV)NS4B was a kind 
gift from Dr S. Gretton. 
2.1.5 Antibodies 
Anti-NS2 serum (Rabbit) (A kind gift from Dr A. Pause) was used at 1:5,000 
Anti-NS5A serum (Sheep) was used at 1:5,000 (Macdonald et al., 2003) 
Anti-NS3 serum (Sheep) was used at 1:10,000 (Aoubala et al., 2001) 
Anti-E2 AP33 clone (Mouse) (A kind gift from Dr A. Patel) was used at 1:2,000 
Anti-placental alkaline phosphatase (PLAP) (SP15 - Abcam) was used at 1:500 
Anti-β-galactosidase (Rabbit) (AB1211 - Abcam) was used at 1:2,000 
Anti-GAPDH antibody (Mouse) (AB8245 - Abcam) was used at 1:30,000 
Anti-ICAM-I 208 clone (Rabbit) (A kind gift from Dr D. Rowlands) was used at 1:1,000 
Anti-FLAG M2 clone (Mouse) (F1804 – Sigma-Aldrich) was used at 1:5,000 for Western blotting 
or 1:1,000 for immunofluorescence microscopy. 
Anti-neomycin phosphotransferase II antibody (06-747 - UpState) was used at 1:5,000 
Anti-core serum (Sheep) was used 1:5,000 
Anti-GFP raised against full-length GFP (SC-8334 - Santa Cruz) was used 1:5,000 
Horseradish peroxidase (HRP) conjugated secondary antibodies; goat anti-rabbit, goat anti-
mouse and donkey anti-sheep (Sigma-Aldrich) were used at 1:10,000. 
Alexafluor conjugated secondary antibodies (Invitrogen) were used at 4 µg/ml for confocal IF 
microscopy. 
All antibodies were diluted 0.1% v/v Tween20, 5% w/v milk powder (Marvel) in phosphate 
buffered saline (PBS) for Western blotting or 1% w/v bovine serum albumin (BSA) in PBS for 
immunofluorescence staining. 
2.1.6 Chemicals 
Phenol, phenol:chloroform, phenol:chloroform:isoamyl alcohol (25:24:1), MOPS, G418 and 
dithiothreitol (DTT) were obtained from BDH.  
Chapter 2: Materials and Methods 
 
65 
 
Sodium dodecyl sulphate (SDS), magnesium chloride (MgCl2) and ethylenediamine tetraacetic 
acid (EDTA) were obtained from VWR. 
Formalydehyde, Triton X-100, Z-Leu-Leu-Leu-al (MG132), ONPG, and protease inhibitors 
(leupeptin, pepstatin, aprotinin and AEBSF (perfabloc)) were obtained from Sigma. 
Sodium chloride (NaCl), methanol, ethanol, tris (hydroxymethyl) aminomethane (Tris) and 
bovine serum albumin (BSA) were obtained from Fisher Thermoscientific.  
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), yeast extract and tryptone were 
obtained from Melford Laboratories.  
PEI was obtained from Polysciences, CDPStar was from Tropix and 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (X-gal) was from AnaSpec. 
2.2 Methods 
2.2.1 DNA manipulation 
2.2.1.1 Purification of DNA 
For plasmid DNA analysis small scale DNA purifications from 1 ml cultures were prepared by 
alkaline lysis. Bacteria from a single colony were inoculated into 1 ml of liquid LB medium 
containing appropriate antibiotic and cultured over night at 37°C. Bacteria were pelleted by 
centrifugation and resuspended in 50 µl liquid LB medium followed by the addition of 300 µl 
TENS lysis solution (10 mM Tris, 1 mM EDTA, 100 mM sodium hydroxide, 0.5% sodium dodecyl 
sulphate (SDS)) and thoroughly mixed. Lysates were neutralised with 150 µl 3 M sodium 
acetate pH 5.3 and cellular debris was removed by centrifugation followed by transferral of the 
supernatants to a fresh tube containing 900 µl ethanol (ice-cold to aid precipitation). Samples 
were mixed thoroughly and precipitates were collected by centrifugation, resuspension in 500 
µl 70% ethanol v/v and repeat centrifugation. The precipitated DNA was finally resuspended in 
50 µl of 10 µg/ml RNaseA. All centrifugation steps were carried out at 16,100 x g for 5 minutes. 
For large scale purifications of 400 ml cultures the Qiagen Maxiprep kit was used as per the 
manufacturer's instructions. For high purity small scale DNA preparations the Qiagen Miniprep 
kit was used. 
2.2.1.2 Quantification of nucleic acids  
Quantitation of nucleic acid preparations was performed by comparison of nucleic acid 
samples with markers of known concentration (Millenium Markers – Millipore; for RNA 
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samples and Hyperladder I – Bioline; for DNA samples) by agarose gel electrophoresis or by 
measuring the absorbance at 260/ 280 nm using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific) according to the manufacturer’s instructions. 
2.2.1.3 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used to amplify regions of the HCV JFH-1 sequence or the 
SEAP and β-gal genes using the high-fidelity polymerase pfu Turbo (Stratagene). PCR reaction 
mixtures comprised 1.25 mM deoxynucleotide triphosphates (dNTPs), 10-20 ng template 
vector DNA, 50 nM of each primer, 1.25 U Pfu Turbo DNA polymerase in a reaction volume of 
50 µl Pfu Buffer (Stratagene), 5% v/v dimethyl sulphoxide (DMSO). Reactions were initially 
denatured at 95°C for 30 seconds then subjected to 30 seconds of denaturing at 95°C, 30 
seconds of annealing at 65°C and extension at 70°C for an appropriate length of time. This was 
repeated for 20 cycles. An additional extension step of 10 minutes was used immediately prior 
to termination of amplification reactions. Gradient PCRs were used for PCR optimisation; the 
annealing temperature was varied from 55 – 70°C. 
2.2.1.4 QuikChange Mutagenesis  
Single amino acid mutations were introduced by QuikChange mutagenesis. Complimentary 
primers were designed with 17-20 nucleotides of homologous sequence flanking non-
homologous nucleotides. PCR was carried out as described in section 2.2.1.3. Following PCR 
reactions, parental DNA was degraded by Dpn I treatment. 20 U units of Dpn I and 10% v/v 
Buffer 4 (NEB) to PCR volume were added and samples incubated at 37°C for 1 hour. PCR 
reactions were then transformed into competent bacteria as described in section 2.2.1.13. 
2.2.1.5 Oligo-Cloning 
When oligo cloning was used complimentary oligonucleotides were synthesised with 5’ 
phosphate modifications and with appropriate over-hangs corresponding to the restriction 
endonuclease used in the cloning strategy. An 50 nM of each oligo was added to annealing 
reaction buffer containing 10 mM Tris-HCl, pH 7.5, 100 mM NaCl and 1 mM EDTA and 
incubated at 95°C for 10 minutes and allowed to equilibrate to room temperature over 1 hour. 
Annealed oligos were then incubated on ice prior to ligation (section 2.2.1.11) into pre-
digested vector, or stored at -20°C.  
2.2.1.6 Removal of protein from DNA solutions  
1 volume of dH2O and 2 volumes of phenol:chloroform:isoamylalcohol (25:24:1) (equilibrated 
with Tris pH 8.0) were added to DNA-protein mixtures and vortexed thoroughly. Samples were 
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then centrifuged at 16,100 x g for 5 minutes and the top, aqueous phase was collected as the 
DNA containing fraction. 
2.2.1.7 Restriction digestion of DNA  
Restriction digests were carried out in volumes of 20 µl containing the recommended buffer 
and 10-20 enzyme units according to the manufacturer’s guidelines. Digests were carried out 
for a minimum of 1 hour at the optimal temperature. For double digests using enzymes with 
differing optimal temperatures, the digest mix was incubated with the more heat stable 
enzyme for 1 hour at its optimal temperature prior to addition of the second enzyme and 
overnight incubation at the lower temperature. 
2.2.1.8 Agarose gel electrophoresis  
Gels were prepared by dissolving 0.8-1.0% w/v agarose in 0.5 x TBE (45 mM Tris, 45 mM boric 
acid, 1 mM EDTA) or 1 x TAE (40 mM Tris, 0.11% acetic acid, 1 mM EDTA) with the addition of 
10 ng/ml ethidium bromide. Gels were submerged in gel running tanks (Bio-Rad) containing 
either TBE or TAE and supplemented with a further 0.5 µg/ml ethidium bromide. Samples were 
equilibrated using TBE loading buffer (TBE buffer in 5% v/v glycerol containing Orange G dye) 
or TAE loading buffer (TAE buffer in 5% v/v glycerol containing bromophenol blue dye) and 
separated though the gel. The size of DNA fragments was determined by comparison with 
Hyperladder I (Bioline) markers. DNA bands were visualised using Gene Genius Bio-imaging 
System. 
2.2.1.9 Extraction of DNA from agarose gels  
DNA bands were excised from agarose gels and frozen at -20°C for 20 minutes. The gel slices 
were mashed with a pipette tip and twice the volume of phenol, equilibrated with Tris pH 8.0, 
was added. The mixture was vortexed and incubated at -80°C for 30 minutes. Thawed samples 
were added to ¼ volume v/v dH2O and vortexed thoroughly. Phases were separated by 
centrifugation at 16,100 x g for 5 minutes. The aqueous phase was collected and ethanol 
precipitated (section 2.2.1.10). Final DNA pellets were resuspended in an appropriate volume 
of dH2O. 
2.2.1.10 Ethanol precipitation of DNA 
Protein-free DNA suspensions were precipitated by the addition of 2 volumes of ice-cold 100% 
ethanol v/v and sodium acetate pH 5.2 to a final concentration of 100 mM. Samples were 
vortexed briefly and incubated at -20°C for 20 minutes. DNA was precipitated by centrifugation 
at 16,100 x g for 20 minutes. DNA pellets were washed in 70% ethanol v/v and resuspended in 
appropriate volumes of dH2O. 
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2.2.1.11 DNA ligation 
Ligation reactions were carried out in 20 µl volumes of T4 Ligase buffer (Invitrogen) containing 
1 Unit T4 Ligase with a 1:4 molar ratio of vector to insert. Ligations were incubated for 30 
minutes on the bench with subsequent overnight incubation at 4°C. 1 µl of ligation mix was 
transformed (section 2.2.1.13) into 50 µl aliquot of chemically competent DH5α E. coli (section 
2.2.1.12) following 30 minute and overnight incubations steps, and grown on solid LB-agar 
supplemented with the appropriate antibiotic over night at 37°C. 
2.2.1.12 Preparation of chemically competent bacteria - Inoue Method 
Competent bacteria were produced using the Inoue method as detailed in (Sambrook, 2001). A 
single bacterial culture was grown in 25 ml LB medium for 6‐8 h at 37°C with aeration. This 
starter culture was used to inoculate 250 ml LB medium and grown at 18°C with aeration until 
an OD
600 
of 0.55 was reached, taking approximately 16 hours. Bacterial cells were incubated in 
an ice water bath for 10 minutes and then collected by centrifugation at 2,500 x g for 10 
minutes at 4°C. The supernatant was removed and the bacterial pellet resuspended in 80 ml of 
ice cold Inoue transformation buffer (55 mM MnCl2 15 mM CsCl, 250 mM KCl, 10 mM 
piperazine-N,N′-bis(2-ethanesulfonic acid (PIPES)‐NaOH (pH 6.7)). The bacteria were again 
pelleted by centrifugation and resuspended in 20 ml cold Inoue transformation buffer by 
swirling. 1.5 ml of dimethyl sulfoxide (DMSO) (Sigma Aldrich) was added and mixed by swirling. 
The bacteria culture was stored on ice for 10 minutes and the bacteria aliquoted into 
pre‐cooled microfuge tubes and immediately snap frozen in liquid nitrogen, and stored at 
‐80°C. 
2.2.1.13 Transformation of Chemically Competent E. coli  
Transformation of chemically competent bacteria was carried out according to the Inoue 
method described by (Sambrook, 2001). Briefly, 100 ng of purified plasmid DNA or 1 µl of 
ligation reaction mix was added to 50 µl of competent bacteria and incubated on ice for 10 
minutes prior to heat-shocking at 42°C for 90 seconds. Bacteria were allowed to recover for 1 
hour in 500 µl LB medium before spreading out onto LB-agar plates supplemented with the 
appropriate antibiotic and culturing overnight. 
2.2.1.14 Colony Screening 
Large scale screening of transformed bacteria colonies was used during plasmid generation. 
Colonies were inoculated using a Gilson tip into 10µl dH2O in a 0.1ml PCR tube and incubated 
on the bench for 10 minutes, after which the tip was transferred to a 1ml culture containing 
the appropriate antibiotic and incubated overnight at 37°C. 10 μl of dH2O was used as the 
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template for a PCR reaction which was carried as described in (section 2.2.1.3). DNA from 1ml 
cultures of colonies screening positive by PCR was purified as described in section 2.2.1.1. 
2.2.1.15 DNA sequencing 
All plasmids and constructs were verified by analytical restriction digest and sequenced by ABI 
3130xl capillary sequencer analysis prior to subsequent use with appropriate primers. 
2.2.2 Cloning of DNA constructs 
A list of oligonucleotides used for cloning along with their sequences and usage are provided in 
Appendix 1. 
2.2.2.1 Generation of NS2-SEAP/β-gal reporter fusions 
The SEAP gene lacking its signal peptide was amplified from the pSEAP2-Control vector 
(Clontech) with 5’ XhoI and 3’ ApaI restriction sites and a 5’ kozak sequence (GCGGCCATG). The 
amplified region was ligated into pcDNA3.1(+) to generate the nsAP control construct. The 
SEAP gene lacking its signal peptide was amplified from the pSEAP2-Control vector (Clontech) 
with 5’ XhoI and 3’ ApaI restriction sites and a 5’ furin cleavage site (R-X-(R/K)-R) flanked by 5’ 
and 3’ flexible linkers (GGCGGAAGCAGGGGTCGACGCGGCGGAAGC). The amplified region was 
ligated into pcDNA3.1(+) to generate the intermediate vector pcDNA-furSEAP. The LacZ gene 
was amplified from the pEBBLacZ vector (a kind gift from Dr T. Tuthill) with 5’ XhoI and 3’ ApaI 
restriction sites and 5’ furin cleavage site and flanker sequences as described above. The 
amplified region was ligated into pcDNA3.1(+) to generate the intermediate vector pcDNA-
furLacZ. The signal peptide encoded by the pSEAP2-Control vector was synthesised as an 
oligonucleotide (composed of a 5’ phosphate group, pre-digested 5’ HindIII and 3’ XhoI 
restriction sites and a 5’ Kozak sequence) and ligated into the pcDNA-furLacZ vector to 
generate the SP-β-gal control vector. 
NS2 C-terminal truncations were amplified from the pJFH-1 plasmid (a kind gift from Dr T. 
Wakita). All HCV sequences were amplified using the same forward primer which contained a 
HindIII restriction site, a Kozak sequence and sequence complimentary to the C-terminal 23 
amino acids of E2 which form a signal peptide for p7. Reverse primers included a XhoI 
restriction site and terminated HCV sequence after amino acid 813, 840, 853, 965, 883, 900, 
908, 923, 933 or 1030 of the JFH-1 polyprotein. Amplified regions of NS2 were ligated into the 
pcDNA-furSEAP and pcDNA-furLacZ vectors to generate the S1-10 and B1-10 constructs. The 
Δ63 construct was generated using the same forward primer and a reverse primer that 
introduced a XhoI restriction site and terminated HCV sequence at 812 (residue 62 of p7). This 
HCV sequence was ligated into pcDNA3.1(+) upstream of the SEAP gene (with 5’ XhoI and 3’ 
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ApaI restriction sites but lacking; a kozak sequence, furin cleavage linker and signal peptide) to 
generate the Δ63 construct in which SPp7 was encoded as a direct fusion to a non-secreting 
form of SEAP. 
The S11, S12 and S13 constructs were generated by Quikchange mutagenesis. Signal peptide 
cleavage site was disrupted by mutation of the C-terminal amino acid of p7 from alanine to 
proline (5' CGGCAGGCTTATCCCCTCGAGGGCG). The furin cleavage site was disrupted by 
mutation of the consensus sequence (R-R-G-R) to A-R-G-R (5' GAGGGCGGAAGCGCGG 
GTCGACGCG).  
2.2.2.2 Generation of NS2-eGFP constructs 
The peGFP-N1.QC vector was generated by Quikchange mutagenesis (5' 
CACCGGTCGCCACCGCGGTG AGCAAGGGCG) whereby the vector-encoded eGFP translation 
initiation codon was mutated resulting in the generation of a unique SacII restriction site. 
Domains of NS2 were amplified from the pJFH-1 vector with 5’ EcoRI and 3’ BamHI restriction 
sites and 5’ Kozak sequences and ligated into the peGFP-N1.QC vector in-frame (by virtue of 
two additional 3’ cytosine nucleotides upstream of the BamHI restriction site) with the eGFP 
gene with a vector-encoded linker of GDPPVAT.  
2.2.2.3 Generation of NS2-FLAG constructs 
NS2-FLAG constructs were generated by ligating in a synthetic, 5’ phosphorylated, pre-
digested, FLAG-tag oligo (p-GATCCAGGCGGAAGCGGCGGAAGCGACTACAAAGACGATGACGACAA 
GTAACCGC). The oligo was composed of a 5’ BamHI restriction site, an in-frame adenine 
nucleotide, a collagen repeat linker, the FLAG coding sequence, a STOP codon and a 3’ SacII 
restriction site. The FLAG oligo was ligated into each of the NS2-eGFP fusion constructs to 
generate the corresponding NS2-FLAG constructs. 
2.2.2.4 Generation of eGFP-NS2 constructs 
Domains of NS2 were amplified from the pJFH-1 vector with 5’ XhoI and 3’ EcoRI restriction 
sites and 5’ cytodine nucleotide (to ensure in-frame translation with the eGFP gene) and 
ligated into the peGFP-C2 vector in-frame with the eGFP gene with a vector-encoded linker of 
SGRTQISS. 
The peGFP-C2-STOP vector was generated by QuikChange mutagenesis of the wt vector to 
encode a STOP codon as the 9th codon after the eGFP sequence (5’ CGGACTCAGATCTCGAGC 
TAAAGCTTCGAAT TCTGCAGTC) corresponding to the first codon of the inserted NS2 sequence. 
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The NS2 deletion constructs Δ25-50, Δ25-92 and Δ51-92 were generated by QuikChange 
deletion mutagenesis. 
2.2.3 RNA manipulations  
All procedures involving RNA were carried out in RNA safe conditions, by treatment of surfaces 
and equipment with RNase Zap® (Ambion).  
2.2.3.1 RNase-free water and phosphate buffered saline (PBS)  
0.1% v/v diethyl pyrocarbonate (DEPC) was added to dH2O or PBS, mixed thoroughly and 
incubated at 37°C overnight with shaking to inactivate any protein present. DEPC was 
inactivated by autoclaving.  
2.2.3.2 Preparation of DNA template  
Plasmids encoding the full-length and SGRs of the JFH‐1 isolate were linearised by XbaI 
digestion overnight at 37°C. XbaI was heat-inactivated at 65°C for 20 minutes after which 
samples were cooled to RT then incubated for 10 minutes on ice. Nucleotide overhangs 
produced by linearization were removed by treatment with 1 μl mungbean nuclease (NEB) for 
45 min at 30°C. Mungbean nuclease was inactivated with the addition of 0.1 % w/v SDS and 
the DNA purified by phenol/chloroform extraction and ethanol precipitation before being 
resuspended in RNase free water.  
2.2.3.3 In vitro transcription of RNA  
Transcriptions were performed using a T7 RiboMAX™ Express Large Scale RNA Production 
System kit (Promega), according to the manufacturer’s instructions. Reaction mixes comprised 
1x RiboMAX™ Express T7 buffer, 1 μg of linearised template DNA, 2 μl of T7 express enzyme 
mix and made to a volume of 20 µl with nuclease free water. Reactions were mixed gently and 
incubated at 30°C for 30 minutes. The DNA template was degraded by the addition of 1 U of 
RQ 1 RNase-free DNase and incubation for 15 minutes at 37°C. Protein was removed by the 
addition of an equal volume of phenol:chloroform:isoamylalcohol (125:24:1) pH 4.0 (Sigma) 
and vortexed for 1 minute followed by centrifugation at 16,100 x g for 2 minutes. The aqueous 
phase was transferred to a fresh tube and extracted with an equal volume of chloroform, 
vortexed for 1 minute and centrifuged for 2 minutes at 16,100 x g. The aqueous phase was 
again transferred to a fresh tube and RNA precipitated by the addition of 1/10th volume v/v of 
3 M sodium acetate pH 5.2 and an equal volume of isopropanol. Samples were vortexed 
thoroughly and incubated on ice for 5 minutes followed by pelleting of precipitated RNA by 
centrifugation at 16,100 x g for 10 minutes. RNA pellets were washed in 70 % v/v ethanol and 
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pelleted again. RNA pellets were air dried and finally recovered in 20 µl RNase-free water 
(section 2.2.3.1). 
2.2.3.4 RNA agarose gel electrophoresis  
RNA transcripts were analysed by denaturing 3‐(N‐morpholino) propanesulfonic acid (MOPS) 
formaldehyde gel electrophoresis. 1% w/v agarose (Sigma‐Aldrich) was heated until molten in 
MOPS buffer (40 mM MOPS, 10 mM sodium acetate, 1 mM EDTA in RNase-free H2O (section 
2.2.3.1). Upon cooling, 6.5% v/v formaldehyde was added and the mixture was poured into the 
casting stand and the comb added. Once set, running buffer (MOPS buffer) was added to the 
tank and RNA samples prepared by the addition of 10 μl loading buffer (56% v/v formamide, 
10% v/v formaldehyde, 6% glycerol, a trace amount of bromophenol blue and 10 μg/ml 
ethidium bromide in MOPS buffer) to 1 μl of RNA transcript or 1 μl of an RNA ladder (Ambion) 
and headed at 65°C for 10 minutes. Gels were run at 0.1 V/mm2 until the dye front had 
migrated two thirds down the gel, RNA was visualised using the UV transilluminator (Syngene) 
bio-imaging system and software.  
2.2.4 Protein biochemistry methods 
2.2.4.1 TNT coupled reactions 
Coupled transcription and translation (TNT) reactions were conducted as follows. 250 ng of 
purified DNA was added to 8.75 µl TNT™ Quick Master Mix (Promega) supplemented with 10 
µCi Trans Label (70% w/v methionine, 15% w/v cysteine, [35S]) (MP Biomedicals) and to a 
reaction volume of 12.5 µl. Reactions were allowed to proceed for 1 hour at 30°C before 
termination by the addition of 1 U of RNaseA. Samples were added to 9 volumes v/v of 2 x 
Laemmli buffer (10% v/v glycerol, 4% w/v SDS, 20 mM DTT, 0.01% w/v bromophenol blue and 
125 mM Tris HCl pH 6.8), denatured at 65°C for 5 minutes and analysed by SDS PAGE (section 
2.2.4.3). Gels were fixed in gel fixing solution (40% v/v methanol, 10% v/v glacial acetic acid) 
for 10 minutes followed by incubation in Amplify solution (Amersham Biosciences) for 10 
minutes. Gels were placed in a gel-drying dock (Model 583 Gel Drier - BioRad) for 1 hour on 
top of two sheets of filter paper (Fisher Scientific). Gels were exposed to film for an 
appropriate length of time at -80C and developed using an automated developer (SRX-101A 
Autorad - Konica). 
2.2.4.2 Acetone precipitation of protein 
Concentration of protein suspensions was achieved by acetone precipitation. 4 volumes v/v 
acetone were added to samples, vortexed and incubated overnight at -20°C. Precipitated 
protein samples were pelleted by centrifugation at 4,000 x g for 10 minutes at 4°C. Pellets 
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were washed in 70% v/v ethanol and finally resuspended in the desired volume of appropriate 
buffer.  
2.2.4.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples in Laemmli buffer were boiled for 5 minutes prior to separation by SDS PAGE. 
Gels were made with 15% resolving gel (50% 30:1 acrylamide:bis-acrylamide, 375 mM Tris-HCl 
pH 8.8, 0.1% w/v sodium dodecyl sulphate (SDS), 0.1% w/v ammonium persulphate (APS), 
0.01% v/v N,N,N',N'-tetramethylethylenediamine (TEMED)) and 5% stacking gel (16.7% v/v 
30:1 acrylamide:bis-acrylamide, 187.5 mM Tris-HCl pH 6.6, 0.1% w/v SDS, 0.1% w/v APS, 0.01% 
TEMED) in Mini Protean 3 chambers (BioRad). Samples were run alongside unstained 
(Precision Plus - BioRad) or pre-stained markers (SeeBlue - Invitrogen) molecular weight 
markers to allow estimation of protein size. 
2.2.4.4 Western blotting  
Specific protein identification was carried out by Western blotting. Gels were transferred to 
polyvinylidene fluoride (PVDF) membrane (Millipore) using a semi-dry trans-blotter (BioRad) in 
transfer buffer (20% v/v methanol, 25 mM Tris-HCl pH 8.3, 192 mM glycine). Membranes were 
activated prior to transfer by washing briefly in methanol. Transfers were run for 45 minutes at 
15 mA. Transferred membranes were then washed in PBS 0.1% v/v Tween20 (PBST) and 
blocked for >1 hour in 10% w/v dried, skimmed milk powder (Marvel) in PBST at room 
temperature on a rotating platform. Blocking solution was removed by washing 3 times for 5 
minutes in PBST before incubation over night in primary antibody at 4°C on a rotating 
platform. For small volumes of antibody solution, membranes were sealed in close-fitting 
plastic wallets. Membranes were washed 3 times in PBST prior to incubation in appropriate 
HRP-conjugated secondary antibody for 1 hour. Secondary antibody was removed by washing 
3 times in PBST and once in dH2O. The enhanced chemiluminescence (ECL) system (Amersham) 
was used according to the manufacturer's instructions to visualise antibody reactive bands. 
Briefly, membranes were soaked in 1ml of ECL (1:1 ratio of Solution 1: Solution 2) for 1 minute 
before removal of the ECL solution and overlaying of the membrane with photographic film for 
varying exposures. Films were developed using a Konica SRX101 Processor. 
2.2.4.5 Densitometry Analysis 
Autoradiographs were scanned in and analyses using ImageJ software. Images were colour-
inverted and a fixed area was boxed for analysis. Protein species were analysed for density and 
the mean density taken for a fixed area. A blank region of the image adjacent to the area 
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under analysis was taken as the background density and subtracted from the mean density 
values of the sample areas. 
2.2.5 Tissue culture techniques 
All samples were examined with a Zeiss Axioplan 2 fluorescence microscope, using a 63x oil 
immersion objective. Images were captured using an AxioCam Mrm CCD camera with 
Axiovision software. 
2.2.5.1 Routine passaging of mammalian cells 
Cell lines were cultured in DMEM (Sigma), supplemented with 10% v/v FBS (Sigma‐Aldrich), 1 
U/ml penicillin (Sigma‐Aldrich), 100 μg/ml streptomycin (Sigma‐Aldrich) in a humidified 5% CO2 
incubator at 37°C. Huh7 cells were supplemented with 1% v/v non‐essential amino acids and 
Huh7 cells for use in virus experiments were further supplemented with 20 mM HEPES 
(GIBCO). To passage the cells the media was removed and the cell monolayer washed with 
PBS. Cells were incubated in 0.5 mg/ml trypsin and 2 mM EDTA in PBS (Sigma) for 
approximately 5 minutes at 37°C to facilitate cell detachment. Trypsin was then inactivated by 
the addition of complete media. Cells were counted using a haemocytometer if required and 
seeded at the desired density.  
Huh7 cells harbouring stably replicating SGRs were cultured in the same manner, however the 
selection of replicon harbouring cells was achieved by supplementing culture media  with 250 
μg/ml G418 (Sigma‐Aldrich)  
2.2.5.2 Electroporation of mammalian cells 
Sub‐confluent Huh7 cell monolayers were detached from the growth surface using 
trypsin/EDTA solution, as described in the previous section, resuspended in complete media 
and counted. The desired number of cells was pelleted by centrifugation at 1,000 x g for 5 
minutes at room temperature, the supernatant was discarded and the cells washed twice in 
4°C RNase-free PBS. Cells were pelleted at 1,000 x g for 5 minutes at room temperature and 
resuspended at 1 x 107 cells/ml for SGR electroporations and at 2 x 107 cells/ml for full-length 
virus electroporations. 4 x 106 cells were added to a pre‐chilled sterile 4 mm electroporation 
cuvette (Geneflow) and 2 µg of subgenomic RNA or 10 µg full-length virus RNA added directly 
to the cells and mixed. Electroporation was carried out using a Bio‐Rad Gene Pulser at 270 
Volts (V) and 0.950 Farads (F). Cells were resuspeneded in complete media using a fine tipped 
Pasteur pipette, and seeded at the desired density. Any equipment that came into contact 
with cells electroporated with full-length infectious virus was treated with 5 % Virkon before 
disposal. 
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2.2.5.3 Transfection of Huh7 cells 
Cells were seeded in 12 well plates at 105 cells per well as with passaging and grown to ~80% 
confluency. 1-4 hours prior to transfection culture media was replaced with serum free media 
(as culture medium except lacking FBS). Transfection mixture (2 µg/ml DNA, 10 µg/ml 
polyethylenimine (PEI), in Optimem (GIBCO)) was prepared by thorough mixing of the DNA and 
PEI with the Optimem and the mixture was allowed to equilibrate at room temperature for 15-
45 minutes. 250 µl of transfection mixture was inoculated per well and plates were incubated 
at 37°C for 48 hours. 
2.2.5.4 Immunofluorescence microscopy 
Cells were seeded onto coverslips in a 12-well tissue culture plate at a low density. Samples 
were prepared by washing coverslips three times in PBS before fixing in 3-4% 
paraformaldehyde (PFA) for 10 minutes on ice prior to a final PBS wash. If necessary, cells were 
permeabilised in 0.1% v/v Triton X-100/PBS for 10 minutes followed by three washes in PBS. 
Cells were blocked prior to antibody incubation in 1% w/v bovine serum albumin (BSA)/PBS for 
30 minutes. Antibodies were diluted in 1% BSA/PBS and incubated at room temperature for 1 
hour followed by removal of unbound antibody with three washes in PBS. Coverslips were 
mounted onto slides using Vector Shield (Vector Laboratories Inc.) and sealed with nail varnish 
(Boots). 
Ice-cold PBS was used throughout the procedure; all other reagents were pre-chilled except 
Vector Shield. 
2.2.5.5 X-Gal staining 
Culture medium was discarded and cell monolayers were washed twice in PBS. Cells were fixed 
with 3% para-formaldehyde in PBS for 5min at 4oC. Cells were washed twice in PBS then 
overlaid with 250 µl reaction mix (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside 
(X-Gal - AnaSpec) dissolved in DMF, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 2 mM MgCl2) and incubated overnight at 37°C. Reaction was stopped by washing 
in PBS and X-Gal staining was observed and imaged using the 10 x objective lens on an eclipse 
TS100 microscope fitted with a Digital Sight DS-L1 camera (Nikon).  
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2.2.6 Cell biology techniques 
2.2.6.1 Lysis of mammalian cells  
Cells were washed three times in PBS and lysed by the addition of Glasgow Lysis Buffer (GLB – 
1% Triton X-100, 120 mM KCl, 30 mM NaCl, 5 mM MgCl2, 10% glycerol, 10 mM PIPES-NaOH, 
pH 7.2) and incubated on ice for 15 minutes.  
2.2.6.2 Isolation of post-nuclear cell suspension  
6.0 x 105 Huh7 cells were seeded into 10 cm dishes 16 hours prior to transfection. 48 hours 
after transfection cells were washed three times in ice-cold PBS and scraped into hypotonic 
buffer (10 mM piperazine-N,N′-bis[2-ethanesulfonic acid] (PIPES)/NaOH pH 7.2, 0.5 mM MgCl2) 
supplemented with protease inhibitors (Leupeptin 1 µg/ml, Pepstatin 1 µg/ml, Aprotinin 2 
µg/ml, AEBSF (Perfabloc) 0.2 mM). Cells were incubated on ice for 15 minutes to induce 
swelling then mechanically lysed on ice by 100 strokes of a Dounce homogeniser grade B. One 
quarter volume v/v of salt-balancing buffer (10 mM PIPES/NaOH pH 7.2, 600 mM KCl, 150 mM 
NaCl, 22.5 mM MgCl2) supplemented with protease inhibitors was added prior to pelleting of 
nuclei and intact cells by centrifugation at 3,000 x g for 10 minutes at 4°C. Supernatants were 
transferred to a fresh tube.  
2.2.6.3 Isolation of membrane-associated proteins 
Post-nuclear supernatants were transferred to ultraspin centrifuge tubes and clarified at 
100,000 x g for 1 hour. Supernatants were collected and acetone precipitated. Pellets were 
resuspended in isotonic buffer (4 volumes v/v of isotonic buffer plus 1 volume v/v of salt-
balancing buffer) supplemented with protease inhibitors and clarified again. Pellets were 
collected into 2x Laemmli buffer (4% w/v SDS, 20% v/v glycerol, 20 mM (dithiothreitol) DTT, 
125mM Tris-HCl pH 6.8, 0.01% w/v bromophenol blue).  
2.2.6.4 Dissociation of membrane proteins 
Post-nuclear fractions were separated into four ultraspin centrifuge tubes and clarified at 
100,000 x g for 10 minutes at 4°C. Supernatants were collected and acetone precipitated. 
Pellets were thoroughly resuspended in either isotonic buffer (1 M NaCl, 100 mM Na2CO3 pH 
11, 4 M urea) or 1% Triton X-100 in isotonic buffer and incubated at room temperature for 30 
minutes. All buffers were supplemented with protease inhibitors. Samples were clarified at 
100,000 x g for 10 minutes at 4°C. Supernatants were collected and acetone precipitated. 
Pellets were thoroughly resuspended in the isotonic buffer used previously and re-clarified. 
Pellets were finally recovered in 2x Laemmli buffer. 
Chapter 2: Materials and Methods 
 
77 
 
2.2.6.5 Immunoprecipitation of exogenous protein 
Culture media was removed from cell monolayers and cells were washed three times in ice-
cold PBS. All residual PBS was removed by aspiration. Cells were harvest by scraping into 200 
µl lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) 
supplemented with protease inhibitors (Leupeptin 1 µg/ml, Pepstatin 1 µg/ml, Aprotinin 2 
µg/ml, AEBSF (Perfabloc) 0.2 mM) and incubated on ice for 30 minutes. 1/10th volume was 
removed as an input sample and added to 2x Laemmli buffer. The remaining sample was made 
up to 1 ml with Tris buffered solution (TBS) (50 mM Tris HCl pH 7.4, 150 mM NaCl) and clarified 
at 20,100 x g at 4°C for 10 minutes.  
10 µl of GFP-Trap_A beads (Chromotek) were used per sample. Beads were washed three 
times in 500µl ice-cold TBS buffer with centrifugation at 2,700 x g at 4°C for 2 minutes and 
aliquoted into fresh microfuge tubes. Clarified lysates were added to pre-washed beads and 
incubated overnight at 4°C on a blood mixer. Bound protein was collected by centrifugation at 
2,700 x g at 4°C for 2 minutes. Supernatants were aspirated off and pellets were washed 3 
times in ice-cold TBS buffer. Immunoprecipitated proteins were finally recovered by the 
addition of 20 µl 2 x Laemmli buffer and incubating at 95°C for three minutes. Beads and 
insoluble material were removed by centrifugation at 2,700 x g 2 minutes at room 
temperature prior to analysis by SDS PAGE. 
2.2.6.6 Acetone precipitation 
Samples were added to 4 volumes v/v of acetone, mixed thoroughly and incubated overnight 
at -20°C. Precipitates were pelleted by centrifugation at 20,100 x g for 10 minutes at 4°C. 
Pellets were resuspended in 70% v/v ethanol and centrifuged again. Pellets were finally 
recovered in 2 x Laemmli buffer. 
2.2.6.7 SEAP Assay 
For analysis of intracellular SEAP activity, cells were lysed in an appropriate volume of 1x 
Passive Lysis Buffer (Promega). Endogenous non-specific alkaline phosphatases were 
inactivated by incubating samples at 65°C for 10 minutes. 20 l of transfection cell lysate or 
culture medium in phosphate buffer (10 mM NaCl, 1 mM MgCl2, 10 mM Tris-HCl pH 9.5) were 
transferred to separate wells of a 96 well plate. The chemiluminescent substrate CDP Star - 
Ready to use (Sigma) was added to a final concentration of 0.125 mM. Light emission was 
determined in relative light units (RLU) using a FLUOstar Optima luminometer (BMG Labtech). 
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2.2.6.8 ONPG assay 
90 l of transfection cell lysate or culture medium were transferred to separate wells of a 96 
well plate containing 10 x LacZ buffer (500 mM NaCl, 100 mM MgCl2, 100 mM β-
mercaptoethanol). An equal volume v/v of substrate (10mM ortho-nitrophenyl-β-D-
galactopyranoside (ONPG - Sigma) in 100 mM sodium phosphate buffer (22 mM sodium 
dihydrogen orthophosphate, 22 mM disodium hydrogen orthophosphate, pH 7.5) was added 
to each well. The reaction was stopped with a final concentration of 250 mM Na2CO3 after 45 
minutes and the absorbance was read at 400 and 450 nm.  
2.2.6.9 Endoglycosidase H (Endo H) treatment 
5x104 cells were seeded into 6 well culture dishes 16 hours prior to transfection and samples 
were harvested 48 hours post-transfection. Lysates were prepared by harvesting into 100 µl 
PLB; supernatants were prepared by acetone precipitation of 1 ml culture medium and 
resuspension in 100 µl PLB. Samples were glycosidase treated according to the manufacturer’s 
(New England Biolabs (NEB)) instructions. Briefly, samples were made up to 17 µl by the 
addition of 10 x denaturing buffering and denatured at 95°C for 10 minutes.  Samples were 
made up to 20 µl with 10 x G5 reaction buffer and 500 U of Endo H and incubated for 1 hour at 
37°C. Samples were finally recovered in 5x Laemmli buffer and analysed by SDS PAGE. 
2.2.6.10 Peptide: N-Glycosidase F (PNGase F) treatment 
5x104 cells were seeded into 6 well culture dishes 16 hours prior to transfection and samples 
were harvested 48 hours post-transfection. Lysates were prepared by harvesting into 100 µl 
PLB; supernatants were prepared by acetone precipitation of 1 ml culture medium and 
resuspension in 100 µl PLB. Samples were glycosidase treated according to the manufacturer’s 
(NEB) instructions. Briefly, samples were made up to 15 µl by the addition of 10x denaturing 
buffering and denatured at 95°C for 10 minutes. Samples were made up to 20 µl with 10 x G7 
reaction buffer, a final concentration of 1% v/v nonident P40 (NP40) and 500 U of PNGase F 
and incubated for 1 hour at 37°C. Samples were finally recovered in 5x Laemmli buffer and 
analysed by SDS PAGE. 
2.2.7 In silico protein sequence analysis 
Alignment of the NS2 amino acid sequence from each HCV sub-genotype was carried out using 
ClustalW2 (Goujon et al., 2010; Larkin et al., 2007). Hydropathy analysis was carried out using 
the AlignMe program (Khafizov et al., 2010) using a window size of 19 and Kyte-Doolittle 
scoring. Membrane topology predictions were generated using 6 prediction programs: Sosui 
(Hirokawa et al., 1998), HMMTOP (Tusnady & Simon, 1998), TMpred (Hofmann & Stoffel, 
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1993), ConPred II (Arai et al., 2004), PHDhtm (Rost et al., 1995) and TMHMM (Krogh et al., 
2001).  
Sosui uses four parameters of primary sequence analysis: the Kyte-Doolittle hydropathy scale 
(Appendix 2), an amphiphilicity index (used to determine potential helix capping residues), 
amino acid charges and the length of each hydrophobic domain. 
TMpred and PHDhtm make predictions by comparison of primary sequence to those of known 
trans-membrane protein. The TMpred algorithm uses statistical analysis of the TMbase 
database which contains characterised topology information of transmembrane proteins. 
PHDhtm topology predictions are based upon homologous protein sequences. Firstly a BLAST 
search is performed of the entered sequence against the SWISSPROT database. Secondly a 
prediction is made as to whether the entered sequence encodes a transmembrane protein by 
analysing the highest-scoring putative TMD. Finally dynamic algorithms are applied to achieve 
the most probable number, position and orientation of TMDs (Melen et al., 2003). 
HMMTOP and TMHMM use hidden Markov models with 5 and 7 state types respectively (such 
as helix core composition, helix caps, short cytosolic loops, short and long non-cytosolic loops) 
to predict over all topology. Rather than just taking into account absolute prediction values for 
each residue and segment in turn, these programs generate the most probable model based 
on overall sequence (Melen et al., 2003).  
ConPred II compiles and averages data from numerous different prediction programs 
regarding i) the total number of predicted TMDs and ii) the predicted position of TMDs to 
achieve an overall predicted topology. Among others, this software uses outputs from SOSUI, 
TMpred, TMHMM and HMMTOP. 
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3.1 Introduction 
Early studies determined that NS2 is a trans-membrane protein which associates with ER-
derived membranes (Santolini et al., 1995). Although the structure of the C-terminal sub-
domain of NS2 (aa93-217), termed the catalytic domain, has been solved by X-ray 
crystallography (Lorenz et al., 2006b), the precise membrane topology of the mature NS2 
protein remains unclear, specifically  with regard to the number and position of the trans-
membrane domains (TMDs) within the N terminal region. 
The 92 amino acids comprising the N-terminal portion are collectively referred to as the trans-
membrane domain. Analyses of this domain, by topology prediction and dissection of the 
cleavage events which culminate in the release of mature NS2, provided strong evidence that 
aa 1-92 form three distinct TMDs (Phan et al., 2009; Pietschmann et al., 2006). Cleavage of the 
N-terminus of NS2 from p7 occurs in the ER lumen (Carrere-Kremer et al., 2002), whilst 
cleavage of the C-terminus of NS2 from NS3 is thought to occur in the cytosol as NS3 has been 
shown to localise to the cytosol and nuclei of infected cells (Errington et al., 1999) and recruits 
NS4A to cleave the downstream viral protein junctions (Failla et al., 1994; Grakoui et al., 
1993a; Tomei et al., 1993). Orientation of the N- and C-termini to opposing faces of a lipid bi-
layer to allow the release of NS3 into the cytosol could theoretically be achieved by a single 
TMD topology. Similarly, a single TMD would be sufficient if NS2 function was solely 
dependent on anchorage to membranes. However, NS2 has known interactions with E1, E2 
and p7 which are hypothesised to occur via intra-membrane contacts (Jirasko et al., 2010; 
Popescu et al., 2011; Stapleford & Lindenbach, 2011). If this hypothesis is correct, a triple TMD 
topology may create a luminal loop capable of interacting with the glycoprotein ectodomains 
as well as providing more opportunities for intra-membrane protein:protein interactions with 
the TMDs of E1, E2 and p7. In contrast to these findings, there is also evidence to support a 
four TMD composition of NS2 (Yamaga & Ou, 2002).  
Work investigating the topology and membrane integration of NS2 from two different 
genotype 1 strains (HCV-BK and HCV-J) expressed in vitro, in the presence of canine 
microsomal membranes (CMM), showed NS2 membrane association occurred in a p7-
independent, NS3-dependent manner (Santolini et al., 1995). The group also described a 17 
kDa fragment which localised to a protease-protected environment when NS2 was expressed 
in cis with NS3 or as part of a polypeptide spanning the C-terminal domain of E2 through to 
NS3. Although these experiments were primarily conducted in cell-free environments 
supplemented with CMM, validation was provided using a cell-based system, suggesting that 
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the majority of NS2 resides within the membrane or lumen of vesicles or organelles (Santolini 
et al., 1995). Subsequently, Yamaga and Ou (Yamaga & Ou, 2002) found that in vitro expressed 
NS2 from a different genotype 1 strain (HCV-1) also associated with membranes, even when 
expressed separately from other HCV proteins and that the full-length protein behaved as an 
integral membrane protein. In vitro analysis of an NS2 deletion series identified two internal 
signal sequences within peptides aa 30-74 and aa 119-151, whilst the introduction of synthetic 
glycosylation acceptor sites led to the conclusion that residues 3, 50, 179 and 209 were 
oriented to the lumen of the ER (Yamaga & Ou, 2002). From these observations, and a Kyte-
Doolittle hydropathy plot, a four TMD topology for NS2 was consequently proposed, with  
both termini oriented to the ER lumen and residues (4-26), (34-57), (63-110) and (119-147) 
containing membrane spanning domains (Yamaga & Ou, 2002). The 17 kDa protease protected 
peptide observed by Santollini et al., (Santolini et al., 1995) was proposed to correspond to the 
C-terminal domain of NS2 which would correlate with the observations of Yamaga and Ou 
(Yamaga & Ou, 2002) who predicted that the largest fragment of NS2 not exposed to 
exogenous protease would be the residues aa119-217. This work has been questioned by the 
solution of the catalytic domain by X-ray crystallography, which has cast doubt on the 
hypothesis of a four TMD topology and the orientation of the C-terminus to the ER lumen 
(Lorenz et al., 2006b), as discussed in section 1.8.1. In addition, a 17kDa peptide of NS2, based 
on the HCV-H sequence, would require the protection of either the first 152 residues of NS2 or 
the C-terminal 157 residues (calculated) i.e. residue 61 onwards, making a four TMD topology 
less likely. More recently, several studies have proposed models predicting NS2 to form three 
TMDs based upon primary sequence analysis (section 1.8.1), however little has work been 
carried out to validate these models. 
The role of p7 in conferring NS2 topology, as well as the sub-cellular trafficking of these two 
proteins, is poorly understood. The signal peptide capability of the C-terminal helix of p7 
suggests that it may function as such in the HCV polyprotein to facilitate NS2 topology 
(Carrere-Kremer et al., 2002). NS2 expressed alone has a diffuse, ER-like distribution, whereas 
virus-expressed NS2 co-localises with NS5A to lipid droplets by a mechanism that is dependent 
upon the expression of functional p7 in cis (Ma et al., 2011; Tedbury et al., 2011). It was also 
demonstrated that NS2 partitioning to a triton-resistant compartment was dependent upon 
addition of signal peptide-p7 to NS2-5B replicons (Tedbury et al., 2011). A sub-population of 
E2-p7 precursor has been shown to localise to the surface of cells (Isherwood & Patel, 2005) 
and p7 is able to alter the pH of intracellular vesicles (Wozniak et al., 2010), yet the precise 
cellular trafficking of  p7 has not been described.  
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A complementary reporter enzyme system utilising alkaline phosphatase (PhoA) and β-
galactosidase (β-gal) has been widely used in combination with the bacterial plasma 
membrane to provide a complementary activity profile for truncation fusions of bacterial 
polytopic plasma membrane proteins. This combination of reporter was used in the initial 
identification of many of the trans-membrane domains of the mammalian plasma membrane 
proteins TAP1 and TAP2 (Vos et al., 1999).  
Placental alkaline phosphatase (PLAP) is expressed on the surface of mammalian cells and is 
anchored to the membrane by a glycosylphosphatidylinositol (GPI) anchor (Micanovic et al., 
1988). Secreted alkaline phosphatase (SEAP) is a modified form of PLAP in which the C-
terminal 8 amino acids responsible for covalent addition of the GPI anchor have been deleted 
(Berger et al., 1988). This results in trafficking of the enzyme to the cell surface and secretion 
from the cell. SEAP is a heat-stable enzyme and several methods are available for the 
detection of its enzyme activity. Enzyme activity can be determined using substrates that are 
converted to colourimetric or chemi-luminescent products and specific SEAP activity can be 
obtained following heat inactivation of endogenous phosphatases. SEAP can therefore replace 
PhoA in a dual reporter-fusion system. SEAP possesses one confirmed N-glycosylation site at 
N249 (Endo et al., 1988; Le Du et al., 2001) (Appendix 3) and SEAP maturation has been shown 
to be ER-dependent as non-cytotoxic levels of reagents that induce ER-dysfunction (Hiramatsu 
et al., 2006) and deoxynojirimycin (DNJ), an inhibitor of the ER chaperone calnexin, impair 
SEAP enzyme activity (Norton et al., 2005). 
β-gal catalyses hydrolysis of β-galactosides into monosaccharides. Both prokaryotic and 
eukaryotic β-gal is active in the cytosol and inactive in the oxidising environment of a bacterial 
periplasm. The activity of β-gal when anchored to the luminal face of the ER membrane is 
unknown. If β-gal is inactive when orientated to the ER lumen then it will complement SEAP as 
part of a dual reporter system for the topological analysis of ER-resident trans-membrane 
proteins. 
The novel application of a SEAP/ β-gal dual reporter system to assess the topology of an ER 
transmembrane protein was investigated by expression of a series of C-terminal truncations of 
NS2, in hepatocellular carcinoma (Huh7) cells. The sub-cellular trafficking of NS2 and p7 was 
also investigated by introduction of a consensus cleavage motif for the trans-Golgi network 
(TGN) -localised furin protease between the HCV protein sequence and the reporter fusion. 
The truncation fusions were designed such that release of the reporter fusion from the HCV 
Chapter 3: NS2 Topology Analysis 
 
84 
 
protein sequence would only occur if the reporter was oriented to the lumen and the HCV 
protein sequence enabled trafficking to the TGN. 
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3.2 Results 
3.2.1 Sequence based analysis of NS2 
The NS2 coding sequence from 9 different HCV isolates encompassing all 7 genotypes were 
analysed for sequence homology. The NS2 amino acid sequences were aligned using the 
ClustalW2 program (Goujon et al., 2010; Larkin et al., 2007). As the crystal structure of the C-
terminal catalytic domain (aa 93-217) revealed no membrane spanning domains (Lorenz et al., 
2006b), the attention of this study focused on the N-terminal 100 aa (Figure 3.1). The most 
striking feature of these sequences was their relative hydrophobicity and in particular the 
conserved stretches of hydrophobic amino acids (red) from aa 10-24, aa 29-37, aa 51-57, aa 
64-77 and aa 82-92. All domains were too small to form a typical α-helical TMD (>16 residues) 
in isolation, suggesting that membrane-spanning domains of NS2 may contain polar residues 
which could be involved in intra-membrane interactions. 
Residues 51-62 and 76-81 contained highly conserved or synonymous residues, indicating that 
they may form interaction motifs or key structural features, with regions proximal to the N-
terminus and residue 27 also showing high degrees of sequence conservation. In addition four 
conserved prolines, with disrupt α-helical structures, noted at positions 24, 53, 73 and 89 could 
represent TMD boundaries.  
HCV sequences were also aligned with the corresponding coding sequence from the two 
closest genetic relatives to HCV: canine hepatitis virus (CHV) and GB virus B (GBV-B). Although 
GBV-B NS2 was 9 amino acids shorter than HCV NS2, the catalytic domain showed a high 
degree of homology; with H134, E163 and C184 which form the catalytic triad being conserved 
across viruses (Kapoor et al., 2011). In contrast, despite showing a similar degree of 
hydrophobicity, the N-terminal domain of GBV-B NS2 has markedly less sequence homology 
with that of HCV. The NS2 coding sequence of the recently characterised CHV sequence 
(Kapoor et al., 2011) was the same length as HCV NS2 and sequence alignment highlighted a 
greater level of sequence homology between these viruses than between HCV and GBV-B. A 
similar pattern of hydrophobic and hydrophilic sections, as well as two small clusters of 
conserved residues around aa 26 and 35, were evident within the trans-membrane domain of 
NS2 from HCV and CHV. It should be noted that to date only one isolate of CHV has been 
submitted to the European HCV database (http://euhcvdb.ibcp.fr/euhcvdb/) so this isolate 
may not be representative. 
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Figure 3.1 Alignment of the NS2 amino acid sequence from a group of representative 
genotype isolates. 
The NS2 coding sequences of 9 HCV isolates from different genotypes were aligned for 
sequence conservation. Residues are coloured to denote biochemical properties: hydrophobic 
(red), polar (green), acidic (blue) and basic (magenta). Sequence alignment from the closest 
genetic relatives to HCV – canine hepacivirus (CHV) and GB virus B (GBV-B) are also shown. 
Circles below residues denote: conserved residue throughout HCV sequences (black), residues 
conserved between HCV and CHV (orange) and residues conserved between all three viruses 
(white). Amino acid numbering is shown above the alignments; isolate genotype and reference 
name are shown to the left.  
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The protein sequence for NS2 was also analysed for hydropathy (Figure 3.2) using Kyte-
Doolittle scoring (Appendix 2). From this analysis it is evident that the N-terminal ~30 residues 
form a hydrophobic domain consistent a TMD. A second hydrophobic domain is formed by 
residues ~31-50, although this is not sufficiently hydrophobic to be predicted as forming a TMD 
by this method as it does not reach a peak hydrophobicity of 1.8. This could be indicative of an 
amphipathic helix i.e. one that lies parallel to the membrane with a non-polar face that 
interacts with the membrane and a polar face that is solvent exposed. It is also possible that 
this domain forms a predominantly hydrophobic α-helix with polar residues that are involved 
in forming intra-membrane interactions. These possibilities have been previously noted for the 
corresponding domain of NS2 from the Con1 isolate (Jirasko et al., 2010). A third extended 
domain of hydrophobicity was calculated from approximately residue 70 through to residue 
110, within the catalytic domain, and forming two distinct shoulders. This domain is long 
enough to form two TMDs or, as it extends into the catalytic domain, a single TMD the leads 
into a hydrophobic, membrane-proximal domain of the catalytic domain. 
The amino acid (aa) sequence of JFH-1 NS2 was used as the reference for sequence analysis. 
The JFH-1 isolate is able to undergo a full round of infectivity in cell culture allowing for the 
potential to directly translate observations from protein expression studies into the full-length 
virus system and so was the focus of this study. The JFH-1 NS2 amino acid sequence was 
analysed using 6 topology prediction programs. The outputs from these programs are 
summarised in Table 3.1. The programs use varying methods to prdict protein topology. SOSUI 
uses a set of 4 fixed scales to analyse primary sequence. TMpred and PHDhtm are closely 
based upon comparison with known and homologous sequences from characterised trans-
membrane proteins. HMMTOP and TMHMM use hidden Markov models taking into account 
several factors based on statistical bias determined by analysis of the primary peptide 
sequences of characterised trans-membrane proteins. ConPred II analyses outputs from 5 
different programs for eukaryote protein topology, combines the 4 most similar and 
dynamically refines a model of the highest probability. More detail is provided in Methods 
section 2.2.7. 
Every program used predicted NS2 as a polytopic membrane protein comprising three or four 
TMDs with the N-terminus oriented ‘Out’, that is, on the extracellular or luminal face of a lipid 
bi-layer. Consistent with the previous predictions (detailed in section 1.8.1, Figure 1.9) (Jirasko 
et al., 2008; Phan et al., 2009; Pietschmann et al., 2006), all but one of the programs predicted 
a membrane-spanning domain within aa 5-33. Two less consistently identified sequences (aa  
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Figure 3.2 Hydropathy analysis of JFH-1 NS2 protein sequence. 
Analysis was carried out using the AlignMe software using Kyte-Doolittle scoring (Appendix 2) 
and a window size of 19. Stretches of sequence scoring higher than 1.8 are consistent with 
membrane spanning domains. 
 
 
Table 3.1 Defining a computer model for the membrane spanning domains of NS2 using 
topology prediction software. 
7 topology predictions for JFH-1 NS2 were obtained using 6 programs shown on the left. 
Comparable domains predicted to a section of sequence are shaded. An inferred consensus 
computer model for NS2 topology is shown (Consensus). All programs used predicted the N-
terminus to be orientated to the luminal/ extracellular face of a membrane bi-layer. 
 
Chapter 3: NS2 Topology Analysis 
 
89 
 
28-53 and aa 60-93) were also predicted to contain membrane-spanning domains. From these 
data a consensus computer model (hereafter referred to as the ‘computer model’) for NS2 
topology was inferred, which defined three putative TMDs between positions 7-27, 29-49 and 
63-86. The computer model was roughly determined by-eye as amino acid sequences 
predicted to form membrane spanning domains by the majority of the programs. The 
computer model placed the N-terminus on the luminal side of the ER membrane with the C-
terminus oriented to the cytosol (Table 3.1). The predicted orientation of the termini to 
respective sides of the ER membrane was consistent with the known cleavage events that 
release mature NS2. 
The computer model predicted NS2 to form a tight, cytosolic hairpin loop between the first 
and second TMDs. The computer model also defined a short luminal loop of approximately 15 
aa between the second and third predicted TMDs. Half of the programs utilised predicted a 
TMD within the N-terminal portion of the catalytic domain, however the position and length of 
the domain was inconsistent. Therefore the computer model did not include the prediction of 
a TMD within the catalytic domain.  
The prediction of a TMD within the catalytic domain by some programs was consistent with a 
previous report (Yamaga & Ou, 2002), inspection of the X-ray crystal structure of the  catalytic 
domain suggest it is likely due to misinterpretation of extended hydrophobic stretches shown 
to form ordered structural domains (Lorenz et al., 2006b). Together, the computer model and 
previous experimental observations strongly suggested that NS2 contained 3 TMDs (Figure 
3.3A).  
3.2.2 Development of an NS2 dual reporter-fusion system  
Topology analysis was undertaken using a series of C-terminal truncations of NS2 from the 
JFH-1 isolate expressed as fusions to a reporter enzyme. It was hypothesised that progressive 
C-terminal truncations through a polytopic membrane protein would result in changes to the 
orientation of the reporter about the ER membrane as single TMDs were removed from the 
sequence (Figure 3.3B). The activity of a C-terminally fused reporter molecule should enable 
the identification of NS2 truncations that orientate their C-terminus to the ER lumen by 
assessing the enzyme activity of the reporter fusion. A complementary dual reporter system 
was designed using SEAP and β-gal. It was anticipated that SEAP would be selectively active if 
orientated to the ER lumen and β-gal would be selectively active in the cytosol. 
C-terminal truncations of NS2 were generated such that they would terminate NS2 sequence 
either within or between predicted TMDs defined by the computer model (Table 3.1). Reporter  
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Figure 3.3 Model of predicted NS2 topology and principle of C-terminal truncation mapping. 
(A) A cartoon of NS2 modelled onto a lipid bi-layer. TMDs are shown as cylinders and key 
residues are noted. Residues marking the TMD boundaries are noted (green boxes). (B) 
Topology mapping of C-terminal truncations of a polytopic protein fused to a reporter enzyme 
(R.E.) result in re-orientation of the C-terminus about the membrane. The N-terminus (N) 
remains oriented to one side of the membrane.  
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fusions to SEAP (S) or β-gal (B) were numbered 1-10 in order of the magnitude of the 
truncation being made: S1 contained full-length NS2, S9 contained the shortest section of NS2 
sequence (the N-terminal 27 residues) and S10 contained no NS2 sequence. A schematic 
outlining the NS2 truncation SEAP-fusions is shown in Figure 3.4. 
Taking into account the ambiguous role of p7 in NS2 topology and subcellular trafficking; the 
C-terminal NS2 truncation-SEAP fusions were encoded in cis with p7 and the E2-derived 
cognate signal peptide, collectively termed signal peptide-p7 or SPp7 (Tedbury et al., 2011).  
To determine whether p7 and NS2 traffic via the Golgi, viral protein sequences were separated 
from reporters by a cleavage motif specific for furin. To more thoroughly characterise the 
trafficking of p7 within the cell, the C-terminal residue of p7 (p7-A63) was mutated to proline 
in the S10 background and the resulting mutant termed S11 (Figure 3.4). In line with this 
another mutant of S10 was designed containing a mutation to the consensus furin cleavage 
site, whereby the first arginine of the motif R-X-(R/K)-R was mutated to alanine and the 
resulting construct termed S12. A double mutant was also generated - S13. As it was feasible 
that mutations predicted in silico to abrogate peptidase cleavage may not function accordingly 
in tissue culture an additional construct was generated whereby SEAP was encoded 
immediately downstream of SPp7 without an intervening furin cleavage motif site and where 
the C-terminal amino acid of p7 was also deleted and termed Δ63. The p7 trafficking mutants 
were not generated in the β-gal background as the reporter was predicted to be inactive in 
these constructs. 
3.2.3 Characterisation of SEAP control reporters 
To verify the use of SEAP as a reporter enzyme it was necessary to demonstrate that wild type 
(wt) SEAP, expressed from the pSEAP control vector, was active and secreted from cells. 
Conversely it was necessary to confirm that if SEAP is orientated to the cytosol rather than the 
ER lumen the opposite would be observed. To this end a non-secreted form of SEAP was 
generated by cloning the sequence encoding SEAP but lacking the N-terminal signal peptide 
sequence into pcDNA3.1(+). This construct was termed ‘non-secreted alkaline phosphatase’ 
(nsAP) (Figure 3.5).  
COS7 cells were transfected with pcDNA3.1(+) plasmid (vector) alone, pSEAP (wt SEAP) or nsAP 
and the reporter phenotypes assessed. The vector pcDNA3.1(+) was used as the backbone for 
all novel constructs described in this chapter and is hereafter refered to as ‘vector’ or ’vector 
alone’ and was used as a negative control. Enzyme activity was determined by assessing cell 
lysates and culture supernatants for SEAP activity by chemi-luminescence assay (Figure 3.6A).  
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Figure 3.4 Schematic of NS2-SEAP fusion truncation series. 
Schematic representation of the expression constructs are shown alongside predicted 
membrane topology and reporter orientation about the membrane. Constructs comprise p7 
along with the E2-derived cognate signal peptide (SPp7) (blue), NS2 sequence (red) and 
secreted alkaline phosphatise (SEAP) reporter fusion (green). Terminating residue of NS2 
sequence is noted above each construct. FL refers to full length NS2. Nomenclature of 
constructs is noted to the left of each fusion construct. The predicted topology the SEAP 
reporter is represented either by an empty ellipsoid (inactive) or a green ellipsoid (active) 
denoting the predicted enzyme activity of the reporter expressed from the fusions. Signal 
peptidase and furin cleavage mutations (A63P and mfur respectively) are indicated.  
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Figure 3.5 Schematic diagram showing the maturation of SEAP. 
Wt SEAP is translocated to the lumen of the ER by recognition of the signal peptide by the 
signal recognition particle (SRP). Signal peptidase releases the enzyme domain of SEAP from 
the membrane and oligo-saccharyltransferase (OST) glycosylates SEAP at asparagine 249. Wt 
SEAP is trafficked to the trans-Golgi network (TGN) where the glycan group is modified prior to 
secretion of the mature protein. Modification of the glycan moiety to a more complex or 
hybrid saccharide chain renders it insensitive to endoglycosidase H (Endo H) treatment. SEAP 
lacking an N-terminal signal peptide (nsAP) is not targeted to membranes and is therefore not 
post-translationally modified or functionally active. 
  
Chapter 3: NS2 Topology Analysis 
 
94 
 
 
  
Chapter 3: NS2 Topology Analysis 
 
95 
 
Figure 3.6 Enzyme activity of SEAP control reporters. 
SEAP activity was determined by chemi-luminescence assay using the CDPStar™ substrate. 
COS7 cells were transfected with 1µg pcDNA3.1(+) (vector), pSEAP (wt SEAP) or pcDNA3.1-
nsAP (nsAP). Cell lysates and culture supernatants were collected 48h post-transfection. 
Endogenous alkaline phosphatases were inactivated by heating of samples at 65°C for 10 min. 
(A) Chemi-luminescence signal was monitored for 2 hr after addition of substrate. Extra- and 
intracellular enzyme activities are plotted on opposing axes. Peak enzyme activity was 
achieved approx. 10-20 mins after substrate addition. (B) Peak extra- and intracellular SEAP 
activity. Measurement of chemi-luminescence was initiated 10 min (T=10) after addition of the 
substrate (T=0) whereby readings were taken every minute for 10 min (T=20). Values 
represent mean of values for a sample taken between T=10 and T=20. Where possible, each 
sample was assessed in triplicate. The numerical means are shown and positive standard 
deviations were calculated and included for each sample. 20µl of culture media or 5% cell 
lysate were used. Enzyme activity is shown in relative light units (RLU).  
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Cells expressing wt SEAP had high levels of extracellular SEAP activity with intracellular activity 
approximately 20-fold lower. Cells transfected with empty vector or nsAP showed neither 
extra- nor intracellular activity. Monitoring of reactions for 2 hours after addition the substrate 
revealed that the intracellular chemi-luminescence signal peaked 8 minutes after substrate 
addition and at 19 minutes after substrate addition for extracellular SEAP (Figure 3.6A). To 
expedite data collection measurement of chemi-luminescence was initiated 10 minutes (T=10) 
after addition of the substrate (T=0) whereby readings were taken every minute thereafter for 
10 minutes (T=20). Values therefore represented the mean of 11 readings per sample taken 
from T=10 to T=20 (Figure 3.6B).  
3.2.4 Expression of SEAP fusions in mammalian cells 
NS2-SEAP fusions were initially expressed in the hepatocellular carcinoma cell line Huh7. 
However, due to poor expression levels the truncations were subsequently expressed in COS-7 
cells. COS-7 cells contain the SV40 large T antigen which enables episomal replication of 
transfected plasmids that contain the SV40 origin of DNA replication within mammalian cells, 
leading to enhanced expression of recombinant proteins. Analysis of equal amounts of cell 
lysate by SDS PAGE and immunoblotting for SEAP revealed that all fusion proteins were 
expressed, but at varying levels (Figure 3.7). This was confirmed by probing for the vector-
encoded neomycin phosphotransferase (NPT) as a measure of transfection efficiency, and the 
cellular protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. NPT 
levels were relatively constant indicating that the discrepancy did not arise as a consequence 
of unequal transfection rates and GAPDH levels demonstrated that protein loading was 
consistent and that none of the constructs were noticeably cytotoxic. The vector encoding wt 
SEAP did not encode the NPT resistance gene. Fusion peptides that included NS2 sequence (S1-
S9) were detectable at significantly lower levels than those where NS2 was not present (Δ63 
and S10-S13). Full-length NS2 has a molecular mass of 23 kDa and the SEAP-reactive species 
seen for S1 migrated at a slower rate equivalent to an increase in size of approximately 20 kDa 
over wt SEAP. The altered migration of the NS2-containing fusions in comparison to wt SEAP 
was consistent with the respective NS2 sequences remaining fused to the reporter. Lysates 
were not clarified prior to analysis by SDS PAGE because up to 50% of NS2 has been shown to 
associate with detergent insoluble lipid-rafts when expressed in a replicon also containing 
SPp7 (Tedbury et al., 2011).  
3.2.5 Expression of NS2-SEAP fusions in vitro 
Since the consistent expression of NPT had already excluded transfection efficiency as the 
cause of low fusion-protein expression levels seen in some of the constructs, it was important  
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Figure 3.7 Expression of NS2-SEAP fusions in COS7 cells. 
COS7 cells were transfected with NS2-SEAP fusion series and cells harvested 48h post-
transfection. Fusion protein expression levels were determined by probing for SEAP following 
separation by SDS PAGE. Transfection efficiency was gauged from levels of the vector-encoded 
neomycin phosphotransferase II resistance gene (NPT). The cellular protein glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) was used as loading control. Vector alone, wt SEAP and 
nsAP were separated on both gels for comparison. The vector encoding wt SEAP did not 
encode NPT. Molecular weight markers (kDa) are shown to the left. 
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to determine whether there were unequal levels of transcription or translation across the 
panel of constructs. To investigate this; equal amounts of each plasmid were added to the 
coupled transcription and translation (TNT) reactions supplemented Trans-35S-label containing 
with 35S methionine and 35S cysteine. Transcription from these constructs in vitro was 
facilitated by the T7 promoter encoded by the vector. TNT reactions proceeded for 90 minutes 
at 30°C before termination through the addition of ribonuclease A (RNase A). The levels of 
radiolabelled amino acids incorporated-protein were determined by separation of samples by 
SDS PAGE followed by autoradiography (Figure 3.8). The reporter fusions migrated 
corresponding to the varying size of the NS2 sequence encoded by each construct. In this 
context wt SEAP and nsAP would be expected to run at similar sizes as neither reporter should 
be post-translationally modified, although this could not be demonstrated. The vector 
encoding wt SEAP did not contain a T7 promoter site and so could not be used in this system. 
SPp7 should have been present as part of the precursor polyprotein as no signal peptidase or 
furin were present in this system. A slightly retarded migration of the p7-SEAP fusions (S10-
S13) in comparison to the nsAP control was evidence of this (Figure 3.8). 
Trans-35S-label includes radio-labelled methionine and cysteine which are incorporated in 
growing peptide chains and enable their detection by autoradiography. All of the fusions 
appeared to express to similar levels, with the possible exceptions of S2 and S5 which gave less 
intense signals which could not be explained by the different number of methionines and 
cysteines encoded by the constructs (Figure 3.8).  From this it was concluded that the low 
expression levels in COS7 cells of the NS2-containing fusions in comparison to the p7-SEAP 
fusions was not due to poor transcription or translation from the plasmids. Rather it was likely 
that observed phenotypes were a result of differential stability of the resultant proteins, either 
caused by specific targeting motifs present within NS2 or due to recognition of incorrectly 
folded proteins by cellular quality control mechanisms.  
3.2.6 Enzymatic activity of NS2-SEAP fusions 
Cells expressing the NS2-SEAP fusion were assayed for extra- and intracellular SEAP activity 
(Figure 3.9). The fusion peptides examining p7 trafficking (Δ63, S11, S12 and S13) are discussed 
in section 3.2.11. Wt SEAP showed high levels of SEAP activity both extra- and intracellularly. 
Cells transfected with the non-secreted form of SEAP, nsAP, or vector alone had undetectable 
enzyme activity. S10 i.e. SPp7-SEAP, displayed extracellular levels of reporter activity 
comparable to wt SEAP and intracellular levels slightly reduced in comparison with wt SEAP. S9 
was the only NS2-containing fusion that repeatedly showed significant extra- and intracellular 
enzymatic activity above that of background i.e. nsAP or vector alone. All NS2-containing  
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Figure 3.8 In vitro translation of NS2-SEAP fusions. 
NS2-SEAP fusions were expressed in vitro using a coupled transcription and translation system 
in the presence of 35S radiolabelled amino acids. Reactions were incubated for 90 min at 30°C. 
Samples were separated by SDS PAGE and reaction products detected by autoradiography. 
250ng of plasmid DNA was used per reaction. Molecular weight markers (kDa) are shown to 
the left. nsAP and S1 were loaded on both gels for size comparison. 
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Figure 3.9 Reporter activity of NS2-SEAP fusions. 
COS7 cells were transfected with NS2-SEAP fusion series and extra- and intracellular reporter 
enzyme activity determined by chemiluminescent assay using CDPStar substrate. Each sample 
was assayed in triplicate, numerical means were plotted and standard deviations shown. Assay 
was carried out ≥3 times. A representative data set is shown. Enzyme activity is shown in 
relative light units (RLU). 
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fusions (S1-S9) were expressed at comparable levels, although expression was significantly 
reduced compared with S10, nsAP and wt SEAP. In light of these findings, the relative inactivity 
of the reporters within the NS2-containing fusions S1-S8 compared with S9 cannot be 
attributed solely to sub-optimal levels of expression.  
Unfortunately, no information regarding NS2 topology could be inferred directly from the 
reporter activity. However, as it is not known at what stage during maturation SEAP becomes 
active it is possible that NS2 sequences oriented the reporter to the ER lumen but undefined 
trafficking signals prevented trafficking of the fusion proteins through the secretion pathway 
and thus prevented activation of SEAP.  
SEAP is a characterised glycoprotein and initial addition of a core oligosaccharide 
(Glc3Man9GlcNAc2), to an acceptor asparagine on a nascent protein by 
oligosaccharyltransferase (OST), occurs in the ER lumen. Upon trafficking to the Golgi, glycan 
chains are modified to produce high-mannose, complex or hybrid oligosaccharide chains. 
Endoglycosidase H (Endo H) removes only high mannose and some hybrid oligosaccharides 
whereas Peptide: N-Glycosidase F (PNGase F) cleaves nearly all types of N-linked glycan chains 
except those containing core α1-3 fucose (Tretter et al., 1991). If an NS2 truncation orients the 
C-terminus to the ER lumen but prevents trafficking through the secretory pathway, the 
reporter should be glycosylated and thus sensitive to Endo H. Therefore the glycosylation 
status of wt SEAP and nsAP was assessed for the potential investigation of topology using 
glycosidase treatment. To exclude the possibility that any NS2 truncation was enabling 
modification of the SEAP glycan chain to an Endo H resistant form but were still sequestered in 
an inactive form; PNGase F sensitivity was also assessed.  
3.2.7 Validation of wt SEAP as a glycosidase reporter 
The activity of Endo H and PNGase F were confirmed using the HCV envelope glycoprotein E2. 
E2 is well characterised and contains 11 potential N-linked glycan acceptors (Goffard & 
Dubuisson, 2003). Lysates from Huh7 cells electroporated with full-length JFH-1 RNA were 
treated with both glycosidases (Figure 3.10A). A protein species at ~58 kDa was detected in 
untreated samples (E2) using the anti-E2 monoclonal antibody. Upon treatment with Endo H 
and PNGase F this species was lost and replaced by two protein species equivalent to ~36 (E2*) 
and ~34 kDa (E2†), respectively. This pattern corresponds to the cleavage of the 11 high-
mannose N-linked glycans within the core of the chains and the complete removal of the 
glycans respectively (Stapleford & Lindenbach, 2011). The 30 kDa protein species was thought 
to be a non-specific host protein. 
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Figure 3.10 Functional confirmation of glycosidases and glycosylation state of SEAP 
expressed from reporter control constructs. 
 (A) Functional activity of Endo H and PNGase F was confirmed using HCV E2 glycoprotein. 
Huh7 cells were harvested 72 hr post-electroporation with full length JFH-1 virus. Lysates were 
denatured for 10 min at 95°C prior to incubation with indicated enzyme for 3 hr at 37°C. 
Samples were separated by SDS PAGE and the glycosylation sensitivity of E2 determined by 
immunoblotting with anti-E2 antibody (AP33 clone). E2 was completely de-glycosylated with 
PNGase F (E2†) and partially de-glycosylated with Endo H (E2*). (B) Glycosidase sensitivity of 
extra- and intracellular SEAP expressed from control vectors. COS7 cells were harvested 48 
hours post-transfection. Extracellular protein was obtained from acetone-precipitated culture 
media resuspended in lysis buffer. SEAP was detected using anti-PLAP antiserum (Abcam). 
Lysate from untreated nsAP-transfected cells was used as a comparator for vector alone (Pos. 
C). Molecular weight markers (kDa) are shown to the left of SDS-PAGE gels. 
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Next, the intra- and extracellular glycosylation states of the control reporter enzymes were 
determined. SEAP possesses two putative N-linked glycan acceptor sites, although one is 
thought to be glycosylated in mammalian cells (Le Du et al., 2001) (Appendix 3). To allow 
detection of proteins secreted into the culture media, one quarter volume of culture 
supernatant was acetone precipitated and resuspended in lysis buffer in an equivalent volume 
to that used for harvesting the cellular fraction. Samples were treated with Endo H and 
PNGase F and analysed by SDS PAGE and western blotting for the SEAP reporter using an anti-
PLAP antibody (Figure 3.10B). A SEAP-specific species was observed in extracellular and 
intracellular wt SEAP samples but only in intracellular nsAP samples. No SEAP-specific species 
was detected in vector control samples as compared with an untreated intracellular nsAP 
control sample (Pos C.). A slower migrating non-specific protein species was observed in 
intracellular empty vector samples on higher exposures. Intracellular wt SEAP was susceptible 
to both glycosidases whereas extracellular wt SEAP was only deglycosylated by PNGase F. 
Protein expressed from the nsAP control vector was insensitive to both glycosidases. 
The glycosylation and secretion patterns for wt SEAP and nsAP correlated to the enzyme 
activity data (Figure 3.9) and were consistent with a previous investigation which 
demonstrated that secreted SEAP was Endo H resistant but PNGase F sensitive (Davis, 1993). 
Together these observations confirmed that the enzyme produced by the nsAP construct was 
not oriented to the ER lumen and consequently not glycosylated (as demonstrated by 
insensitivity to glycosidases and a similar migration to glycosidase-treated wt SEAP). 
To validate the application of glycosidase treatment of SEAP to an NS2-fusion system it was 
first necessary to determine the sensitivity of NS2 expressed alone to Endo H and PNGase F. C-
terminally FLAG-tagged NS2 (JFH-1) was expressed in COS7 cells and lysates analysed by SDS 
PAGE and western blotting, and probed using antibodies raised against JFH-1 NS2 and the 
FLAG epitope (Figure 3.11A). Four protein species were detected using the anti-NS2 antibody 
(Figure 3.11A left panel) but only two prominent protein species were detected when the 
same membrane was re-probed for the FLAG epitope (Figure 3.11A right panel), with the 
larger species in each case corresponding to full-length NS2.  
Glycosylation of p7 has not been reported in any context and in the proposed reporter-fusion 
system the p7/NS2 junction would be maintained for all NS2-SEAP fusions allowing cleavage by 
signal peptidase, thus p7 should not form part of the mature NS2-SEAP fusions. Taking these 
into account, and combined with the technical difficulties of reliably detecting p7, the 
glycosidase sensitivity of p7 was not determined.  
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Figure 3.11 Glycosidase treatment of full-length NS2. 
 (A) Expression of C-terminally FLAG-tagged NS2 (JFH-1). Lysates from untransfected COS7 cells 
or cells transfected with NS2-FLAG were separated by SDS PAGE and NS2 was detected by 
immunoblotting using anti-NS2 polyclonal antisera (left panel) or M2 anti-FLAG monoclonal 
antibody (right panel). (B) Protein species were labelled to the right. Lysates from COS7 cells 
transfected with NS2-FLAG expression construct were treated with Endo H and PNGase F. 
Samples were immunoblotted using rabbit anti-NS2 antibody (top panel) then re-probed with 
mouse anti-FLAG antibody (bottom panel). Samples were collected 48 hours post-transfection. 
Molecular weight markers (kDa) are shown to the left. (C) Schematic representation of 
possible NS2-FLAG degradation products. NS2 sequence (green) with FLAG epitope (blue). 
Speculative N-terminus of tNS2 was placed at aa 30. Predicted masses for each fusion peptide 
are shown to the right. 
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The migrations of the four NS2-specific protein species were unaltered upon treatment with 
either glycosidase, indicating that NS2 was not N-glycosylated (Figure 3.11B). Thus glycosidase 
sensitivity of an NS2-SEAP fusion could be deduced to be the result of a SEAP-specific 
glycosylation event and therefore provide a means of determining the C-terminus orientation 
of the NS2 sequence within the fusion. 
Several groups have reported a truncated form of NS2 (tNS2) detectable using polyclonal NS2 
antiserum which migrates at ~18kDa. Corresponding truncations were observed when 
expression of tagged NS2 confirmed using antibodies directed against C-terminal tag epitope 
but not against N-terminal tags. The nature of tNS2 has not been determined but it is likely to 
be the product of a specific cleavage event in the vicinity of aa 35 of NS2. Furthermore, as NS2 
is responsible for catalysing the cleavage of the NS2/3 junction it is possible that NS2 catalyses 
the cleavage of non-native sequences i.e. a non-NS3 sequence, from the NS2 C-terminus. It 
was therefore proposed that the four protein species corresponded to full-length NS2-FLAG, 
full-length NS2, tNS2-FLAG and tNS2 (Figure 3.11C). 
Alternatively, as NS2-SEAP showed no evidence of auto-cleavage (Figure 3.7 lane 5) it is 
possible that the fusions were subjected to non-specific cleavage by cellular proteases within 
the linker sequence, causing the pattern described in Figure 3.11C. This appears to be a 
common phenomenon encountered with reporter fusions and has recently be noted by 
Popescu et al., for YFP (Venus yellow fluorescent protein)-tagged NS2 and CFP (Cerulean 
fluorescent protein)-tagged p7 (Popescu et al., 2011). 
3.2.8 Glycosidase sensitivity of NS2-SEAP fusion proteins 
To investigate whether any NS2 truncations orientated the reporter to the ER lumen, the 
sensitivity of the panel of fusion proteins to glycosidases were determined. Lysates from cells 
transfected with SEAP reporters were treated with Endo H and PNGase F (Figure 3.12). As 
shown previously (Figure 3.10) wt SEAP was sensitive to both glycosidases as characterised by 
a reduction in size of ~2 kDa by SDS PAGE corresponding to the removal of a glycan chain, 
whereas nsAP results showed no evidence of glycosylation. All p7-SEAP fusions (S10-S13 and 
Δ63) were sensitive to both glycosidases. Of the NS2 containing fusions only S6 and S9 
appeared to facilitate glycosylation of the reporter. Two distinct protein species were detected 
in the untreated samples for S6 which migrated to just under and just over 58 kDa respectively 
(Figure 3.12). Upon treatment with either glycosidase the protein remained unchanged in size, 
although somewhat reduced in intensity. This protein was thought to represent a non-specific 
protein as it was also detected in vector only transfected cells. The smaller protein species was  
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Figure 3.12 Glycosidase sensitivity of NS2-SEAP fusions. 
Lysates from COS7 cells expressing the NS2-SEAP fusions were treated with Endo H and 
PNGase F. Cells were harvested 48h post-transfection. Molecular weight markers (kDa) are 
shown to the left. 
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noticeably shifted down indicating the complete removal of a high-mannose glycan chain from 
all fusion peptides. A third protein appeared upon glycosidase treatment which was smaller 
still; however, the nature of this protein was not clear. While wt SEAP and Δ63 were efficiently 
de-glycosylated by both enzymes, S9-S13 showed varying degrees of sensitivity to Endo H and 
PNGase F. All untreated samples contained a single predominant protein species. Two species 
of varying prominence were detected in treated samples: one of a similar weight as the 
untreated sample and one slightly smaller, equivalent to a reduction in molecular weight of ~2 
kDa. Interestingly, a further species was detected at a low level of expression in the untreated 
samples that corresponded to the prominent de-glycosylated form of the reporters. This may 
represent an unglycosylated population of the fusion proteins, possibly caused by inefficient 
glycosylation of the cryptic glycan acceptor site. 
Collectively the data suggests that NS2 forms a three TMD topology with the N- and C-termini 
oriented to the lumen and cytosol respectively, and a luminal loop in the vicinity of residue 70. 
The glycosylation of S9 suggests that either the first 27 residues of NS2 cannot function as a 
TMD in this system, or that the residues do not completely represent the first TMD of NS2. 
3.2.9 Analysis of reporter activity in NS2-β-galactosidase fusions 
To determine whether the use of β-gal as part of a dual reporter system could be extended for 
the study of ER trans-membrane proteins by displaying localisation dependent enzyme 
activity; a control reporter construct was also generated where the signal peptide encoded  
within the SEAP reporter vector was generated as an oligo-nucleotide and inserted upstream 
of the wt β-gal coding sequence.  This construct, termed ‘SP β-gal’, was therefore predicted to 
orientate the enzyme into the ER lumen. The same NS2 truncations used in the NS2-SEAP 
fusions (Figure 3.4) were generated as C-terminal fusions to β-gal and termed B1 – B10.  
NS2 β-gal fusions were expressed in COS7 cells and assessed for fusion protein expression 
levels and reporter activity by colorimetric O-nitrophenyl-β-D-galactopyranoside (ONPG) 
solution-based assay and 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining of 
fixed cells (Figure 3.13). All NS2-β-gal fusions showed reporter activity to varying degrees by 
both enzyme functionality methods. The specificity of the assays for β-gal activity was 
confirmed by a completely negative response from cells transfected with vector alone. Enzyme 
responses in the ONPG and X-gal staining assays appeared to mirror fusion-protein expression 
levels, which matched the previously described SEAP fusions in that all NS2-sequence 
containing fusions were detected at lower levels than controls and the B10/S10 fusion. 
Unfortunately, as the SP β-gal control reporter displayed positive enzyme activity in both  
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Figure 3.13 Expression and reporter activity of NS2-β-gal fusions. 
COS7 cells were transfected in duplicate with NS2-β-gal fusion series. 48h post-transfection 
cells were either; lysed and used to determine reporter activity by ONPG colorimetric assay 
(top graph) and fusion expression by immunoblotting (middle three panels) or; fixed and 
incubated with X-gal reagent (bottom row of panels).  Lysates were incubated for 10 min in 
ONPG reaction mixture at 37°C. Absorbance was read at 420nm. Fusion protein expression 
levels were determined by probing for β-galactosidase. Transfection efficiency was gauges 
from levels of the vector-encoded neomycin phosphotransferase II resistance gene (NPT). The 
cellular protein glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as a loading 
control. Molecular weight markers (kDa) are shown to the left. Fixed cells were overlaid with 
X-gal reagent and incubated for 16h at 37°C. Cells were viewed microscopically and imaged 
using a Digital Sight DS-L1 (Nikon). Cells positive for β-galactosidase activity stained blue. 
Representative wide-field images are shown. 
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formats no further information could be discerned regarding fusion protein topology from 
analysis of enzymatic function.  
Low resolution separation of cell lysates by SDS PAGE indicated that SP β-gal ran slower than 
wt β-gal. This could represent irregular folding in the ER lumen or a non-native post-
translational modification, such as the addition of a glycan chain to a cryptic glycosylation site. 
As enzyme function was maintained for it is unlikely that folding differed significantly from wt. 
B1 migrated as a doublet with the larger protein appearing to correspond to the full-length 
NS2 β-gal fusion, and the smaller possibly representing a cleavage event product near the 
NS2/β-gal junction, as it migrated faster than the other fusion peptides and at a similar rate to 
SP β-gal. 
3.2.10 Glycosidase sensitivity of NS2-β-galactosidase fusions  
β-gal is a cytosolic protein and so is not glycosylated under normal conditions. Analysis of the 
β-gal sequence identified 4 possible N-linked glycan acceptor sites (Appendix 3); two of which 
were predicted with a high probablility to be glycosylated of oriented to the ER lumen. To 
investigate whether this apparent gain in molecular weight was due to the glycosylation of a 
cryptic glycan acceptor site, lysates from COS7 cells transfected with the NS2-β-gal fusions 
were treated with Endo H and PNGase F and analysed by SDS PAGE (Figure 3.14). Samples 
were run for longer than in the initial expression profile (Figure 3.13) to achieve better 
separation. As expected wt β-gal migrated as a single protein that was unaltered by treatment 
with either glycosidase. Surprisingly, the SP β-gal control migrated as two distinct species, and 
the more intense larger species was lost after treatment with both enzymes. Concomitantly, 
the smaller protein became more intense. Consistent the SEAP fusion data; the only NS2-β-gal 
fusion that displayed sensitivity to glycosidase treatment was B6. Unlike the corresponding 
SEAP fusion, B9 did not show signs of having been glycosylated. B10, which encodes p7 as a 
fusion to β-gal with no intervening NS2 sequence, also showed sensitivity to glycosidase 
treatment. As with the SP β-gal control, untreated B6 and B10 appeared to migrate as doublets 
but were reduced to single protein species with the loss of the higher molecular weight protein 
after treatment with either enzyme. This pattern was indicative of only a sub-population 
having been glycosylated and was consistent with the SEAP fusions, in that truncation of NS2 
at residue 70 resulted in orientation of the artificial NS2 C-terminus to the ER lumen. 
3.2.11 Analysis of p7 trafficking  
As described in section 3.2.2; a series of S10-derived mutants were generated to enable the 
examination of p7 trafficking. S11 contained a mutation to the signal peptidase cleavage site;  
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Figure 3.14 Glycosidase sensitivity of NS2-β-gal fusions. 
Lysates from COS7 cells expressing the NS2-β-gal fusions were treated with Endo H and 
PNGase F. Cells were harvested 48h post-transfection. Molecular weight markers (kDa) are 
shown to the left. 
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S12 contained a mutation to the furin cleavage site, S13 contained both mutations and Δ63 
encoded p7 as a direct fusion to SEAP without the intervening furin cleavage linker and 
without the C-terminal residue of p7 (alanine 63), which was expected to abrogate signal 
peptidase cleavage at this site. 
Initially it was found that the p7-trafficking mutant fusions expressed to similar, high levels 
(Figure 3.7) and that the reporters were all active and sensitive to both Endo H and PNGase F 
suggesting that p7 does indeed orient the C-terminus to the ER lumen (Figure 3.12). To 
investigate whether any of the constructs showed altered reporter activity they were 
transfected into cells and the supernatants and lysates assessed for SEAP activity and protein 
expression, respectively. Surprisingly, S10-S13 each showed extracellular SEAP activity levels 
comparable to wt SEAP, and Δ63 showed SEAP activity nearly double that of wt SEAP (Figure 
3.15). Western blotting of cell lysates following SDS PAGE separation showed all fusions 
expressed at similarly high levels, and significantly higher than wt SEAP (Figure 3.15). 
To further examine whether the increased SEAP activity of the Δ63 peptide over wt SEAP was a 
result of higher transfection efficiency; the extracellular SEAP activities of each of the 
trafficking mutants and the nsAP control vector were normalised to respective NPT expression 
levels and represented graphically (Figure 3.16). When secreted SEAP activity was shown as a 
function of NPT expression it became apparent that all of the p7-SEAP fusion peptides secreted 
active SEAP to comparable levels. Δ63 and S13 were engineered to possess neither functional 
signal peptidase or furin cleavage sites yet were still able to secrete active reporter. There are 
several possible explanations for this observation; i) these fusions were subject to an 
additional cleavage event by a cellular protease resulting in secretion of the active reporter; ii) 
p7 was unable to anchor to membranes and was being secreted as an uncleaved fusion to 
SEAP; iii) extracellular activity noted for all p7-fusions was the result a population of p7 
released from the cell in exosomes.  
The amino acid sequence for the p7-SEAP fusions was analysed for the presence of non-SP, 
non-furin cleavage motif. This revealed a consensus motif for thrombin cleavage within the C-
terminal domain of p7, but because thrombin is activated from pro-thrombin in the 
extracellular matrix by the pro-thrombinase complex it was not considered to be the cause of 
intracellular p7-SEAP cleavage. Core protein of HCV is released from E1 by signal peptidase in 
the ER lumen and the C-terminal domain of core is further processed within the membrane by 
signal peptide peptidase (SPP) (McLauchlan et al., 2002). If p7 is cleaved within the C-terminal  
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Figure 3.15 Analysis of p7 trafficking mutants. 
Constructs encoding SPp7 fused to SEAP without any intervening NS2 sequence were 
expressed in COS7 cells and analysed for the levels of active extracellular reporter (top graph). 
Reporter activity is shown in relative light units (RLU). Lysates were assessed for levels of SEAP, 
vector-encoded NPT as a marker of transfection efficiency and endogenous GAPDH as a 
loading control (bottom panels). Molecular weight markers (kDa) are show to the left. 
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Figure 3.16 Normalised activity of secreted reporter enzymes expressed from p7 trafficking 
mutants. 
Extracellular SEAP activity values of p7-SEAP fusion shown in Figure 3.15 were normalised to 
their corresponding, background-subtracted, NPT expression levels and re-plotted. Reporter 
activity was defined in normalised relative light units (RLU).  
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helix it would be a credible target for SPP, unfortunately there is no known cleavage consensus 
sequence for SPP.  
As p7 has a mass of 7 kDa uncleaved p7-SEAP fusion would be expected to have a retarded 
migration by SDS PAGE analysis compared with wt SEAP, yet no such difference was apparent 
between any of the p7 trafficking mutants and wt SEAP (Figure 3.7). The presence or absence 
of uncleaved p7 in lysates, on the cell surface or in precipitated culture supernatants could not 
be directly addressed due to poor detection of genotype 2a p7 under these conditions. 
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3.3 Discussion 
A model of NS2 topology involving an odd number of TMDs has been proposed whereby the N- 
and C-termini are oriented to the ER lumen and cytoplasm respectively (Jirasko et al., 2008; 
Phan et al., 2009; Pietschmann et al., 2006) (Figure 3.17 - Model B). However this model 
conflicts with experimental data suggesting a four TMD topology with both termini oriented to 
the ER lumen (Yamaga & Ou, 2002) (Figure 3.17 - Model A).  
3.3.1 Membrane topology of NS2 
Comparison of the outputs from 6 different topology prediction programs was used to 
generate a consensus computer model (Figure 3.3A, Figure 3.17 – Model C) for NS2 topology 
which defined three putative TMDs between positions 7-27, 29-49 and 63-86 (Table 3.1). The 
similarity between the computer model (Figure 3.17 – Model C) and the model published by 
Jirasko et al., (Jirasko et al., 2008) (Figure 3.17 – Model B) are unsurprising as 5 of the 6 
programs used were common to the two studies. The computer model (Figure 3.17 – Model C) 
predicted that the fusion of a reporter to aa 52 and aa 70 would result in luminal orientation of 
the reporter as they were modelled to terminate NS2 sequence after the second TMD and 
within the third TMD, respectively (Table 3.1).  
Control reporter enzymes where SEAP was expressed in the ER lumen (wt SEAP) or the cytosol 
(nsAP) were active and inactive respectively (Figure 3.6). These localisations were further 
confirmed by glycosidase treatment; intracellular wt SEAP was functionally active and sensitive 
to both Endo H and PNGase F, whereas extracellular wt SEAP was active but insensitive to 
Endo H treatment. nsAP was insensitive to this treatment. This pattern of glycosidase 
sensitivity demonstrates that secretion of SEAP following final glycan modification in the Golgi 
occurs rapidly and efficiently and that activity of SEAP is dependent on luminal localisation 
(Figure 3.10B).  
The corresponding β-gal controls produced active enzyme irrespective of predicted reporter 
orientation about the ER membrane (Figure 3.13). As a result, topological information of the 
NS2-truncations could not be gained from the enzyme activity of the β-gal series. However, the 
apparent N-glycosylation of a cryptic asparagine acceptor residue when β-gal was translocated 
to the ER lumen (SP β-gal; Figure 3.14) enabled comparative characterisation of the 
glycosylation states of NS2 fusions to both reporters.  
The extracellular and intracellular reporter activities of the NS2-SEAP fusions were determined 
by chemi-luminescent assay (Figure 3.9). Of the NS2-containing fusions only fusion of SEAP to 
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the first 27 amino acids of NS2 (S9) resulted in the secretion of active reporter. The relatively 
low extracellular reporter activity of S9 (nearly 5 fold down on wt SEAP) could have been due 
to instability or inefficient secretion of this fusion compared to wt SEAP and the p7-SEAP 
fusions S10 – S13 (Figure 3.7). The inability of a fusion to secrete the reporter would have led 
to accumulation of intracellular active SEAP; however intracellular reporter activity followed a 
similar trend with only S9 showing levels markedly above background (Figure 3.9). S6 displayed 
a small but reproducible level of SEAP activity albeit only 3 times that of background. These 
data suggest that only the first 27 residues of NS2 orient the reporter to the ER lumen where it 
subsequently becomes activated and secreted from the cell.  
Consistent with the enzyme activity assays intracellular S9 and S10 were sensitive to both 
glycosidases (Figure 3.12). Interestingly, S6 also displayed sensitivity to both enzymes. A similar 
pattern of apparent glycosylation was noted for the NS2-β-gal fusions (Figure 3.14) with SP β-
gal, B6 and B10 all displaying sensitivity to both enzymes, although corresponding 
glycosylation of the reporter encoded by B9 was not detected.  
The computer model (Figure 3.17 – Model C) for NS2 predicted that a reporter fused to the C-
terminus of aa 52 would be orientated to the ER lumen. Glycosylation analysis of the SEAP and 
β-gal fusions suggested that this was not case (Figure 3.12 and 3.14). This could be due to 
incorrect assignment of the second TMD within the computer model or that fusion of the 
reporter immediately proximal to the C-terminus of the second TMD impeded the ability of 
residues 1-52 to stably form a second TMD. The glycosidase sensitivity of S6 and B6 (aa 1-70) 
was concurrent with the predicted phenotype in that it appeared to orientate the reporter to 
the ER lumen. The computer model positioned residue 70 within the N-terminal half of a 24 aa 
TMD, spanning residues 63-86. Truncations either side of S6 (S5 – aa 87, S7 – aa 52) were not 
glycosylated implying that their respective C-termini were oriented to the cytosol. Taken 
together, the glycosylation data for S/B5, S/B6 and S/B7 describes NS2 topology in that 
residues 1-52 are sufficient to form only one stable TMD, aa 1-70 form two TMDs and that 
residues 1-87 are capable of forming 3 TMDs. This provided firm evidence for the presence of a 
luminal loop in NS2 between residues 52-87.  
The glycosylation profile of S9 was inconsistent with the computer model and previous 
experimental data identifying this sequence contains the first TMD of NS2 (Jirasko et al., 2008; 
Pietschmann et al., 2006; Yamaga & Ou, 2002), in that fusion of a reporter to the C-terminus of 
the first 27 aa of NS2 appeared to orientate NS2 to the ER lumen. Due to the poor expression 
and low SEAP activity of the S9 fusion it was not possible to discern whether all fusion 
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molecules or only a sub-population oriented their reporter to the lumen. Attempts to 
determine whether aa 1-27 could be recovered in the extracellular media were unsuccessful 
(data not shown). Furthermore, limited resolution of the S9 and S10 fusions by SDS PAGE 
analysis meant that it was not possible to investigate the presence of uncleaved S9 fusion 
molecules (Figure 3.7). The disparity between S9 and B9, whereby S9 was sensitive but B9 
insensitive to glycosidase treatment, was likely caused by disruption to the correct topology by 
one of the reporters and thus prevented definitive characterisation of the topology of aa 1-27. 
As the reporters encoded by S6 and B6 were oriented to the ER lumen, yet S6 displayed little 
to no SEAP activity, either intra or extracellularly, it is likely that the N-terminal 70 residues of 
NS2 were capable of retaining the fusion protein in a pre-TGN compartment as trafficking to 
the TGN would have resulted in cleavage by furin. The lack of extracellular reporter activity 
also suggests that NS2 is not secreted from the cell (Figure 3.9). 
Several membrane proteins including HCV NS4B and p7 have been speculated to assume 
multiple topologies (Isherwood & Patel, 2005; Lundin et al., 2003) with their C-termini able to 
orientate to both sides of the ER membrane. Two distinct topologies for NS2 have been 
predicted in which the C-terminus is oriented to opposing sides of the ER membrane, while the 
N-terminus is always predicted as luminal (Figure 3.17). Numerous inconsistencies have been 
noted between the studies carried out in vitro and those examining NS2 as part of the viral 
polyprotein. The studies that led to the generation of the 4 TMD model (Figure 3.17 – Model 
A) were principally conducted in vitro and it was reported that the C-terminus of NS2 is 
oriented to the ER lumen (Yamaga & Ou, 2002). More recently, experiments employing partial 
membrane permeabilisation in combined with confocal IF microscopy or protease treatment 
showed that the C-terminus of NS2 in virus-expressing cells to be oriented to the cytosol (Ma 
et al., 2011). In the present study neither S1 nor B1, encoding the full-length NS2 protein, 
displayed any glycosidase sensitivity. This study, combined with the work of Ma and colleagues 
(Ma et al., 2011), demonstrates that NS2 likely forms a single topology in cells with the C-
terminus oriented to the cytosol. It is possible that the observed difference in the localisation 
of the C-terminus of NS2 between cell-based and in vitro studies could be due to a 
requirement for a cellular chaperone to achieve correct topology. 
Together, the data presented here enabled the generation of an experimentally defined model 
topology of NS2 topology (Figure 3.17 – Model E). As discussed, NS2 C-terminal truncations 
displayed phenotypes consistent with a three TMD topology. The difference in glycosidase 
sensitivity between S9 and B9 meant that no clear conclusions could be made regarding its  
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Figure 3.17 Models of NS2 Topology. 
Model A - 4 TMD topology defined based upon glycosylation, protease protection and primary 
sequence analysis (Yamaga & Ou, 2002). Model B - 3 TMD topology based on predictions from 
6 different programs (Jirasko et al., 2008). Model C - Consensus computer model defined in 
Table 3.1. Model D - 3 TMD topology composition following 3D structure determination of 
three distinct peptides (aa 1-27, aa 27-59 and aa 60-99) by solution NMR (Jirasko et al., 2008; 
Jirasko et al., 2010). Model E - Generated from the experimental data described in this 
chapter. Model F - Predicted position of TMDs based upon experimental data and 
computation Model C. Residues marking the predicted boundaries of TMDs (green boxes), the 
position of C-terminal truncation points (red boxes) or both (green and red box) are noted. The 
means by which the models were derived are noted. NS2 sequence within fusions S6 and B6 
was terminated at residue 70. The N-terminus in each model is localised to the ER lumen. The 
catalytic domains are not shown.  
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orientation about the membrane. In this model, aa 27 it is shown as positioned on the 
cytosolic face of the ER membrane in accordance with the computer model (Figure 3.17 – 
Model C).  
Since the commencement of this work solution NMR structures for three peptides 
representing the N-terminal 99 residues of NS2 from the Con-1 isolate have been published 
(Jirasko et al., 2008; Jirasko et al., 2010). Residues 1-27 synthesised as a peptide were shown 
to adopt an overall α-helical conformation in 50% TFE and the authors proposed that residues 
3-22 form the first TMD of NS2. As with the first TMD, peptides spanning the predicted second 
(aa 27-59) and third (aa 60-99) TMDs were expressed as peptides and shown to assume α-
helical conformations in 50% TFE. Analysis of the second putative TMD revealed that it formed 
a single helix spanning residues 31-52 and possessed characteristics of an amphipathic helix 
i.e. one that interacts with the membrane interface rather than penetrating the hydrophobic 
core of the membrane. The authors noted that charged and polar residues along the spine of 
the helix would need to be neutralised by residues in a complementary domain to enable a 
stable, membrane spanning conformation (Jirasko et al., 2010). It is therefore possible that in 
the full length protein aa 52 is oriented to the ER lumen and that polar trans-membrane 
residues are not stabilised when NS2 sequence is terminated at aa 52, but are when sequence 
is terminated at aa 70.  
The third peptide formed three small helical domains with the N-terminal domain predicted to 
lie parallel to the membrane with the other domains forming a third putative TMD between 
residues 74-95 (Jirasko et al., 2010). A reconstruction of the three separate peptide structures 
is shown in Figure 3.17 – Model E. The positions of the first and second putative TMDs defined 
in Model E map closely to those modelled based upon the current work (Figure 3.17 - Model 
D). The most significant difference between Model D and Model E is the position of the C-
terminus of the putative third TMD. Jirasko et al. modelled this TMD as terminating at residue 
95 (Jirasko et al., 2010), whereas truncation analysis presented in the current work suggested 
that aa 87 was oriented to the cytosol. Another difference between the two models is the 
positioning of the C-terminal boundary of the second TMD. From the NMR structure data it 
was calculated that α-helical structure ended at residue 49 (Jirasko et al., 2010). However, in 
the present study aa 52 was not oriented to the ER lumen. 
By combining the experimentally determined Model D with the computer model (Figure 3.17 - 
Model C); a more detailed model for NS2 topology was defined (Figure 3.17 - Model F). Model 
F defines three TMDs between residues 7-27, 35-54 and 63-86 and provides a more detailed, 
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experimentally developed, model for future investigations to more precisely map NS2 
topology. 
3.3.2 P7 topology and trafficking 
The N- and C-termini of p7 are thought to localise to the ER lumen as cleavage of p7 from 
adjacent proteins (E2 and NS2) is facilitated by signal peptidase in the ER lumen(Carrere-
Kremer et al., 2002). Purified p7 spontaneously inserts into lipid bi-layers and was proposed to 
form two membrane-spanning domains (Griffin et al., 2005; Pavlovic et al., 2003; StGelais et 
al., 2007) and p7 expressed without a signal peptide is functionally active (Griffin et al., 2005; 
Jones et al., 2007; Wozniak et al., 2010). The p7 monomer has been solved by solution NMR 
and shown to assume a hair-pin structure in methanol with two α-helical domains separated 
by a short, basic-charged loop (Foster et al., 2011; Montserret et al., 2010).  
S10 encoded a polypeptide of SPp7 and SEAP separated by a furin cleavage linker. Cells 
transfected with S10 and S10-derived mutants secreted high levels of active SEAP (Figure 3.7). 
Treatment of cell lysates with Endo H and PNGase F caused a decrease in the molecular weight 
of the SEAP reporter, such that its migration was equivalent to nsAP; consistent with it having 
been glycosylated (Figure 3.12). Together these observations confirm previous work 
characterising the orientation of the C-terminus of p7 to the ER lumen and therefore that p7 
likely forms two TMDs in a hairpin-like topology.  
Analysis of the extracellular reporter activity expressed from the p7-SEAP trafficking mutants 
revealed that they all secreted high levels of active reporter (Figure 3.15). The amount of 
active reporter released from S10-S13 was comparable to the wt SEAP control vector and the 
Δ63 showed significantly more secreted active reporter, albeit to varying levels. Moreover, 
when extracellular reporter activities were normalised to levels of the vector-encoded 
resistance gene NPT, there was no discernible difference in levels of active reporter secretion 
caused by mutation of the two potential cleavage sites (Figure 3.16).  
While it is possible that the fusion proteins were undergoing an additional cleavage event, 
possibly mediated by SPP, it is interesting to note that intracellular SEAP protein levels of the 
p7 mutants were far in excess of the wt SEAP control (Figure 3.15), yet extracellular reporter 
activities were comparable between the wt SEAP control and the p7 mutants (Figure 3.15). 
This implies that either only a population of the reporter was secreted from cells transfected 
with the p7 mutants, or that the specific activity of the fusion reporter compared to the wt 
SEAP was much lower. While both hypotheses are testable by chemical inhibition, time 
constraints prevented further investigation, it was not possible to distinguish between 
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whether p7 is retained in the ER where the fusion protein was cleaved and secreted, or that a 
population of p7 is secreted from the cell in exosomes.   
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3.4 Conclusions 
The topology analysis of a series of NS2 C-terminal truncations has provided evidence that the 
N- and C-termini of NS2 are oriented to the ER lumen and the cytosol respectively. 
Furthermore, termination of the NS2 sequence at aa 70 resulted in glycosylation of the C-
terminal reporter, while truncation at aa 52 and aa 87 did not result in reporter glycosylation. 
Taken together, these results provide conclusive evidence that NS2 forms three TMDs.  
The confirmation that NS2 forms a luminal loop region enabled the generation of a more 
defined model of NS2 topology providing a firm basis for precise mapping of the TMDs of NS2. 
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4.1 Introduction 
The extent to which a peptide domain interacts with membranes i.e. whether it forms a TMD 
or an peripheral association via an amphipathic helix, can be determined by chemically 
treating isolated cellular membranes with high molarity NaCl, urea or alkaline carbonate to 
selectively remove peripherally associated proteins or detergents like Triton X-100, to 
solubilise lipids and integral membrane proteins (Fujiki et al., 1982; Matsunaga et al., 2002). 
NS2 is an integral membrane protein as its association with microsomal membranes cannot be 
disrupted post-translationally by washing with 4.5M urea (Santolini et al., 1995), high molar 
salt or alkaline carbonate (Yamaga & Ou, 2002). NS2 is capable of independently inserting into 
membranes and deletion mapping indicated the presence of two internal membrane-targeting 
sequences within residues 30-74 and 119-151 (Yamaga & Ou, 2002). The presence of these 
sequences, and whether they confer an integral or peripheral membrane association, has not 
been explored in a cell-based system. Furthermore, although expression of NS2 alone has been 
known to co-localise with ER markers by confocal IF microscopy (Franck et al., 2005; Kim et al., 
1995; Yamaga & Ou, 2002; Yang et al., 2006), the domains responsible for this sub-cellular 
targeting have not been determined.  
Prior to the completion of the studies described in Chapter 3 a solution NMR structure of the 
N-terminal 27 aa of NS2 was published (Jirasko et al., 2008). This structure described the 
putative first TMD of NS2 as spanning residues 4-23. Based upon this evidence the computer 
model of NS2 topology described in the previous chapter (Table 3.1) was refined. Using this 
refined model a series of NS2 truncations were designed to functionally dissect NS2 
membrane-targeting, subcellular distribution and membrane affinity in the absence of other 
viral protein sequence.   
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4.2 Results 
Concomitantly with the C-terminal truncation analysis described in Chapter 3; the computer 
model (Figure 4.1A) was altered to take into account the publication of the solution NMR 
structure for aa 4-23 (Jirasko et al., 2008) which was proposed to form the first TMD of NS2. 
The refined computer model (Figure 4.1B) described three TMDs spanning residues 4-23 
(rather than residues 7-27 as defined in the original computer model - Figure 3.3A), 29-49 and 
63-86. A novel series of NS2 truncation and deletion constructs were generated as N- and C-
terminal fusions to eGFP and as C-terminal FLAG-tagged fusions i.e. eGFP-NS2, NS2-eGFP and 
NS2-FLAG. NS2 truncations were defined based upon the description of three distinct sections 
within the trans-membrane: aa 1-24 encompassing the first putative TMD; aa 25-50 
encompassing the second putative TMD; and aa 51-92 comprising the remainder of the trans-
membrane domain (Figure 4.2). 
These NS2 fusion constructs were generated, without any additional HCV protein sequence, in 
order to further characterise the role of the trans-membrane domain with regards to NS2 
membrane-targeting, topology and subcellular distribution. To facilitate direct comparison 
with the work presented in the previous chapter and the potential for translation of findings 
into the fully infectious virus system, the constructs were generated using JFH-1 (genotype 2a) 
coding sequence.  
4.2.1 Generation and expression of eGFP and FLAG-tagged NS2 fusions 
The NS2 constructs were cloned into the peGFP-N1 vector to generate the NS2-eGFP series. 
However, when lysates from transfected cells were probed with antibodies to GFP and the NS2 
catalytic domain it was found that the GFP and the NS2 proteins were detectable as separate 
proteins as well as the expected fusion proteins (Appendix 4). Detection of GFP alone 
suggested that the fusion proteins were either being cleaved or that eGFP was being 
translated from a second mRNA transcript. To eliminate the chance of secondary initiation of 
eGFP alone, the vector- encoded initiation site, which enables the use of this plasmid as an 
eGFP expression control vector, was mutated from ATG to GCG by QuikChange mutagenesis 
generating a mutant form of the vector and termed peGFP-N1.QC (QC). 
To confirm the mutation at the protein level the parental (wt) and mutant (QC) peGFP-N1 
vectors were transfected into Huh7 cells and analysed for exogenous protein expression and 
direct eGFP fluorescence 48 hours post-transfection. Confocal IF microscopy of cells 
transfected with wt and QC vectors and stained with anti GFP antibody demonstrated that the  
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Figure 4.1 Refined computer model of NS2 membrane topology 
(A) The original computer model described in Figure 3.3. (B) A refined computer taking into 
account the description of the first putative TMD of NS2 by solution NMR to aa 4-23 (Jirasko et 
al., 2008). Residues marking the predicted TMD boundaries are noted (green boxes). Note the 
altered prediction of the first TMD from aa 7-27 to aa 4-23. 
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Figure 4.2 Cartoon of NS2 peptides generated as fusions to eGFP or with a C-terminal FLAG-
tag. 
A series of N-terminal and C-terminal truncations and deletion peptides were generated. The 
Residues encompassed by each peptide are noted at either end except for the three deletion 
peptides where the residues deleted are noted. 
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QC vector produced a protein that lacked direct fluorescence but reacted with the anti-GFP 
antibody (Figure 4.3A). Analysis of the wt and QC vector by western blot revealed that the 
mutation did not prevent the expression of a GFP-specific species migrating at the rate as 
mature eGFP (Figure 4.3B). A second GFP-specific protein species migrating close to the 17 kDa 
marker was also detected in cells transfected with the QC form of the vector. The next ATG in-
frame with the eGFP ORF is approximately 240 nt downstream. Translation initiated from this 
ATG would produce a severely truncated eGFP molecule with an estimated mass of 18. 5 kDa 
(wt eGFP is 26.9 kDa). This could explain the 17 kDa protein species noted in peGFP-N1.QC 
expressing cells. As a protein species of comparable size to mature eGFP was detected in cells 
expressing the mutant vector it is possible that translation in-frame with the eGFP ORF was 
being initiated from a non-ATG codon proximal to the native eGFP initiation codon as no 
examples of GCG initiated translation could be found. It has been shown that the N-terminal 
residues of GFP are vital for its direct fluorescence, to the extent that deletion of aa 2-8 
abrogated the fluorescent activity of the protein (Dopf & Horiagon, 1996) it reasonable to 
assume any non-native N-terminal region of eGFP would not possess fluorescence activity. The 
NS2-eGFP constructs generated in the peGFP-N1.QC vector were carried forward as aberrant 
initiation products could be differentiated from fusion molecules by SDS PAGE and the lack of 
fluorescence from these aberrant products would enable confocal fluorescence studies of the 
fusions. 
The majority of N-terminal fusions of NS2 to eGFP expressed to low levels or were 
undetectable in whole cell lysates from multiple, repeated transfections. Therefore, lysates 
from transfected cells were immunoprecipitated prior to SDS PAGE analysis using GFP-Trap 
beads to confirm expression (Figure 4.3C). However, even under these circumstances (51-217) 
eGFP expression was undetected. Despite mutation of the vector encoded eGFP start site; all 
of the NS2-eGFP fusions, with the exception of (1-92) eGFP, expressed a protein which reacted 
with the GFP antibody and migrated at a similar rate to eGFP alone. As discussed in section 
3.2.7, it is possible that those fusions that contained the catalytic domain may have been 
capable of cleaving the junction between the NS2 sequence and C-terminal reporter. However, 
this GFP-specific species was present in all other fusions it is more likely that it is the result of 
cleavage of the fusions by a cellular protease.  
A linker comprising the FLAG epitope followed by a stop codon (FLAG-STOP) was cloned into 
the NS2-eGFP following the NS2 sequence to generate the NS2-FLAG constructs. Expression of 
the NS2-FLAG fusions in Huh7 cells produced a further pattern of protein expression/stabilities   
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Figure 4.3 Expression of NS2-eGFP fusions 
(A) Huh7 cells transfected with the wild type peGFP-N1 vector (.wt) or the QuikChange mutant 
(.QC) were assessed by confocal IF microscopy and (B) immuno-blotting. For IF cells were fixed 
and permeabilised 48 hours post-transfection and eGFP expression was determined directly by 
observing direct fluorescence (green) or by indirectly using an anti-GFP antibody (red). 
Representative images are shown. Scale bar - 10nm. For immuno-blotting cells were harvested 
48 h post-transfection, analysed by SDS PAGE and transferred to PVDF membranes. 
Membranes were probed with a polyclonal GFP antibody and a GAPDH antibody. (C) Huh7 cells 
were transfected with the NS2-eGFP fusions. 48 hours post-transfection cells were lysed in 1% 
triton and immunoprecipitated using the GFP-Trap system prior to analysis by SDS PAGE and 
subsequent immunoblot. Molecular weight markers are shown to the left of each immunoblot 
panel. Molecular weight markers are shown to left and lane numbers are given below. 
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(Figure 4.4A). All peptides could be detected to some degree except (1-24) FLAG, which was 
never detected following multiple, repeated transfections. Similarly consistent was the 
detection of a second protein species (tNS2-FLAG – described in section 3.2.7) using the anti-
FLAG antibody in lysates of cells transfected with the full-length NS2-FLAG fusion which 
migrated at the predicted molecular weight of (25-217) FLAG. Both (51-217) FLAG and (25-217) 
FLAG migrated as single protein species suggesting that they are not susceptible to cleavage. 
This could be due to lacking the cleavage site as a result of the truncation or different folding 
of the cleavage site.  
C-terminal fusions of NS2 to eGFP were generated in the peGFP-C2 vector and typically 
expressed to detectable levels, with the exception of (25-92) and (Δ51-92) (Figure 4.4B). 
Thethree smallest eGFP- NS2 fusions (1-24), (25-50) and (51-92) were expressed to markedly 
higher levels than the other fusions. 
4.2.2 Membrane-targeting of NS2 truncation fusions by membrane fractionation 
In vitro studies of NS2 (described in Chapter 3) identified the presence of two distinct 
membrane-targeting domains within residues 30-74 and 119-151 (Yamaga & Ou, 2002). To 
confirm these findings in a cell-based system the membrane targeting of NS2 truncations were 
assessed by membrane fractionation. By analysing all three fusion sets any phenotype 
observed for a given peptide of NS2 was more likely to be a result of the specific NS2 sequence 
involved. Huh7 cells were harvested and mechanically lysed in hypotonic buffer 48 hours post-
transfection. Post-nuclear supernatants were subjected to centrifugation at 100,000 x g for 1 
hour (Figure 4.5). Membrane-associated proteins were pelleted under these conditions (M) 
whereas soluble proteins remained in the supernatant (S). The endogenous integral 
membrane protein intercellular adhesion molecule I (ICAM-I) and the soluble protein 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from mock transfected Huh7 cells were 
found exclusively in the membrane and soluble fractions respectively (Figure 4.5 right hand 
side western blot panels). The fractionation of GAPDH exclusively to the soluble fraction 
demonstrates that this method of homogenisation did not result in the formation of 
microsomes that could engulf soluble cytosolic protein leading to mis-interpretation of their 
membrane association.  
4.2.2.1 Membrane-targeting: NS2-eGFP fusions 
Full-length NS2-eGFP associated entirely with membranes. However, the truncated form of the 
fusion, tNS2-eGFP, was predominantly soluble (Figure 4.6). When the trans-membrane domain 
(aa 1-92) and the catalytic domain (aa 93-217) were analysed separately the trans-membrane  
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Figure 4.4 Expression of NS2 peptides with C-terminal eGFP or FLAG fusions 
(A) Huh7 cells were transfected with either NS2-FLAG truncation panel or (B) the eGFP-NS2 
panel. 48 hours post-transfection lysates were collected and fusion peptide expression was 
detected by probing for the appropriate fusion reporter following SDS PAGE analysis. 
Molecular weight markers are shown to the left, the epitope probed for is noted to the right 
and lane numbers are provided below each panel.  
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Figure 4.5 Flow diagram outlining the membrane targeting and dissociation procedures. 
The membrane targeting (Left) and membrane dissociation (Right) experiments are described 
in brief. Control blots for each procedure using mock transfected Huh7 cells are shown below 
each procedure. Membrane targeting experiments: (M) membrane fraction (S) soluble 
fraction. Membrane Dissociation experiments: (P) pelleted fraction (S) soluble fraction. 
Colouring is used as a visual aid. Molecular weight markers are shown to the left of each panel 
and lane numbers are given below.  
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domain was not expressed to sufficient levels to permit detection, whereas as majority of the 
catalytic domain was detected in the soluble fraction. Dissection of the trans-membrane 
domain showed that peptides (1-50) and (25-92) were predominantly or entirely soluble. This 
pattern was mirrored when the individual putative TMDs were expressed individually: the 
majority of (1-24) was not entirely membrane associated although a modest portion pelleted 
with membranes, (25-50) was entirely soluble and (51-92) was mostly soluble. Interpretation 
of the latter’s fractionation profile was hampered by a non-specific protein species at similar 
size to the fusion protein. Due to a lack of detectable protein expression in these experiments, 
it was not possible to determine the effect of aa 51-92 on membrane targeting of the catalytic 
domains as (51-217) and (Δ51-92) fusion peptides were. Interestingly (25-217) displayed the 
same phenotype as the full-length fusion (1-217) whereas (Δ25-50) showed disrupted 
membrane targeting comparable to the catalytic domain alone (93-217), yet the more severe 
deletion peptide (Δ25-92) was recovered in the membrane fraction (Figure 4.6).  
The unexpected phenotypes of (Δ25-50) and (Δ25-92) could be explained by their predicted 
topologies. As residues 25-50 and 51-92 were predicted to encompass the second and third 
TMDs, it is possible that the deletion of a single TMD from (Δ25-50) eGFP resulted in incorrect 
orientation of the catalytic domain to the ER lumen, which in turn acted to destabilise the 
membrane interactions. Whereas the deletion of two TMDs from the (Δ25-92) eGFP construct 
produced the correct orientation of the C-terminus about the ER membrane. 
The ability of (1-24) and (25-217) to partially target to membranes indicated the presence of 
two distinct membrane-targeting sequences within NS2 (Figure 4.6). 
4.2.2.2 Membrane-targeting: eGFP-NS2 fusions 
Full-length eGFP-NS2 was detected as a single protein species that associated with membranes 
(Figure 4.7). In contrast with the NS2-eGFP fusions; eGFP (1-92) was detectable and found in 
the membrane fraction. Fractionation of eGFP (93-217) was inconsistent. While other fusions 
gave reproducible phenotypes; of the four times eGFP (93-217) was examined it was recovered 
in either one or the other fractions or not detected at all. It was not clear why this 
inconsistency was observed, however because of this it was omitted from the analysis. Both 
(25-217) and (51-217) were able to associate completely with membranes. Further truncation 
analysis of the trans-membrane domain revealed that (1-24) and (25-50) may be involved in 
membrane targeting as individually they both evenly distributed between the soluble and 
membrane fractions while as a single polypeptide (1-50) they were fully able to target to 
membranes. (51-92) was also evenly distributed when expressed in isolation but was not able  
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Figure 4.6 Membrane targeting of the NS2-eGFP fusions. 
Truncations of NS2 were expressed in Huh7 cells as C-terminal fusions to eGFP and analysed 
for their abilities to target to membranes. Those fusions able to target to membranes were 
found in the pellet fraction (M) following centrifugation of lysates at 100,000 x g. Fusions 
unable to target to membranes were recovered in the supernatant (S). Fusions were detected 
by immuno-blotting for the eGFP fusion. The reporter protein expressed in isolation is shown 
in the top left panel and full-length NS2-eGFP is shown in the middle at the top. Two distinct 
protein species were seen for the full-length fusion: full-length NS2 (FL NS2) and an N-terminal 
truncation (tNS2) (black arrow heads). Two protein species were detected for (25-50); (25-50) 
eGFP (white arrow head) and ‘free’ eGFP (black arrow head). The NS2 sequence analysed in 
each blot panel is shown above. 
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Figure 4.7 Membrane targeting of the eGFP-NS2 fusions. 
Truncations of NS2 were expressed in Huh7 cells as N-terminal fusions to eGFP and analysed 
for their abilities to target to membranes. Those fusions able to target to membranes were 
found in the pellet fraction (M) following centrifugation of lysates at 100,000 x g. Fusions 
unable to target to membranes were recovered in the supernatant (S). Fusions were detected 
by immuno-blotting for the eGFP fusion. The membrane targeting of the reporter protein 
expressed from the wild type vector (peGFP.C2.wt) is shown in the top left panel. The 
phenotype of the reporter protein following introduction of a STOP codon at the site of NS2 
sequence insertion is shown in the top right panel. Full-length NS2-eGFP is shown in the 
middle at the top. The NS2 sequence analysed in each blot panel is shown above. 
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to influence the targeting of (25-50) to membranes as (25-92) was similarly evenly distributed. 
A second slightly faster migrating protein species was observed in the soluble fraction of (51-
92); this second protein species was not consistently observed but probably corresponded to 
‘free’ eGFP. The only deletion peptide to be detected from this panel was (Δ25-50) which fully 
associated with membranes (Figure 4.7). This was in stark contrast to the equivalent C-
terminally eGFP-tagged peptide ((Δ25-50 eGFP) - Figure 4.6), which was predominantly 
soluble.  
The ability of eGFP (1-50) and eGFP (51-217) to both completely target to membranes was 
evidence of two distinct membrane-targeting sequences within NS2. Evidence in support of 
three membrane-targeting sequences was given by the partial targeting of (1-24), (25-50) and 
(51-92) which were recovered to a similar degree in both fractions. 
4.2.2.3 Membrane-targeting: NS2-FLAG fusions 
The NS2-FLAG fusions were similarly analysed for their abilities to target to membrane (Figure 
4.8). As noted previously (Figure 4.4A) two FLAG-specific species were detected in lysates from 
cells transfected with the full-length NS2-FLAG peptides. The top protein species, 
corresponding to full-length NS2-FLAG, pelleted in the membrane fraction while the lower 
species, corresponding to the truncated form (tNS2), was more evenly distributed between the 
two phases (Figure 4.8). As with the previous fusion sets; specific truncations or deletions of 
NS2 with C-terminal FLAG-tags were assessed for their ability to associate with membranes. 
 The trans-membrane domain (1-92) was found exclusively in the membrane fraction while the 
catalytic domain (93-217), although mostly detected in the membrane fraction, was also 
present in the soluble fraction. This pattern was mirrored by the N-terminal truncations (51-
217) and (25-217) and the deletion peptides (Δ25-50) and (Δ25-92). Of those constructs 
encoding the catalytic domain only (Δ51-92) showed significantly impaired membrane 
targeting. Examination of the trans-membrane domain revealed that (1-50) and (25-50) were 
entirely membrane associated whereas (25-92) and (51-92) were evenly distributed between 
the two fractions. Despite being able to independently target to membranes (25-50) was not 
able to influence the targeting of (51-92), as seen by the similar targeting of (25-92) and (51-
92). Consistent with the initial expression blots, (1-24) FLAG was not detectable in the 
membrane-targeting experiments (Figure 4.8). 
The detection of both (1-50) FLAG and (51-217) FLAG in the membrane fraction demonstrated 
that each of these domains contains a distinct membrane-targeting sequence (Figure 4.8). 
Interestingly, dissection of these peptides revealed the potential for three membrane- 
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Figure 4.8 Membrane targeting of the NS2-FLAG panel. 
Truncations of NS2 were expressed in Huh7 cells with C-terminal FLAG-tags and analysed for 
their abilities to target to membranes. Those peptides able to target to membranes were 
found in the pellet fraction (M) following centrifugation of lysates at 100,000 x g. Peptides 
unable to target to membranes were recovered in the supernatant (S). Peptides were detected 
by immuno-blotting for the FLAG epitope. Two distinct protein species were seen for the full-
length fusion: full-length NS2 (FL NS2) and an N-terminal truncation (tNS2) (black arrow 
heads). The NS2 sequence analysed in each blot panel is shown above. 
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targeting sequences within NS2 as (25-50) FLAG and (93-217) FLAG could target efficiently to 
membranes and a significant proportion of (51-92) FLAG was also recovered in the membrane 
fraction. 
4.2.3 Analysis of subcellular localisation by confocal IF microscopy 
Membrane targeting analysis suggested the presence of multiple signal sequences within NS2. 
In order to discern whether these sequences were also responsible for the sub-cellular 
localisation of NS2 Huh7 cells expressing the NS2 fusion sets were analysed 48h post-
transfection by confocal IF microscopy.  
4.2.3.1 Subcellular localisation: NS2-eGFP fusions 
The subcellular localisation of the NS2-eGFP fusions was assessed (Figure 4.9). Some fusions 
showed no direct eGFP fluorescence. Fusion expression from these constructs was determined 
indirectly by staining cells with an anti-GFP antibody and imaged in red. Those with direct eGFP 
fluorescence were imaged in green. GFP expressed from the wild type vector showed typical 
staining (Figure 4.9 - top right frame) whilst a GFP-antibody-reactive species was expressed 
from the mutant vector that lacked direct fluorescence and had a different sub-cellular 
distribution to the wt protein (Figure 4.9 - top left frame). Full-length NS2-eGFP (1-217) 
showed a diffuse, non-nuclear fluorescence pattern, reminiscent or ER staining. When the two 
domains of NS2 were assessed in isolation (1-92) gave a similar pattern of eGFP fluorescence 
to the full-length NS2 fusion. This was in contrast to (93-217) which showed a dramatically 
disrupted staining pattern. The less severe N-terminal truncation (51-217) also showed 
disrupted staining and was only detectable using the anti-GFP antibody. Subcellular 
fluorescence similar to the full-length fusion was achieved when only the first TMD of NS2 was 
lacking in the case of the (25-217) fusion (Figure 4.9). Of the deletion mutants (Δ25-50) 
showed staining comparable to full-length NS2 while (Δ25-92) and (Δ51-92) showed a mixed 
phenotype of significant diffuse distribution combined with bright punctae, but not the extent 
of aggregation seen for (93-217). Dissection of the trans-membrane domain showed that each 
of the three sub-domains expressed in isolation disrupted the direct fluorescence of the eGFP 
reporter molecule. Expression of two of the putative sub-domains in tandem, either as (1-50) 
or (25-92) resulted in either wild-type staining or the formation of aggregates similar to those 
seen for (93-217) respectively (Figure 4.9). 
No interpretation was made of those fusions lacking direct eGFP fluorescence as this was 
possibly due to mis-folding of the reporter protein which could result in fusion peptides being  
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Figure 4.9 Subcellular localisation of the NS2-eGFP fusions. 
The NS2-eGFP fusions were expressed in Huh7 cells and fixed 48 hours post-transfection and 
visualised for eGFP fluorescence (green). Expression of those fusions that displayed no direct 
reporter fluorescence was confirmed by permeabilisation of fixed cells and detection of the 
fusions by indirect IF using an anti-GFP antibody (red). eGFP expressed from the wild type 
peGFP-N1 (wt) vector is shown in the top left panel. The vector into which the NS2 truncations 
were cloned (peGFP-N1.QC) which contains a mutation within the vector encoded eGFP 
initiation codon is shown in the top right. Cells transfected with this mutant empty vector 
displayed no direct eGFP fluorescence. Full-length NS2-eGFP is shown in the middle at the top. 
Representative images are shown. 
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targeted to protein recycling pathways. Thus any apparent subcellular localisation of these 
fusions may not have been determined solely by the NS2 sequence involved. 
Analysis of those constructs that displayed direct eGFP fluorescence suggested the 
trans-membrane domain as the domain responsible for NS2 sub-cellular localisation as (1-92) 
eGFP displayed a wt pattern, whereas the localisation of (93-217) eGFP was disrupted 
compared with the full-length fusion (Figure 4.9). Furthermore, the putative first and second 
TMDs may be responsible for NS2 localisation as (1-50) eGFP also displayed localisation 
comparable to wt. 
4.2.3.2 Subcellular localisation: eGFP-NS2 fusions 
eGFP expressed from the wt and mutant STOP peGFP-C2 vectors were diffuse and displayed 
characteristic nuclear staining. As described earlier, the mutant STOP vector encoded an 
additional STOP codon, preventing translation of the multiple cloning site (MCS) as a C-
terminal extension to the eGFP molecules.  
The non-nuclear, diffuse staining observed for full-length NS2-eGFP was corroborated by the 
fusion of eGFP to the N-terminus of NS2 which produced a similar staining pattern (Figure 4.10 
(1-217)). Removal of the catalytic domain (1-92) did not alter the subcellular distribution of the 
eGFP reporter. However, fusion of eGFP to the catalytic domain alone resulted in the 
accumulation of eGFP in small cytoplasmic foci. Surprisingly (51-217) and (25-217) both 
displayed a more exaggerated disruption to full-length NS2 staining than (93-217), as did (Δ51-
92). Further investigation of the trans-membrane domain revealed that (1-50) was able to 
target eGFP in a similar pattern to full-length NS2 while (25-92) showed a large degree of 
fusion peptide aggregation in addition to the more typical diffuse staining. None of the three 
sub-domains in isolation were able to produce a fluorescence pattern similar to full-length 
NS2: (1-24) had a pattern more similar to wt eGFP, in that it was present throughout the cell, 
but also appeared to be aggregating in nuclear or peri-nuclear compartments; (25-50) 
produced a distinctive punctuate distribution somewhat similar to (Δ51-92); while (51-92) was 
diffuse throughout the cytoplasm as well as in large aggregates, akin to (25-217). The staining 
pattern observed for (Δ25-92) was comparable to (93-217) but the less severe deletion (Δ25-
50) was like full-length NS2 (Figure 4.10). 
Consistent with the NS2-eGFP fusion (Figure 4.9), this data set also indicate that the trans-
membrane domain mediates NS2 localisation as eGFP (1-92) sub-cellular distribution was 
indistinguishable from full-length eGFP NS2 (Figure 4.10). eGFP fused to the catalytic domain, 
eGFP (93-217), showed a partially disrupted pattern of fluorescence compared to the full- 
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Figure 4.10 Subcellular localisation of the eGFP-NS2 fusions. 
The eGFP-NS2 fusions were expressed in Huh7 cells and fixed 48 hours post-transfection and 
visualised for eGFP fluorescence (green). eGFP expressed from the wild type peGP-C2 (wt) 
vector is shown in the top left panel. The vector containing a stop site corresponding to the 
site of NS2 sequence insertion (peGFP-C2.STOP) is shown in the top right. Full-length NS2-eGFP 
is shown in the middle at the top. Representative images are shown. 
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length fusion. While (1-50) eGFP also displayed localisation comparable to wt, it maybe that 
the first putative TMD (aa 1-24) is more important for achieving correct localisation than the 
second TMD (aa 25-50) as eGFP (25-92) and (25-217) showed disrupted localisation but eGFP 
(Δ25-50) was comparable to wt (Figure 4.10). 
4.2.3.3 Subcellular localisation: NS2-FLAG fusions 
The NS2-FLAG fusions were generated in the peGFP-N1.QC vector background which displayed 
no direct fluorescence (Figure 4.3B). Indirect detection of the FLAG epitope enabled the 
analysis of the NS2-FLAG fusions. The ability of NS2 to determine its own sub-cellular 
distribution in spite of fusion to other proteins was confirmed as (1-217) FLAG had a non-
nuclear diffuse staining pattern (Figure 4.11), although the staining appeared to be more 
discrete when directly compared to NS2-eGFP (Figure 4.9) and eGFP-NS2 (Figure 4.10). This 
discrepancy may be due to the respective fluorophores and techniques used to identify the 
three fusion sets.  
Analysis of the NS2-FLAG fusion revealed that the only FLAG-tagged peptides to show a similar 
staining pattern to full-length NS2-FLAG were (25-217) and (Δ25-50) (Figure 4.11). (Δ25-92) 
FLAG was similarly diffuse but lacked the defined perinuclear staining observed in the full-
length protein. The only consistent feature of these three fusions was the catalytic domain, 
which expressed on its own, (93-217 FLAG, showed a disrupted phenotype. Surprisingly (Δ51-
92) showed a more disrupted phenotype than the more extensive deletion peptide (Δ25-92) 
(Figure 4.11).  
It was not clear from the NS2-FLAG fusions which domains of NS2 were necessary to confer 
wild-type NS2 sub-cellular localisation, in the absence of the other viral proteins. 
4.2.4 Affinity of the membrane interactions of NS2 truncation fusions  
To investigate whether any of the fusions were forming integral or peripheral membrane 
associations; the membrane affinity of the fusion peptides was determined following 
treatment of the membrane fraction with isotonic buffer, 1 M NaCl, 100 mM Na2CO3 pH 11.5 
and 1% Triton X-100 (Figure 4.5). When this procedure was applied to mock-transfected Huh7 
cells the endogenous protein intercellular adhesion molecule 1 (ICAM-I) was found in the 
pellet fraction following treatment of the membranes with isotonic buffer, high salt and 
alkaline carbonate. ICAM-I was fully recovered in the soluble fraction only following treatment 
with detergent (Figure 4.5).  
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Figure 4.11 Subcellular localisation of the NS2-FLAG fusions. 
The NS2-FLAG peptides were expressed in Huh7 cells and fixed 48 hours post-transfection. 
Cells were permeabilised and tagged NS2 peptides were visualised following indirect 
immunofluorescence (IF) labelling of the FLAG epitope (green). Where necessary, nuclei are 
outlined (white rings). Full-length NS2-eGFP is shown in the middle at the top. Representative 
images are shown. 
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The eGFP control expression vectors were assessed by this procedure and GFP expressed from 
the C2.wt and C2.STOP vectors was found predominantly in the supernatant of the initial 
clarified membrane fractionation such that they could not be further removed from 
membranes by this technique (Figure 4.12A and B). The protein produced by the peGFP-N1.wt 
vector was almost entirely soluble however a trace amount did pellet with the initial 
membrane fraction (Figure 4.12C). This population could be partially removed from 
membranes was not removed by washing in 1 M NaCl, which strips proteins from membranes, 
but was extracted by alkaline carbonate, which strips proteins from membranes and linearises 
membrane vesicles suggesting that a small population of eGFP expressed from this vector was 
being packaged into vesicles. 
These controls demonstrate that the eGFP reporter has a very low affinity for membranes 
allowing the examination of NS2 sequences expressed as fusions to eGFP. Therefore this 
method was applied to the eGFP and FLAG-tagged NS2 peptides. Whenever possible the FLAG-
tagged versions were shown for simplicity as they represented the least altered versions of the 
NS2 sequence. Full-length NS2 fusions could only be removed from the membrane fraction 
with detergent (Figure 4.13A and B) consistent with previous data describing NS2 as an integral 
membrane protein (Santolini et al., 1995). Interestingly the truncation form of NS2, tNS2, 
observed in the full-length NS2-FLAG transfected cells showed a partial association with 
membranes in the membrane-targeting experiments (Figure 4.8), yet that which was 
associated with membranes was also only solubilised after detergent treatment (Figure 4.13B). 
The two N-terminal truncations of NS2 within the trans-membrane domain (25-217) and (51-
217) also appeared to insert into membranes as neither could be stripped from membranes 
using high salt or alkaline carbonate washes (Figure 4.13C and D respectively). Analysis of the 
complete trans-membrane domain (aa 1-92) showed that it was able to act like an integral 
membrane polypeptide (Figure 4.14A) as it was only recovered in the soluble fraction after 
treatment with detergent. As the three catalytic domain fusions showed different propensities 
towards membranes (Figure 4.6, 4.7 and 4.8 – (93-217)) all versions were tested for their 
membrane affinity. In the membrane-targeting experiment the catalytic domain expressed as 
either eGFP (93-217) or (93-217) FLAG targeted predominantly to the membrane fraction 
(Figure 4.6 and 4.8). When the membrane-associated molecules were treated to disrupt the 
membrane interactions; washing in isotonic buffer and high molarity salt removed little or no 
fusion peptides but they were partially solubilised by alkaline carbonate treatment (Figure 
4.14B and C). This behaviour is most consistent with that of a soluble protein that has become 
trapped in microsomes as alkaline carbonate linearises membrane bi-layers, as well as 
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Figure 4.12 Membrane dissociation of eGFP expression control plasmids. 
Huh7 cells were transfected with (A) peGFP-C2.wt, (B) peGFP-C2.STOP and (C) peGFP-N1.wt 
and the membrane affinity of the expressed eGFP molecules was determined by treatment 
with chaotropic agents and detergent. Proteins associated with the membrane fraction 
following centrifugation of the post-nuclear supernatant at 100,000 x g for 10 minutes were 
resuspended in either isotonic buffer (Un.), 1 M NaCl (NaCl), 100 mM Na2CO3 pH 11.5 (Na2CO3) 
or 1% triton (Triton) and incubated at 25°C for 30 minutes. Fusions were either recovered in 
the pellet (P) or soluble (S) fraction following centrifugation of treated membranes at 100,000 
x g. Molecular weight markers are shown to the left, the fusion tag probed for by immuno-blot 
is noted to the right and lane numbers are provided below each panel. 
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Figure 4.13 Membrane dissociation of full-length NS2 and two N-terminal truncations. 
Full length NS2 with either (A) an N-terminal eGFP fusion, (B) a C-terminal FLAG-tag and (C) the 
FLAG-tagged N-terminal truncations (25-217) and (D) (51-217) were assessed for the affinity of 
their interactions with membranes. Proteins associated with the membrane fraction following 
centrifugation at 100,000 x g for 10 minutes were resuspended in either isotonic buffer (Un.), 
1 M NaCl (NaCl), 100 mM Na2CO3 pH 11.5 (Na2CO3) or 1% triton (Triton) and incubated at 25°C 
for 30 minutes. Fusions were either recovered in the pellet (P) or soluble (S) fraction following 
centrifugation of treated membranes at 100,000 x g. Molecular weight markers are shown to 
the left, the fusion tag probed for by immunoblot is noted to the right and the lane numbers 
are provided below each panel. 
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Figure 4.14 Membrane dissociation of the trans-membrane and catalytic domains of NS2. 
 (A) The FLAG-tagged NS2 trans-membrane domain and (B) the catalytic domain expressed 
with a C-terminal FLAG-tag, (C) an N-terminal eGFP fusion or (D) a C-terminal eGFP fusion were 
assessed for the affinity of their interactions with membranes. Proteins associated with the 
membrane fraction following centrifugation at 100,000 x g for 10 mins were resuspended in 
either isotonic buffer (Un.), 1 M NaCl (NaCl), 100 mM Na2CO3 pH 11.5 (Na2CO3) or 1% triton 
(Triton) and incubated at 25°C for 30 minutes. Fusions were either recovered in the pellet (P) 
or soluble (S) fraction following centrifugation of treated membranes at 100,000 x g. Molecular 
weight markers are shown to the left and the fusion tag probed for by immunoblot is noted to 
the right of each panel. 
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stripping them of protein content. As a similar profile was not observed for the soluble protein 
control GAPDH (Figure 4.5) this indicates that (93-217) FLAG and eGFP (93-217) may be 
packaged to vesicles. The incomplete solubilisation after triton treatment seen for eGFP (93-
217) was likely the result of experimental error as all peptides were consistently solubilised by 
detergent treatment. Only a small amount of the (93-217) eGFP fusion was able to target to 
membranes (Figure 4.7) and this population was readily disrupted by further washing of the 
membrane pellet in isotonic buffer alone as well as high molarity salt and alkaline carbonate 
(Figure 4.14D). The fractionations shown in Figure 4.14B, C and D were carried out at the same 
time. Attempts to repeat these findings, particularly using (93-217) FLAG, were highly 
inconsistent. In some instances they did not associate with membranes at all, in others they 
were so poorly expressed as to prevent effective phenotyping and in other instances they were 
resolutely associated with membranes such that they could only be solubilised following 
detergent treatment. 
While the reason for the inconsistencies was not clear, it is possible that the catalytic domain 
forms weak or unstable interactions with membranes such that variations in pellet 
resuspension between experiments or fluctuations in ambient laboratory temperature were 
responsible for the lack of reproducibility as membrane dissociations incubations were carried 
at room temperature, rather than on ice, to enhance membrane fluidity and lipid solubility. 
Isolated sub-domains of the trans-membrane domain were analysed for the affinity of their 
membrane interactions (Figure 4.15). As the structure of the putative first TMD had been 
solved by solution NMR (Jirasko et al., 2008), dissociation experiments focused on the putative 
second and third TMDs encoded by aa 25-50 and 51-92, respectively. Analysis of both putative 
TMDs together (25-92) showed that, like the complete trans-membrane domain, it was able to 
form a strong interaction with membranes as it was only found in the soluble fraction after 
triton treatment (Figure 4.15A). In the membrane-targeting experiments eGFP (51-92) and (51-
92) FLAG were recovered to equal amounts in both fractions. Despite numerous attempts (51-
92) FLAG could not be detected to sufficient levels under these conditions. The membrane-
targeted population of the eGFP (51-92) fusion could be detected and displayed a dissociation 
profile more consistent with that of an integral membrane protein than an amphitropic protein 
(Figure 4.15B). Residues 25-50 showed a varying affinity for membranes. eGFP (25-50) showed 
even distribution between the membrane and soluble fractions in the membrane-targeting 
experiments and the membrane-associated portion could be partially disrupted by washing 
with high molarity salt or alkaline carbonate (Figure 4.15C). This response following incubation 
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with agents that exhibit chaotropic properties is characteristic of a peripherally-associated 
protein. However, when (25-50) was examined with either a C-terminal eGFP fusion or FLAG-
tag the membrane targeted population was insensitive to all but detergent treatment (Figure 
4.15D and E, respectively) suggesting that it is capable of forming a TMD. 
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Figure 4.15 Membrane dissociation of the putative membrane spanning domains of NS2. 
Isolated sub-domains of the NS2 trans-membrane domain were assessed for the affinity of 
their interactions with membranes. Proteins associated with the membrane fraction following 
centrifugation at 100,000 x g for 10 mins were resuspended in either isotonic buffer (Un.), 1M 
NaCl (NaCl), 100mM Na2CO3 pH 11.5 (Na2CO3) or 1% triton (Triton) and incubated at 25°C for 
30 minutes. Fusions were either recovered in the pellet (P) or soluble (S) fraction following 
centrifugation of treated membranes at 100,000 x g. Molecular weight markers are shown to 
the left, the fusion tag probed for by immunoblot is noted to the right and lanes number are 
provided below each panel. 
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4.3 Discussion 
Building upon the topology analysis of the previous chapter, truncations of NS2 were assessed 
for their ability to interact with membranes, the affinity of those interactions and whether the 
ability to target to membranes determined NS2 subcellular distribution in the absence of the 
other viral proteins.  
4.3.1 NS2 contains multiple membrane-targeting sequences  
Examination of the membrane-targeting of the NS2 fusions revealed the presence of multiple 
membrane-targeting sequences. As both eGFP (1-50) and eGFP (51-217) were recovered in the 
membrane fraction this was evidence of two distinct membrane-targeting sequences within 
NS2. Further investigation revealed that (1-24) and (25-50) were able to partially target to 
membranes suggesting that the targeting of residues 1-50 may be a result of two inefficient 
membrane-targeting sequences working synergistically. This hypothesis would support 
interactions between the predicted first and second TMD of NS2.The NS2-eGFP fusions 
indicated the presence of two membrane-targeting sequences located within residues 1-24 
and 25-217, although targeting was inefficient.  
The NS2 FLAG constructs displayed a higher propensity for membrane-targeting than the eGFP 
fusion, with both the trans-membrane domain (1-92) and the catalytic domain (93-217) 
targeting to membranes. This could be because a FLAG-tag (8 aa) represented a less disruptive 
feature to NS2 topology formation and membrane interactions than an eGFP molecule (238 
aa). (1-50) FLAG and (51-217) FLAG both targeted exclusively to the membrane fraction (Figure 
4.8) demonstrating that they each contain a distinct membrane-targeting sequence. 
Interestingly, dissection of these peptides revealed the potential for three membrane-
targeting sequences within NS2 as (25-50) FLAG and (93-217) FLAG were targeted efficiently to 
membranes and a significant proportion of (51-92) FLAG was also recovered in the membrane 
fraction. This demonstrated the sequence spanning the second predicted TMD (aa 25-50) 
could efficiently target to membranes. However, the apparent membrane-targeting sequence 
located within aa 25-50 was not able to enhance the membrane targeting capacity of the 
sequence spanning the third predicted TMD (51-92) as both (51-92) and (25-92) FLAG were 
recovered in both the membrane and soluble fractions. 
Solution of the catalytic domain by X-ray crystallography showed a tightly packed dimer with 
no apparent trans-membrane helices (Lorenz et al., 2006b) (Figure 1.8). However the dimer 
was crystallised with two molecules of n-decyl-β-D-maltopyranoside (DM), a lipid-like non-
ionic detergent. These detergent molecules co-crystallised on what is believed to be the 
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membrane-proximal face of the crystal dimer (Lorenz et al., 2006b). The presence of these 
molecules and the requirement for detergent in NS2/3 cleavage buffers (Thibeault et al., 2001) 
could indicate that the catalytic domain requires a stabilising hydrophobic environment which 
is ensured by the C-terminal membrane-targeting sequence. In agreement with this the FLAG-
tagged catalytic domain, (93-217) FLAG, was able to target to membranes. On the surface, this 
appeared to be contradicted by expressed as a fusion to eGFP which was either soluble, (93-
217) eGFP, or inconsistent, eGFP (93-217). In the absence of the trans-membrane domain the 
catalytic domain may only form a weak associate with membranes. Expression of the catalytic 
domain as a fusion to a large, soluble eGFP molecule may be sufficient to destabilise the 
interaction between the catalytic domain and membranes. 
Overall these data suggest that residues 25-50, which are predicted to encompass the second 
TMD of NS2, contain a membrane-targeting sequence that may interact with upstream 
sequences in the putative first TMD. A second membrane-targeting sequence may be located 
within residues 51-92 (predicted to encompass the third TMD) as this domain expressed as a 
FLAG-tagged peptide or as an N-terminal fusion to eGFP i.e. eGFP (51-92), was able to partially 
target to membranes. The FLAG-tagged truncations also indicated the presence of a 
membrane-targeting sequence within the catalytic domain (aa 93-217). These data are 
consistent with the observations of Yamaga and Ou who reported the presence of two 
membrane-targeting sequences within between residues 30-74 and 119-151 (Yamaga & Ou, 
2002). As no truncations were made into the catalytic domain no refinement can be made 
regarding the proposed location of the C-terminal membrane-targeting sequence (aa 119-151). 
However, the data presented here suggests that the N-terminal membrane-targeting sequence 
located between residues 30-74 may in fact represent two distinct targeting domains between 
residues 30-50 and 51-74. 
4.3.2 Correlation between membrane-targeting and subcellular localisation 
NS2 has been shown to target to membranes (Santolini et al., 1995; Yamaga & Ou, 2002) and 
to co-localise with markers of the ER (Franck et al., 2005; Kim et al., 1995; Yamaga & Ou, 2002; 
Yang et al., 2006). Consistent with this all three tagged versions of full-length NS2 (wt) 
associated with membranes and produced a diffuse, peri-nuclear staining pattern by confocal 
IF microscopy. However, NS2-FLAG appeared to localise to more discrete structures (Figure 
4.11) compared to the two full-length eGFP-tagged versions (Figure 4.9 and 4.10), possibly as a 
result of the detection methods used.  
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One of the questions addressed by this work was whether the membrane-association of NS2 
determined its subcellular distribution. To aid in the analysis of the NS2 truncations; a table 
was generated summarising their membrane-targeting abilities and whether they achieved a 
sub-cellular localisation similar to their respective full-length NS2 fusions (Table 4.1). From this 
summary it was evident that membrane-targeting of NS2 truncation was not sufficient to 
confer correct localisation as numerous fusions were recovered in the membrane fraction and 
yet were unable to achieve a cellular distribution similar to wt. Furthermore, it was apparent 
that the two mechanisms may be entirely distinct as two truncations, (1-50) eGFP and (Δ25-50) 
eGFP, achieved wt localisation despite being unable to target to membranes (Table 4.1). 
The trans-membrane domain, in particular residues 1-50, seems to be involved in both 
processes as the (1-92) and (1-50) fusions showed a general ability to target to membranes 
and assume a wt localisation (Table 4.1). However, it appears as though neither of the 
sequences predicted to contain the first and second TMDs (aa 1-24 and 25-50 respectively) are 
absolutely required for membrane-targeting or subcellular localisation. All of the (25-217) 
fusions were able to target to membranes and all had subcellular distributions similar to wt 
protein. Dissection of the trans-membrane domain into three peptides (1-24, 25-50 and 51-
92), each predicted to encompass one of the three TMDs, suggested a co-operative effect of 
the three domains as individually they displayed aberrant sub-cellular localisations and a 
reduced ability to target to membranes (Table 4.1). 
4.3.3 Domains responsible for subcellular distribution 
As membrane association did not appear to dictate the subcellular distribution of NS2, the 
fusions were scrutinised with an aim to identifying sequences responsible for producing NS2 
subcellular distribution. However no single domain appeared to be solely responsible for 
achieving wt subcellular distribution.  
Analysis of the FLAG-tagged peptides implicated sequences within the trans-membrane 
domain and the catalytic domain that combined to achieve wt staining as only the catalytic 
domain was common to the three fusions which displayed similar distribution to full-length 
NS2, yet the catalytic domain on its own, (93-217) FLAG, displayed an aberrant phenotype.  
A greater degree of consistency was seen between the two sets of eGFP fusions (Figure 4.9 
and 4.10). In both cases (1-92) and (1-50) redistributed the reporter in similar pattern to that 
of the full-length fusions. The catalytic domains in isolation were unable to achieve a correct 
subcellular distribution, but could be partially or fully recovered by the addition of all but the 
putative first TMD in the form of (25-217) eGFP and eGFP (25-217), respectively. Deletion of   
Chapter 4: Membrane Association Studies 
 
155 
 
 
Table 4.1 Summary of the membrane-targeting and subcellular localisation of the eGFP and 
FLAG-tagged NS2 fusions. 
The phenotypes observed for the membrane-targeting (M/S) i.e. recovered in the membrane 
(M), soluble (S) or both fractions (M/S), of each fusion and their subcellular distributions were 
similar to that of the full-length proteins (WT IF) i.e. yes (Y), no (N) or mixed (Y/N), as 
determined by confocal IF are summarised. Phenotypes were either comparable to (green) or 
different from (red) the full-length fusions. Peptides that were recovered in both the 
membrane and soluble fractions or displayed subcellular localisation similar to wt but with 
limited additional punctate structures are shown in yellow. (-) denotes peptides where no 
phenotype could be assigned. 
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the second sub-domain (Δ25-50) had no effect on the staining pattern for either eGFP fusion 
or the corresponding FLAG fusion (Figure 4.11). Deletion of the both second and third sub-
domains (Δ25-92) from the eGFP fusions resulted in a partially disrupted phenotype yet 
surprisingly this was more significantly disrupted by deletion of the third putative TMD, (Δ51-
92). A hypothesis suggesting that interactions between the trans-membrane domain and the 
catalytic domain combine to achieve wt distribution was further added to by the wt 
distribution of (25-217) eGFP yet when it was expressed as two constituent domain (25-92) 
and (93-217) they aggregated in large punctae.  
In conclusion, truncation analysis of NS2 indicated that the catalytic domain is not required for 
subcellular localisation and that regions of the trans-membrane domain may interact to induce 
NS2 subcellular localisation.  
4.3.4 Membrane affinity 
The membrane targeting experiments highlighted that multiple domains of NS2 were capable 
of interacting with membrane. To determine whether truncations of NS2 that targeted to 
membranes were forming integral membrane domains the membrane-targeted fractions were 
treated with high molarity salt (1 M NaCl) and alkaline carbonate (100 mM Na2CO3, pH 11.5) 
which remove peripherally associated proteins from membranes (Fujiki et al., 1982; 
Matsunaga et al., 2002).   
Treatment of full-length NS2  fusions with high molarity salt and alkaline carbonate confirmed 
previous reports that NS2 is an integral membrane protein as all three tagged versions were 
resistant to both agents (Figure 4.13A and B) (Santolini et al., 1995; Yamaga & Ou, 2002).  
Deletion of the first or the first and second putative TMDs did not prevent NS2 from inserting 
into membranes as neither (25-217) nor (51-217) FLAG were displaced with high molarity salt 
or alkaline carbonate (Figure 4.13C and D). Similarly, the complete trans-membrane domain 
(1-92) with a C-terminal FLAG was efficiently targeted to and inserted into membranes.  
The membrane-targeting experiments highlighted that the phenotype of the catalytic domain 
(93-217) varied dramatically depending upon the fusion situation. A similar inconsistency was 
noted in the membrane affinity of those molecules able to target to membranes (Figure 4.14B, 
C and D). As discussed earlier, the catalytic domain may form a weak association with 
membranes that could be disrupted by the fusion of this domain to an eGFP molecule, 
whereas epitope tagging of this domain with the FLAG peptide may be less disruptive. The 
inconsistency of membrane-targeting and membrane affinity of the catalytic domain is highly 
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suggestive that this domain does not integrally insert into the membrane. In support of this 
conclusion; the integral membrane protein ICAM-I was consistently recovered in the 
membrane fraction and only extracted following addition of detergent, as were full-length NS2 
(1-217) and the NS2 trans-membrane domain alone (1-92). In agreement with the X-ray crystal 
structure of the catalytic domain it was concluded that residues 93-217 likely form a soluble 
domain that interacts superficially with membranes via an internal membrane-targeting 
sequence. 
In the previous chapter a model was presented for the topology of NS2 based upon the 
glycosylation data (Figure 3.17 – Model F). The glycosylation data showed that NS2 achieves a 
three TMD topology but little could be concluded as to the precise position of the TMDs suffice 
to say they are all contained within the N-terminal 86 residues.  
It has previously been shown that aa 1-27 of NS2 from the Con1 isolate, expressed with a C-
terminal eGFP molecule, displayed a comparable subcellular localisation to that of full-length 
NS2 from the same isolate (Jirasko et al., 2010). The fusions involving only residues 1-24 of NS2 
described in this chapter were either not detected by confocal IF microscopy or showed highly 
altered distribution compared with full-length NS2 fusions. The subtle difference in peptide 
length or the different genetic origins of the sequences examined may be responsible for these 
inconsistencies. Analysis of S9 and B9 in the previous chapter, which included aa 1-27 of NS2, 
suggested that this sequence may not encompass the whole of the first TMD of NS2. Two of 
the fusions examined in the present chapter including aa 1-24 of NS2 showed a partial 
membrane association (Figure 4.6 and 4.8). The N-terminal domain of NS2 may form the first 
TMD but in the systems employed in this study it was not able to do so very efficiently. Poor 
efficiency of this integration could be inferred from the low levels of active SEAP detected for 
the S9 fusion and minimal sensitivity of B9 to glycosidase treatment. The NMR structure of this 
domain led the authors to speculate that this domain could form a trans-membrane helix 
provided hydrophilic residues within the helix were neutralised by complementary interactions 
with another intra-membrane domain (Jirasko et al., 2010). 
Analysis of (25-50) and (51-92) in isolation showed that they did not target efficiently to 
membranes (Table 4.1). More interesting though was the affinity of the interactions of those 
molecules that were able to target to membranes. Both of these domains, once targeted to 
membranes, appeared to form integral associations as only eGFP (25-50) was displaced from 
the membranes following treatment with chaotropic agents (Figure 4.15). Further evidence for 
aa 51-92 containing a TMD was provided by the membrane dissociation response of (51-217) 
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FLAG, which responded as an integral membrane protein while (93-217) did not. These data 
are consistent with aa 25-50 and 51-92 each containing a TMD, thus supporting the 
experimentally determine model proposed in the previous chapter (Figure 3.17 – Model F). 
4.3.5 Truncated NS2 (tNS2) 
A truncated form of NS2 (tNS2) was observed in lysates of cells transfected with the full-length 
NS2-FLAG and NS2-eGFP constructs. Termed tNS2 this protein has been detected with 
antibodies raised against the C-terminal catalytic domain of NS2 and antibodies targeting C-
terminal tag epitopes, but not with corresponding N-terminal tagged NS2 (Popescu et al., 
2011; Stapleford & Lindenbach, 2011). In this study tNS2 appeared to be generated from a 
specific cleavage event occurring in the vicinity of residue 25 as side by side comparison of 
tNS2 with (25-217) FLAG showed them to migrate at similar rates by SDS PAGE analysis (Figure 
4.8 top right panel). Membrane-targeting analysis revealed that although only a proportion of 
tNS2-eGFP and tNS2-FLAG were able to target to membranes (Figure 4.6 and Figure 4.8). The 
population of tNS2-FLAG that did associate with membranes appeared to be anchored to the 
membrane as it too was only solubilised by detergent treatment (Figure 4.13B).  
tNS2 has been observed in experiments using full-length JFH-1 virus (Welbourn et al., 2009) 
and chimeric viruses (Boson et al., 2011; Jirasko et al., 2008; Jirasko et al., 2010; Ma et al., 
2011; Stapleford & Lindenbach, 2011). However, tNS2 has not been reported in all virus 
systems (Tedbury et al., 2011; Yi et al., 2009) and was not noted in initial work on NS2 carried 
out in vitro (Hijikata et al., 1993a; Hijikata et al., 1993b; Santolini et al., 1995; Yamaga & Ou, 
2002). The role, if any, of tNS2 within the virus life-cycle has not been explored.  
NS2A of yellow fever virus (YFV) has been shown to undergo an additional internal cleavage 
event mediated by the viral protease (Nestorowicz et al., 1994). As tNS2 was observed here in 
the absence of the other viral proteins this does not seem to be the case in HCV. By 
comparison with the (25-217) FLAG; the tNS2 cleavage event was predicted to occur in the 
vicinity of residue 25. This residue is predicted to reside in the cytosol between the putative 
first and second TMDs making it a potential target for a cytosolic protease. Alternatively, as the 
loop region between TMD 1 and TMD2 is predicted to be very small, the cleavage point that 
produces tNS2 may well be positioned within the membrane making it potential target for 
signal peptide peptidase, which has been shown to cleave HCV core within the membrane 
(McLauchlan et al., 2002). 
Identification of the cleavage site and subsequent mutation within the full length virus would 
help to establish the significance of tNS2 or whether it is an experimental or genotype artefact. 
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4.4 Conclusions  
Full length NS2 associates with membranes regardless of terminal fusion reporter. In addition 
to this NS2 contains specific subcellular targeting motifs, which appear unaffected by N- and C-
terminal reporters/epitope tags. Building on previous findings by Yamaga and Ou (Yamaga & 
Ou, 2002), evidence provided here describes the presence of three internal membrane-
targeting sequences within NS2 between residues 30-50, 51-74 and 119-151.  
The ability of NS2 to associate with membranes is not sufficient for its native sub-cellular 
localisation, nor does native sub-cellular distribution confer membrane association. This 
suggests that different domains are required for the two processes.  
Finally, FLAG-tagged fusions provided evidence that aa 25-50 and 51-92 encode the second 
and third TMDs of NS2, consistent with topology Model F proposed in the previous chapter 
(Figure 3.17). 
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5.1 Introduction 
Since the identification of the JFH-1 isolate, which is capable of undergoing a full round of 
infectivity in cell culture (Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005), the 
roles of NS2 and p7 have been the focus of several studies. The generation of bi-cistronic JFH-1 
viruses allowed the systematic deletion of p7 and NS2 identifying that both had essential roles 
in the morphogenesis of infectious virus particles (Jones et al., 2007; Steinmann et al., 2007). 
Since then there have been numerous studies investigating the interactions between NS2 and 
the other viral proteins. 
Co-immunoprecipitations (co-IP) using epitope tagged NS2 in full-length virus experiments 
identified interactions between NS2 and E1, E2, p7, NS3 and NS5A (Jirasko et al., 2010; Ma et 
al., 2011; Stapleford & Lindenbach, 2011; Tedbury et al., 2011). Since NS2 has previously been 
shown to interact with both structural and non-structural proteins this has strengthened the 
hypothesis that NS2 may function in virion assembly by uniting nascent particles with RNA 
replication complexes (Dimitrova et al., 2003; Pietschmann et al., 2006). A schematic of the 
viral proteins along with two models of NS2 membrane topology are shown in Figure 5.1.  
The interaction between NS2 and E2 has been implicated as essential for the production of 
infectious virions as mutations that block this interaction showed impaired or attenuated 
infectivity (Jirasko et al., 2010; Popescu et al., 2011; Stapleford & Lindenbach, 2011). Mutation 
analysis found that K81A had a slightly reduced E2 binding (Phan et al., 2009; Stapleford & 
Lindenbach, 2011) and that mutation of D62A in NS2, which reduced infectivity 100 fold, could 
be recovered by the additional mutation of I360T in E2 (Phan et al., 2009). Mutation of F77 to 
alanine impaired the NS2:E2 interaction but this could be recovered by a compensatory 
mutation with the TMD of E2 (V341A) (Jirasko et al., 2010). Popescu et al., (Popescu et al., 
2011) found that by introducing alanines after residues 16 and 41, in order to alter the rotation 
of the α-helix of putative TMDs by 130°, that A41 insertion blocked the NS2:E2 interaction but 
was unaffected by the A16 insertion. It was also reported that deletion of residues 10-62 of 
NS2 blocked the NS2:E2 interaction (Popescu et al., 2011). From this it was proposed that the 
NS2 trans-membrane domain is important for mediating an intra-membrane interaction 
between NS2 and E2 (Popescu et al., 2011; Stapleford & Lindenbach, 2011).  
Transposing the JFH-1 coding sequence for aa 1-27 with that of the Con 1 isolate blocked 
infectivity, but long-term passage in cell-culture produced a compensatory mutation of E3D in 
p7 which rescued infectivity, suggesting that p7 plays a regulatory role in the NS2:E2  
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Figure 5.1 Membrane topology of HCV proteins. 
(A) Schematic representation of the membrane interactions of the HCV proteins. The region 
encoding core to p7 (C-p7) (orange rectangle) was translated as a polypeptide in studies 
investigating the E2/NS2 interaction. NS2 is shown with three putative TMDs (green). TMDs of 
other viral proteins and the amphipathic helix of NS5A are shown as cylinders (blue) and the 
membrane is shown as a lipid bi-layer. (B) Model F of NS2 topology inferred from the reporter 
glycosylation and computational analysis (Chapter 3). (C) Model D of NS2 topology based on 
three solution NMR structures for peptides encompassed the 1st (aa 4-23), 2nd (aa 28-49) and 
3rd (aa 73-93) putative TMDs (Jirasko et al., 2008; Jirasko et al., 2010). The catalytic domain is 
not shown. Residues marking the boundaries of predicted TMDs are noted (green boxes). 
JFH-1 coding sequence was used unless otherwise stated. 
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interaction (Jirasko et al., 2010). In addition, it was reported that mutation of the p7 basic-loop 
or deletion of p7 blocked the NS2:E2 interaction (Ma et al., 2011). However the role of p7 in 
the interaction of NS2 and E2 (NS2:E2) is contentious as another group found that neither 
mutation of the basic-loop or deletion of p7 was deleterious to the interaction, although 
deletion of p7 resulted in an increased mobility of the E2-specifc protein species detected 
compared with the wild type virus, suggesting that NS2 was ordinarily interacting with E2-p7 
(Popescu et al., 2011). Furthermore, a third group reported that while deletion of p7 
dramatically impaired the NS2:E2 interaction it did not completely ablate it (Stapleford & 
Lindenbach, 2011).  
In addition to forming interactions with other viral proteins, NS2 is proposed to form dimers. 
Bimolecular cleavage at the NS2/3 junction was first observed by Grakoui et al., (Grakoui, 
1993b; Reed et al., 1995). Subsequent solution of the catalytic domain structure by X-ray 
crystallography combined with biochemical validation provided evidence that the NS2 catalytic 
domain forms active-site dimers (Lorenz et al., 2006b). Specifically, the catalytic residues 
histidine 143 and glutamate 163 are contributed by one monomer while cysteine 184, which 
facilitates cleavage by nucleophilic attack of the peptide bond (Lorenz et al., 2006b), was 
coordinated by the other monomer. Co-expression of two separate precursors with distinct 
active mutations confirmed the potential for bi-molecular cleavage through dimerisation of 
the active site (Lorenz et al., 2006b).  
Further evidence of dimerisation of the catalytic domain was provided using analytical 
ultracentrifugation, protein cross-linking in solution and co-immunoprecipitations from cells 
co-transfected with two differently tagged forms of NS2/3 pre-cursor (Lorenz et al., 2006b). 
Targeted mutagenesis of the dimer interface suggested that dimerisation of the catalytic 
domain was important for the role of NS2 in virus assembly, but not NS2/3 cleavage (Dentzer 
et al., 2009). Whether or not the trans-membrane domain is involved in NS2 dimerisation has 
also not been investigated. 
Taking advantage of the NS2 fusions described in the previous chapter; the NS2 intermolecular 
interactions were explored using the GFP-TrapTM system of co-IP with the aim of identifying 
the specific domains of NS2 involved and whether these interactions correlated to NS2 
membrane-targeting. It was hoped that identification of specific domains or functions of NS2 
required for protein interactions would facilitate consolidation and interpretation of previous 
directed mutagenesis and rescue mutation studies. 
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5.2 Results 
The tagged-NS2 constructs described in Chapter 4 provided an ideal opportunity to explore 
which regions of NS2 are involved in forming protein: protein interactions. As the fusion 
peptides facilitate more detailed characterisation of interactions involving the trans-
membrane domain of NS2; E1, E2 and p7 were considered for initial study. The reliability and 
availability of detection reagents singled out E2 as the primary candidate for interaction 
studies. 
5.2.1 Co-immunoprecipitation of E2 with NS2  
A previous study investigated the interaction between NS2 and other viral proteins by 
performing immunoprecipitations (IPs) of tagged-NS2 in the context of fully infectious virus 
isolates and provided evidence that p7 was essential for facilitating the NS2/E2 interaction (Ma 
et al., 2011).  Taking this into account it was decided to express E2 in cis with p7 by taking 
advantage of a previously characterised construct in which the JFH-1 core-p7 (C-p7) coding 
region is expressed as a single polyprotein (Adair et al., 2009). 
Huh7 cells were singly transfected with a range of control constructs to confirm the specificity 
of the GFP-TrapTM system. Cells were harvested 48h post-transfection into lysis buffer 
containing 1% Triton. 5% of crude lysates were retained as inputs for comparison by 
immunoblot analysis. Clarified lysates were incubated with GFP-TrapTM beads overnight and 
immunoprecipitated proteins were recovered by addition of 2 x Laemmli buffer. Single 
transfections showed that E2 did not bind to the GFP-TrapTM beads as E2 was detectable in the 
input but not the IP fraction (Figure 5.2A - lanes 1 and 2). tNS2-eGFP was not detected under 
these conditions due to limited resolution of samples to facilitate probing of a single 
membrane for multiple protein species. Two protein species were detected using the E2 
antibody, one of approximately 65 kDa; presumed to be mature E2, and a second high 
molecular weight species that was unable to enter the resolving gel matrix. A faint non-specific 
protein species of approximately 46 kDa was evident in the IP fractions of all samples. The 
majority of the eGFP fusions were expressed to levels below the detection limit for the input 
samples but all were concentrated following IP with the GFP-TrapTM beads.  
Co-transfection of the C-p7 expression construct with either eGFP alone or eGFP-tagged NS2 
confirmed previous reports that NS2 is able to immunoprecipitate E2 (Figure 5.2B) (Jirasko et 
al., 2010; Ma et al., 2011; Popescu et al., 2011; Stapleford & Lindenbach, 2011). NS2 as an N 
and C-terminal fusion to eGFP was able to co-IP E2. eGFP alone, despite being  
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Figure 5.2 eGFP-tagged NS2 interacts with E2 expressed from the C-p7 construct. 
(A) Huh7 cells were singly transfected with C-p7, eGFP alone and eGFP-fusions to test for non-
specific interactions. Cells were harvested 48 hours post-transfection and lysed on ice for 30 
minutes in TBS containing 1% Triton X-100. 5% of total input (Input) was kept aside and added 
to 1 volume of 2x protein sample buffer. Remaining lysates were diluted into four volumes of 
TBS, clarified at 20,100 x g for 10 minutes at 4°C and the resulting supernatants incubated O/N 
at 4°C with GFP-TrapTM beads. Beads were pelleted and washed three times in TBS. 
Immunoprecipitated proteins (IP) were harvested by heating the beads at 95°C in 2 x protein 
sample buffer for 3 minutes. Total IP fraction and 5% of total input were analysed by SDS PAGE 
and transferred to PVDF membranes. Membranes were probed with antibodies specific for E2 
(AP33, mouse monoclonal) and GFP (rabbit polyclonal). (B) Huh7 cells were co-transfected 
with C-p7 and eGFP-tagged NS2 or eGFP alone. Immunoprecipitations were carried out as 
above.  
Chapter 5: Characterisation of NS2 protein interactions 
 
166 
 
immunoprecipitated by the GFP-TrapTM beads, did not co-IP E2. Although side-by-side 
comparisons suggested that NS2-eGFP was more efficient at binding E2, the eGFP-NS2 fusion 
was used in subsequent experiments as a precaution because NS2-eGFP appeared to produce 
cleaved fusion molecules as well as tNS2-eGFP (Figure 5.2B and Appendix 4) and it was not 
known what effect these may have on poorly expressing fusions or weak interacting domains. 
Two protein species were detected again using the E2 antibody. As the higher molecular 
weight band may represent an insoluble form of E2, 4 M urea was added to samples to 
increase denaturation. This dramatically reduced the amount of the high molecular weight 
species (data not shown) and so 4 M urea was added to protein sample buffer thereafter.  
5.2.2 Co-IP of E2 with other GFP-tagged proteins 
To verify that the eGFP tag was not in some way responsible for the observed NS2:E2 
interaction cells were co-transfected with C-p7 (JFH-1) and a range of other GFP-tagged 
proteins (Figure 5.3A). GFP-tagged N protein from infectious bronchitis virus (IBV) (Emmott et 
al., 2008) and the cellular protein epidermal growth factor receptor (EGFR) Protein tyrosine 
kinase Substrate #15 (Eps15) (Mankouri et al., 2008a), which is involved in the endocytosis of 
EGFR, showed that GFP expressed as a fusion to other proteins did not interact with E2. A non-
GFP tagged protein, NS5A, was not detected and did not precipitate with E2 further confirming 
the specificity of the GFP-TrapTM system. On high exposures a small, but reproducible, amount 
of E2 was seen to be co-immunoprecipitated by NS4B (Figure 5.3A and B). On review of the 
literature; a physical interaction between E2 and NS4B expressed from an NS3-5B polyprotein 
has been suggested (Selby et al., 1994), however, due to a lack of NS4B-specific reagents, this 
interaction has not been explored further. 
5.2.3 Investigation of the cross-genotype interaction between NS2 and E2  
Studies of chimeric JFH-1 viruses found that the highest extracellular virus titres were achieved 
if the genetic cross-over point was within the trans-membrane domain of NS2 (Pietschmann et 
al., 2006). It was hypothesised that the increase in viral titres was due to increased affinity 
between N-terminal domains of NS2 and the structural proteins and p7 derived from the same 
sequence. As NS2 is able to interact with NS3 (Ma et al., 2011) and p7 (Popescu et al., 2011) 
from different genotypes the question was asked whether the increase in viral titres observed 
by Pietschmann et al., (Pietschmann et al., 2006) was due to a genetic determinant of the 
NS2:E2 interaction. To investigate this, cells were co-transfected with GFP-NS2 and a vector 
encoding C-p7 from the JFH-1 or the Con1 (genotype 1b) isolate (Figure 5.4A). E2 expression 
from the two C-p7 constructs was comparable (Figure 5.4A). Interestingly, the levels of E2 co-
immunoprecipitated by eGFP-NS2 were also comparable.  
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Figure 5.3 Verification of the specificity of the E2/NS2 interaction. 
(A) Huh7 cells were co-transfected with C-p7 and control plasmids. Cells were harvested 48 
hours post-transfection and lysed on ice for 30 minutes in TBS containing 1% Triton X-100. 5% 
of total input (Input) was kept aside and added to 1 volume of 2x protein sample buffer. 
Remaining lysates were diluted into four volumes of TBS, clarified at 20,100 x g for 10 minutes 
at 4°C and the resulting supernatants incubated O/N at 4°C with GFP-TrapTM beads. Beads 
were pelleted and washed three times in TBS. Immunoprecipitated proteins (IP) were 
harvested by heating the beads at 95°C in 2 x protein sample buffer for 3 minutes. Total IP 
fraction and 5% of total input were analysed by SDS PAGE and transferred to PVDF 
membranes. Membranes were probed with antibodies specific for E2 (AP33, mouse 
monoclonal) and GFP (rabbit polyclonal). (B) IPs carried out on lysates from Huh7 cells co-
transfected with C-p7 and either eGFP, NS4B-eGFP or eGFP-NS2. Molecular weight markers are 
shown to the right and lane numbers are noted below.   
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Figure 5.4 The NS2:E2 interaction is genotype-independent. 
 (A) Huh7 cells were co-transfected with eGFP-NS2 and C-p7 from the JFH-1 (genotype 2a) or 
Con1 (genotype 1b) isolates. Cells were harvested 48 hours post-transfection and lysed on ice 
for 30 minutes in TBS containing 1% Triton X-100. 5% of total input (Input) was kept aside and 
added to 1 volume of 2x protein sample buffer. Remaining lysates were diluted into four 
volumes of TBS, clarified at 20,100 x g for 10 minutes at 4°C and the resulting supernatants 
incubated O/N at 4°C with GFP-TrapTM beads. Beads were pelleted and washed three times in 
TBS. Immunoprecipitated proteins (IP) were harvested by heating the beads at 95°C in 2 x 
protein sample buffer for 3 minutes. Total IP fraction and 5% of total input were analysed by 
SDS PAGE and transferred to PVDF membranes. Membranes were probed with antibodies 
specific for E2 (AP33, mouse monoclonal) and GFP (rabbit polyclonal). Molecular weight 
markers are shown to the right. Lane numbers are noted below. (B) Quantification of the 
interaction between NS2 and E2 from the JFH-1 and Con1 isolates by densitometry. 
Immunoblot images were colour-inverted and the background density was subtracted from 
average densities of the input and IP bands for each E2 species. Normalised input values were 
multiplied by 20 to represent total input. IP efficiency was plotted as a ratio of IP: total input 
E2.  
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The comparative affinity of NS2 for E2 was calculated using densitometry analysis of the 
respective input and IP fractions for each of the E2 species on the same exposure. As the IP 
fractions represented the total IP fraction whereas the input fractions represented only 5% of 
the total input sample the normalised input value was multiplied by 20. The efficiency of the 
NS2/E2 interaction was then expressed as a ratio of IP: input (Figure 5.4B). A ratio value of 1 
would have indicated that all the expressed E2 was co-immunoprecipitated with NS2. This 
showed the amount of E2 immunoprecipitated to be approximately 20% of the total input E2 
irrespective of the genetic origin of E2 (Figure 5.4B).  
5.2.4 Analysis of the E2 binding domain of NS2 
Following confirmation of the NS2:E2 interaction using GFP-tagged NS2 the question was 
asked whether any sub-domains of NS2 were dispensable for the interaction. Huh7 cells were 
co-transfected with the eGFP-NS2 fusion constructs and the JFH-1 C-p7 vector (the JFH-1 
vector was used hereafter and all NS2 truncation fusions were generated from the JFH-1 
sequence) and IPs performed on lysates harvested 48 hours post-transfection (Figure 5.5). 
Control samples were transfected in duplicate and the lysates pooled and loaded on both gels 
to allow direct comparison. Input and IP fractions were probed for E2, core and GFP. Core and 
E2 input blots confirmed relatively consistent transfection of the C-p7 plasmid (Figure 5.5).  
As seen in the previous chapter, the eGFP-NS2 fusions expressed to varying levels (Figure 
4.5B), but they were all detected in the IP fractions (Figure 5.5). Full-length NS2 (1-217) was 
able to efficiently interact with E2, but E2 did not co-IP with all of the NS2 fusions. Levels of E2 
comparable to the full-length NS2 fusion were immunoprecipitated by the (25-217) and (Δ25-
50) fusions. (1-50) and (1-92) also interacted with E2 but to a lesser extent. Higher exposures 
showed that trace amounts of E2 were immunoprecipitated by (25-92), (51-92), (51-217) and 
(Δ25-92) (data not shown). No interaction was detected between E2 and (1-24), (25-50), (93-
217) or (Δ51-92). None of the fusions immunoprecipitated core protein. All the core blots 
shown were carried out in parallel and exposed on the same film (Figure 5.5). 
The apparent low levels of input E2 from cells co-transfected with (25-217) and C-p7 (Figure 
5.5 - lane 10) could represent an artefact of the transfer procedure as the corresponding core 
immuno-blots showed protein levels comparable with all other samples. Furthermore levels of 
E2 comparable to that of the full-length eGFP fusion were immunoprecipitated by (25-217). A 
similarly low level of E2 Input was noted for (Δ51-92) (Figure 5.5 - lane 20) but upon repetition 
this was not the case (Figure 5.6A - lane 20). In both transfections there was no evidence of 
(Δ51-92) interacting with E2. 
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Figure 5.5 Characterisation of the E2-binding domain of NS2. 
Huh7 cells were co-transfected with C-p7 and the eGFP-NS2 fusion set. Cells were harvested 
48 hours post-transfection and lysed on ice for 30 minutes in TBS containing 1% Triton X-100. 
5% of total input (Input) was kept aside and added to 1 volume of 2x protein sample buffer. 
Remaining lysates were diluted into four volumes of TBS, clarified at 20,100 x g for 10 minutes 
at 4°C and the resulting supernatants incubated O/N at 4°C with GFP-TrapTM beads. Beads 
were pelleted and washed three times in TBS. Immunoprecipitated proteins (IP) were 
harvested by heating the beads at 95°C in 2 x protein sample buffer for 3 minutes. Total IP 
fraction and 5% of total input were analysed by SDS PAGE and transferred to PVDF 
membranes. Membranes were probed with antibodies specific for E2 (AP33, mouse 
monoclonal), core protein (sheep polyclonal) and GFP (rabbit polyclonal). Fusions are 
numbered according to the NS2 residues they encode. The first four samples, lanes 1-4, were 
performed in duplicate and the lysates pooled and electrophoresed on both gels to allow 
direct comparison. Molecular weight markers are shown to the right and lane numbers are 
noted below.  
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To confirm the phenotypes of these the eGFP-NS2 fusions the experiment was repeated using 
the eGFP-NS2 fusions (Figure 5.6A) and the NS2-eGFP fusions (Figure 5.6B). The eGFP-NS2 
fusions produced the same pattern as before (Figure 5.5) except that on higher exposures (25-
50) appeared to interact with E2 and the weak interaction previously observed between eGFP 
(51-92) and E2 was not reproduced (data not shown).  
Analysis of the NS2-eGFP fusions confirmed the phenotypes of the (1-92) (25-217) and (Δ25-
50) truncations (Figure 5.6B). The most notable discrepancy between the two sets of fusions 
was that eGFP (1-50) efficiently immunoprecipitated E2 while (1-50) eGFP showed no signs of 
an interaction. This suggests that the fusion molecule was disrupting the NS2:E2 interaction in 
the latter instance either by steric inhibition or by altering the targeting or structure of the NS2 
domain. 
Higher exposures only identified a weak interaction between eGFP (25-92) and E2. The 
phenotypes described for eGFP (51-92) and eGFP (51-217) could not be confirmed as only a 
trace amount of (51-92) eGFP was visible on over-exposed films and no expression was 
detected for (51-217) eGFP. Poor expression was repeatedly observed for these fusions, 
particularly (51-217) eGFP; the expression of which was only ever detected by confocal IF 
microscopy (Figure 4.9).  
The apparent cleaved fusion products detected in cells transfected with the NS2-eGFP 
constructs (Appendix 4) did not appear to have a detrimental effect on those fusions displaying 
a high affinity for E2 as (1-217), (25-217) and (Δ25-50) all efficiently immunoprecipitated E2. 
However, the reduced number of weak interactions observed on higher exposures compared 
with the eGFP-NS2 fusions could have been the result of interference by cleaved NS2 species 
competing for E2.  
From comparison of the two GFP-tagged NS2 truncation sets it is clear that certain regions of 
NS2 can interact with E2, however no single domain appeared essential for enabling the 
NS2:E2 interaction. E2 was efficiently co-immunoprecipitated by (1-92), (25-217) and (Δ25-50) 
from both sets and eGFP (1-50). This suggests that NS2 contains multiple E2-binding domains. 
It has also been reported that E1, E2, p7 and NS2 form a complex (Stapleford & Lindenbach, 
2011) which may mean that NS2 has indirect associations with E2 via p7 or E1. Unfortunately 
E1 and p7 expression could not be detected in this system preventing exploration of this 
hypothesis. 
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Figure 5.6 Further characterisation of the E2-binding domain of NS2. 
Huh7 cells were co-transfected with C-p7 and either the eGFP-NS2 fusions (A) or the NS2-eGFP 
fusions (B). Cells were harvested 48 hours post-transfection and lysed on ice for 30 minutes in 
TBS containing 1% Triton X-100. 5% of total input (Input) was added to 1 volume of 2x protein 
sample buffer. Remaining lysates were diluted into 4 volumes of TBS, clarified at 20,100 x g for 
10 minutes at 4°C and the supernatants incubated O/N at 4°C with GFP-TrapTM beads. Beads 
were pelleted, washed three times in TBS and heated at 95°C in 2 x protein sample buffer for 3 
minutes to remove bound proteins (IP). Total IP fraction and 5% of total input were analysed 
by SDS PAGE, transferred to PVDF membranes and probed for E2 and GFP. Fusions are 
numbered according to the NS2 residues they encode. The first four samples, lanes 1-4, were 
in duplicate and the lysates pooled and electrophoresed on both gels to allow direct 
comparison. Molecular weight markers are shown to the right and lane numbers are noted.  
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5.2.5 Interactions between NS2 and the non-structural proteins 
As discussed previously, NS2 has been shown to interact with NS3, NS4A and NS5A (Flajolet et 
al., 2000; Jirasko et al., 2010; Ma et al., 2011; Stapleford & Lindenbach, 2011; Tedbury et al., 
2011). With the aim of identifying which regions of NS2 were capable of interacting with 
individual non-structural proteins, and whether p7 was required for these interactions, Huh7 
cells harbouring the autonomously self-replicating sub-genomic RNA, or sub-genomic replicon 
(SGR), encoding the neomycin resistance gene and the NS3-5B or SPp7-NS5B proteins from the 
JFH-1 isolate were used (Tedbury et al., 2011). The non-structural proteins are thought to form 
replication complexes that may exclude elements of the innate immune response (Moradpour 
et al., 2007), and possibly other viral proteins. As these would be pre-formed in cells stably 
harbouring HCV replicons and may prevent exogenously expressed eGFP-NS2 from interacting 
with the other viral proteins, RNA encoding transient NS3-5B replicon with a luciferase 
reporter gene in place of the antibiotic resistance gene was generated (Tedbury et al., 2011). 
The NS2:NS5A interaction appears to be independent of the structural proteins (Tedbury et al., 
2011) whereas the NS2:NS3 interaction seems to be destabilised by disruption to the structural 
protein suggesting that the NS2:NS3 interaction may require the presence of the structural 
proteins. To enable the investigation of this possibility full-length JFH-1 virus RNA (Wakita et 
al., 2005) was also generated. Schematic diagrams of the two SGRs compared to the full-length 
virus genome are shown in Figure 5.7A.  
Huh7 cells were electroporated in duplicate with full-length JFH-1 virus RNA (Virus) or JFH-1 
NS3-5B transient replicon RNA. 24 hours post-electroporation cells were either transfected 
with eGFP alone or eGFP-NS2 and harvested 72 hours post-electroporation. The two stable 
replicon harbouring cell-lines described above were also transfected in parallel to enable direct 
comparison. Input levels of core, E2 and NS5A confirmed that cells had been electroporated 
with the virus and replicon RNAs (Figure 5.7B). Levels of NS3 and NS5A in the stable replicon 
cells were inconsistent and notably higher in the mock transfected cells. The transfection 
efficiency of all six cell populations was comparable. E2 from virus-electroporated cells co-
immunoprecipitated with eGFP-NS2 and not with eGFP alone (Figure 5.7B - lanes 4 and 14), 
although considerably less efficiently than when the two were expressed from DNA constructs 
(Figure 5.2B). At first it appeared as though a trace amount of NS5A might have co-
immunoprecipitated with eGFP-NS2 in virus-electroporated cells (Figure 5.7B - lane 4 and 14), 
but on closer inspection trace amounts of this protein species were also detected in the GFP 
alone transfected cells. None of the other HCV proteins probed for were detected in IP 
fractions in both the transient and stable expression systems (Figure 5.7B). 
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Figure 5.7 Investigation of the interactions between NS2 and other viral proteins. 
(A) Schematic diagram of the genome organisation of full-length HCV and two sub-genomic 
replicons. The JFH-1 sequence encoding core-p7 (NS3-5B) or core-E2 (SPp7-5B) was replaced 
with a reporter gene enabling the study of replication in stable (neomycin) or transient 
(luciferase) replication systems (Tedbury et al., 2011). Native JFH-1 5’ and 3’ UTRs were 
maintained to enable replication. Translation of HCV proteins from the replicons was 
controlled by an encephalomyocarditis virus (EMCV) IRES. Polyprotein processing events are 
marked by arrow heads: signal peptidase (red), signal peptide-peptidase (purple), NS2 (green), 
NS3/4A (Black). (B) The ability of NS2 expressed in trans to interact with other viral proteins 
expressed from different environments was assessed. Huh7 cells were electroporated with 
full-length JFH-1 virus RNA (virus) or RNA encoding the non-structural protein NS3-5B 
(Transient NS3-5B). 24 hours post-electroporation cells were transfected with either eGFP 
alone or eGFP-NS2. Huh7 cell populations containing stably replicating sub-genomic RNA 
molecules encoding either NS3-5B or SPp7-5B were transfected in parallel. Cells were 
harvested 48 hours post-transfection and lysed on ice for 30 minutes in TBS containing 1% 
Triton X-100. 5% of total input (Input) was kept aside and added to 1 volume of 2x protein 
sample buffer. Remaining lysates were diluted into four volumes of TBS, clarified at 20,100 x g 
for 10 minutes at 4°C and the resulting supernatants incubated O/N at 4°C with GFP-TrapTM 
beads. Beads were pelleted and washed three times in TBS. Immunoprecipitated proteins (IP) 
were harvested by heating the beads at 95°C in 2 x protein sample buffer for 3 minutes. Total 
IP fraction and 5% of total input were analysed by SDS PAGE and transferred to PVDF 
membranes. Molecular weight markers are shown to the right and lane numbers are noted 
below. Membranes were immunoblotted for the proteins indicated to left. 
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The protein species detected with the NS3 (~70 kDa)-specific antibody in the input fractions 
migrated faster than predicted (~58kDa) (Figure 5.7B). Due to the nature of the experiment 
only one gel could be produced for each of the input and IP samples. Consequently the top 
portions of the membranes were probed, then stripped and re-probed twice to allow the 
systematic detection of E2, NS5A and NS3 respectively. NS3 and NS5A antiserum were both 
generated in sheep; therefore it seemed likely that the protein species observed for NS3 were 
due to the re-detection of residual NS5A antibody that had not been completely removed. In 
order to verify that eGFP-NS2 was indeed less efficient at interacting with E2 expressed from 
the full-length virus RNA compared with E2 expressed from the C-p7 plasmid DNA; virus RNA 
electroporated cells were transfected as before and immunoprecipitated in parallel with cells 
co-transfected with eGFP-NS2 and the C-p7 vectors (Figure 5.8A).  
As input levels of core, E2 and GAPDH were higher in eGFP-NS2 transfected cells it was 
possible that over-expression of NS2 in the context of the other viral proteins increased cell 
proliferation (Figure 5.8A). However, as this increase in protein levels was not seen previously 
(Figure 5.7B), it was suspected that virus electroporated cells were unevenly seeded out prior 
to transfection. 
Levels of eGFP-NS2 immunoprecipitated from the virus-electroporated cells and the C-p7-
transfected cells were comparable, yet the amount of E2 they immunoprecipitated was not. 
eGFP-NS2 was able to immunoprecipitate considerably more E2 when it was expressed from 
the C-p7 vector despite the input levels of E2 being significantly higher in cells expressing the 
full virus polyprotein. A similar number of cells were harvested for the eGFP-NS2 transfected 
samples as indicated by the input levels of GAPDH (Figure 5.8 - lane 3 and 4). 
Densitometry was performed to quantify the efficiency of the E2/NS2 co-IPs in a similar 
manner to that described in Figure 5.4B. Due to the continuous nature of the E2 input band it 
was not possible to examine the total density of the bands, instead the average density of a 
vertical line taken through the centre of the E2 bands was used. Similar to the analysis shown 
in Figure 5.4B, NS2 co-transfected with the C-p7 construct was able to precipitate 
approximately 15% of the total E2 (Figure 5.8B). Although crude, this analysis highlighted that 
NS2 was 10-fold more efficient at interacting with E2 expressed from the C-p7 DNA construct 
than when E2 was expressed from an RNA molecule in the context of the complete virus 
polyprotein. 
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Figure 5.8 The eGFP-NS2/E2 interaction is less efficient in virus expressing cells. 
(A) Huh7 cells were electroporated with full-length JFH-1 virus RNA (Virus). 24 hours post-
electroporation cells were transfected with either eGFP alone or eGFP-NS2. In parallel Huh7 
cells were co-transfected with eGFP-NS2 and C-p7. Cells were harvested 48 hours post-
transfection and lysed on ice for 30 minutes in TBS containing 1% Triton X-100. 5% of total 
input (Input) was kept aside and added to 1 volume of 2x protein sample buffer. Remaining 
lysates were diluted into four volumes of TBS, clarified at 20,100 x g for 10 minutes at 4°C and 
the resulting supernatants incubated O/N at 4°C with GFP-TrapTM beads. Beads were pelleted 
and washed three times in TBS. Immunoprecipitated proteins (IP) were harvested by heating 
the beads at 95°C in 2 x protein sample buffer for 3 minutes. Total IP fraction and 5% of total 
input were analysed by SDS PAGE and transferred to PVDF membranes. Molecular weight 
markers are shown to the right and lane numbers are noted below. Membranes were 
immunoblotted for the proteins indicated to left. (B) Quantification of the interaction between 
NS2 and E2 expressed from virus and the C-p7 construct by densitometry. Immunoblots were 
inverted and a vertical line taken through the centre of the E2 bands, the average densities 
were recorded and the background subtracted. Normalised input values were multiplied by 20 
to represent total input. IP efficiency was plotted as a ratio of IP: input E2. The numerical 
values are noted. 
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5.2.6 NS2 oligomerisation 
To confirm previous observations that NS2 is able to dimerise (Dentzer et al., 2009; Lorenz et 
al., 2006b), Huh7 cells were co-transfected with full-length eGFP-tagged NS2 and full-length 
NS2-FLAG. IPs were carried out using GFP-TrapTM beads and the oligomerisation of NS2 was 
established by probing for the FLAG epitope (Figure 5.9A). Both N- and C-terminally eGFP-
tagged NS2 were able to IP NS2-FLAG. The truncated form of NS2, tNS2, with a C-terminal 
FLAG-tag was detected in the IP fraction from eGFP-NS2 expressing cells but not NS2-eGFP. 
The apparent difference could be due to levels of tNS2-FLAG detected in the input fractions. 
The significance of the different expression levels of tNS2-FLAG was unclear and not explored 
further. This experiment also demonstrated that NS2-FLAG did not bind non-specifically to the 
beads and that the protein species detected with the FLAG antibody were specific to FLAG-
tagged NS2 as they were not observed in samples from cells singly transfected with GFP-
tagged NS2 (Figure 5.9A). Because all gels were run under reducing conditions and using ionic 
detergents it was not possible to distinguish between NS2 dimerisation and higher order 
oligomerisation. Therefore the interaction hereafter is referred to as NS2 oligomerisation. 
Previous studies have shown that the catalytic domain of NS2 was capable of oligomerising 
independently of the trans-membrane domain (Lorenz et al., 2006b). In order to establish 
whether the trans-membrane of NS2 is also capable of forming intermolecular interactions, 
Huh7 cells were co-transfected with combinations of full-length NS2, the trans-membrane 
domain alone and the catalytic domain alone (Figure 5.9B). As both conformations of eGFP 
fusions to NS2 were shown to interact with NS2-FLAG the experiment was simplified by the 
omission of the NS2-eGFP fusions. Furthermore, in an attempt to improve the detection of co-
immunoprecipitated FLAG-tagged NS2 co-transfections were carried out with 0.25µg of GFP-
fusion DNA and 0.75µg of FLAG-fusion DNA. 
NS2-FLAG was again immunoprecipitated by eGFP-NS2 demonstrating the reproducibility of 
the interaction (Figure 5.9B), but it was not immunoprecipitated by eGFP alone or NS4B-eGFP. 
Surprisingly, immunoprecipitation of the FLAG-tagged trans-membrane domain was observed 
by the corresponding GFP-tagged domain suggesting that these two domains oligomerise. It 
was interesting to observe that the GFP-tagged trans-membrane domain was not able to IP the 
full-length NS2-FLAG fusion. Contrary to previous reports, no interaction was noted between 
the catalytic domain i.e. eGFP (93-217), and either full-length NS2-FLAG or the FLAG-tagged 
catalytic domain, (93-217) FLAG (Figure 5.9B - lane 7 and 8). 
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Figure 5.9 NS2 oligomerisation. 
(A) To investigate whether NS2 was able to oligomerise, immunoprecipitations were carried on 
lysates from Huh7 cells transfected with full-length NS2 FLAG, eGFP-NS2 and NS2-eGFP. (B) To 
further investigate NS2 oligomerisation combinations of the tagged full-length NS2, the trans-
membrane domain alone and the catalytic domain alone were co-transfected into cells and 
immunoprecipitations performed. Cells were harvested 48 hours post-transfection and lysed 
on ice for 30 minutes in TBS containing 1% Triton X-100. 5% of total input (Input) was kept 
aside and added to 1 volume of 2x protein sample buffer. Remaining lysates were diluted into 
four volumes of TBS, clarified at 20,100 x g for 10 minutes at 4°C and the resulting 
supernatants incubated O/N at 4°C with GFP-TrapTM beads. Beads were pelleted and washed 
three times in TBS. Immunoprecipitated proteins (IP) were harvested by heating the beads at 
95°C in 2 x protein sample buffer for 3 minutes. Total IP fraction and 5% of total input were 
analysed by SDS PAGE and transferred to PVDF membranes. For clarity eGFP (green) and FLAG 
(red) tags in sample names have been coloured. Molecular weight markers are shown to the 
right and lane numbers are noted below. Membranes were immunoblotted for the epitope 
tags indicated to left. 
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An additional protein species detectable with the GFP antibody in the IP fraction of cells 
transfected with eGFP (1-92) + (1-92) FLAG was presumed to be ‘free’ eGFP, although it was 
not clear why this was restricted to this sample and not detected in the eGFP (1-92) + (1-217) 
FLAG sample. It could be that stable dimerisation of the NS2 trans-membrane domain altered 
the stability of the eGFP (1-92) fusion making it more susceptible to cleavage by cells 
proteases. 
Together these data suggest that NS2 does indeed oligomerise and that the trans-membrane 
domain may play a significant role in forming intermolecular interactions. 
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5.3 Discussion 
NS2 has been reported to interact with the majority of the other HCV proteins and also to 
dimerise within the catalytic domain. The X-ray crystal structure of the catalytic domain 
identified the potential dimer interface and allowed the targeted mutation of conserved 
residues about this face (Dentzer et al., 2009), but it did not elucidate the role of the trans-
membrane domain in dimerisation. Most studies looking at the interaction between NS2 and 
other viral proteins have identified residues key to maintaining the interactions. 
Immunoprecipitation studies were undertaken to identify the E2 binding domain of NS2 and 
further characterise NS2 dimerisation. 
5.3.1 E2 interacts with NS2 expressed in trans 
The observation that NS2 and E2 interact in the context of the full-length virus was confirmed 
here as GFP-tagged NS2 expressed in cells containing the full-length replicating virus genome 
was able to specifically co-IP E2 (Figure 5.7 and 5.8). This interaction was also confirmed when 
E2 and NS2 were expressed in trans from DNA vectors (Figure 5.2B). However, despite the 
published observation of NS2 interacting with NS3 and NS5A (Jirasko et al., 2010; Ma et al., 
2011; Stapleford & Lindenbach, 2011), these interactions could not be detected in cells 
containing transiently replicating full-length virus RNA or cells containing stably or transiently 
replicating sub-genomic sequence of HCV RNA (Figure 5.6B and 5.7A). Indeed eGFP-NS2 was 
only able to co-IP a small population of E2 from virus containing cells compared with E2 
expressed from the C-p7 construct (Figure 5.7B). 
Experiments demonstrated that NS2, E2 and numerous other viral proteins aggregate in high 
molecular weight complexes (Stapleford & Lindenbach, 2011) which may form shortly after 
translation and could exclude other proteins or further sequester E2 to an exclusive 
environment. Furthermore, as NS2 has been shown to interact with numerous other HCV 
proteins, it is reasonable to speculate that the eGFP-NS2 molecules could have been 
interacting with E2 and other non-structural proteins that were not included in the co-
transfection system. NS2 has been proposed to localise proximally to proposed sites of 
genome replication (Tedbury et al., 2011) and replication complexes extracted from NS3-5B 
replicon cells have been found to be protease and nuclease resistant (Aizaki et al., 2000; Yang 
et al., 2004). It has also been shown that when NS2 is expressed in cis with p7 it localises to a 
detergent-insoluble compartment (Tedbury et al., 2011). It is therefore possible that NS2 
expressed in trans was unable to access these replication complexes, or that E2 was localised 
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to detergent-insoluble complexes by NS2 expressed as part of the viral polyprotein (vNS2) 
which would have been removed from lysates prior to incubation with GFP-TrapTM beads. 
Proximity following translation could be vital to the establishment of the E2:NS2 interaction as 
the introduction of a second IRES between E2 and p7 resulted in a reduction in the amount of 
E2 immunoprecipitated by NS2 (Stapleford & Lindenbach, 2011). Likewise, introduction of a 
second IRES between NS2 and NS3 impaired the NS2:NS3 interaction by co-IP (Stapleford & 
Lindenbach, 2011). Both of these bi-cistronic viruses had reduced viral titres by 1.5-2 log10. 
This suggests that the spatial separation afforded by translation in trans could have been 
detrimental for the ability of NS2 to interact with other viral proteins and thereby impede its 
role in assembly. Therefore, one explanation for the apparent reduced affinity of eGFP-NS2 for 
E2 in the context of the fully infectious virus system is that vNS2 was competing for E2 and, as 
this species would have been expressed proximally to the E2 molecules, vNS2 could have 
sequestered the majority of the E2 population.  
5.3.2 The E2-binding domain of NS2  
It was hypothesised that the trans-membrane domain of NS2 interacts with E2, as early 
truncation analysis of NS2 and E2 found that the N-terminal 96 residues of NS2 
co-immunoprecipitated with E2 using an antibody specific for E2 (Selby et al., 1994). As the 
catalytic domain is predicted to orientate to the cytosol and contain no membrane-spanning 
domains it was believed that it would not interact with E2 (Lorenz et al., 2006b). Consistent 
with these hypotheses; the trans-membrane domain (1-92) was able to interact with E2 and 
the catalytic domain (93-217) was not, irrespective of the termini to which the eGFP reporter 
was fused (Figure 5.4 and 5.5). Compensatory mutation analysis of NS2 defective viruses 
suggested that the putative third TMD (aa 73-93) of NS2 interacts with E1 and E2 (Jirasko et al., 
2010). Furthermore, Popescu et al., proposed the main E2 interacting domain to be the second 
putative TMD of NS2 (aa 31-49) (Popescu et al., 2011). However, data provided in this chapter 
demonstrated that neither of these domains was capable of interacting with E2 in isolation as 
the truncations (25-50) and (51-92), which encompasses the predicted second and third TMDs, 
did not IP E2, regardless of the position of the eGFP fusion molecule (Figure 5.5). 
Analysis of those fusions that were able to co-IP E2 found that they did not encode a common 
domain although they all encoded two of the putative TMDs in all combinations (Figure 5.10). 
As E2 and NS2 are trans-membrane proteins it was feasible that their interaction may be 
dependent upon membrane association. A table was generated summarising the membrane 
targeting and E2 interaction phenotypes of the two eGFP fusion sets (Table 5.1). A positive 
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correlation was noted between the ability of a protein to target to membranes and to interact 
with E2. Only (Δ25-50) eGFP and (Δ25-92) eGFP did not fit this trend as (Δ25-50) eGFP was able 
to target to membranes but not co-IP while (Δ25-92) eGFP was unable to target to membranes 
but was able to co-IP E2 (Table 5.1). This strongly suggests a link between NS2 membrane 
association and E2 interaction. It could be interesting to investigate the NS2:E2 interaction in 
vitro, expressed in the presence and absence of purified membranes, to determine the 
dependency of the interaction on membranes. 
The major difference between the co-IP-profiles of the two NS2 GFP-fusion sets was that (1-
50) eGFP did not co-IP E2 whereas eGFP (1-50) efficiently bound E2 (Figure 5.6). Comparison 
with the membrane targeting data highlighted that these fusions presented opposing 
membrane-targeting abilities with (1-50) eGFP also unable to target to membranes while eGFP 
(1-50) was detected exclusively in the membrane fraction (Table 5.1; Figure 4.6 and 4.8). This is 
consistent with the hypothesis that the NS2:E2 interaction requires NS2 to be membrane-
associated.  
The ability of (Δ25-92) eGFP to interact with membranes but not E2 suggests that, despite 
eGFP (Δ25-92) showing a weak interaction with E2, the eGFP reporter forming part of the 
(Δ25-92) eGFP fusion disrupted the NS2:E2 interaction. The phenotype of (Δ25-50) eGFP is 
more intriguing as it was unable to target to membranes when expressed in isolation but still 
efficiently interacted with E2 (Table 5.1). It is possible that this fusion, when co-expressed with 
core-p7 was able form protein interactions with p7 that enabled the truncated NS2 fusion to 
associate with the membrane and thus interact with E2. Re-examination of the membrane-
targeting of this (Δ25-50) eGFP from co-transfected cells would help to clarify this. 
5.3.3 Requirements of the E2/NS2 interaction 
Whether or not the E2:NS2 interaction was dependent upon core, E1 or p7 could not be 
addressed using systems employed herein and would have required the generation of 
additional expression constructs. Despite this it is unlikely that the E2:NS2 interaction requires 
the presence of core as it did not interact with any of the eGFP-NS2 fusions when it was 
expressed from a DNA construct (Figure 5.4) or from viral RNA (Figure 5.6B). Stapleford and 
Lindenbach (Stapleford & Lindenbach, 2011) demonstrated that E1 and E2 could be co-
immunoprecipitated by tagged NS2, yet mutations that disrupted the E1:NS2 interaction did 
not alter the E2:NS2 interaction. Therefore it is unlikely that E1 is necessary for stabilisation of 
the E2:NS2 interaction. 
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Table 5.1 Summary of the membrane targeting and E2 interaction of the eGFP fusions. 
The fusions were either able to (Yes – Y, green) or unable (No – N, red) to target to membranes 
and interact with E2. Fusions that were recovered in both the membrane and soluble fractions, 
or displayed only a weak interaction with E2, are shown in yellow (Y/N). As the weak E2 
interactions between eGFP (25-50) and eGFP (51-92) were not reproducible they are not 
included. (-) denotes peptides where no phenotype could be assigned. The position of the 
eGFP tag with respect to the NS2 sequence is noted. eGFP-NS2 fusions, N; NS2-eGFP fusions, C.  
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As highlighted in the introduction to this section, the role of p7 in mediating NS2:protein 
interactions is the subject of current debate. When Jirasko et al., (Jirasko et al., 2010) swapped 
the sequence encoding the first putative TMD from JFH-1 with that of the Con1 coding 
sequence, in the JFH-1 virus, the resulting virus showed impaired intra- and extracellular 
infectivity and reduced interactions with E2, p7, NS3 and NS5A. However, repeated passage in 
cell culture led to the selection and identification of the pseudo-revertant mutation E3D in p7. 
This pseudo-revertant mutation restored NS2 interactions with E2, NS3 and NS5A (p7 was 
undetectable due to mutation of the antibody recognition epitope) and significantly improved 
infectivity (Jirasko et al., 2010). This implied that the NS2:E2 interaction may be dependent 
upon the pre-formation of a functional p7-NS2 interaction via the respective N-terminal 
domains. It had been hoped to address the point of p7 involvement in NS2:NS3 and NS2:NS5A 
interaction by comparing two replicon systems with and without p7, however no NS2 
interactions were detected using these systems (Figure 5.7B) 
The topology of NS2 does not appear to play a role in determining the NS2:E2 interaction as 
the (Δ25-50) and (25-217) truncations could be expected to assume significantly altered 
topologies compared to the full-length protein (Figure 5.10A). Based upon the SEAP fusion S7 
(aa 1-52), which localised the C-terminus to the cytosol and therefore inferred to form a single 
TMD, eGFP (1-50) may form a single TMD topology or an incomplete hairpin topology (Figure 
5.10A). Any fusions of domains (1-24) and (25-50) did not target efficiently to membranes, 
whereas eGFP (1-50) did (Table 5.1). It is therefore possible that hydrophilic residues within 
the first and second putative TMDs (Figure 5.10B) require the formation of stabilising salt 
bridges to facilitate membrane insertion. Whether these interactions occur between the first 
and second TMDs of the same molecule or other molecules is unclear although it is clear that 
the trans-membrane domain is cpapable of forming inter-molecular interactions (Figure 5.9B). 
As (1-50) eGFP did not associate with membranes this adds to the evidence that residue 50 is 
within the membrane. It is possible that fusion of eGFP to this residue prevented insertion of 
the partial second TMD which inturn prevented the formation of stabilising interactions with 
the putative first TMD resulting in the soluble phenotype observed for this construct [(1-50) 
eGFP]. 
While the topology of (Δ25-50) and (25-217) can only be speculated upon, the deletions were 
predicted to remove a single TMD from each of them resulting in a opposed localisation for the 
catalytic domain for these fusions compared to the full-length protein. Although the NS2 
truncations capable of targeting to membranes appeared to be those most able to interact  
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Figure 5.10 Predicted membrane topologies of the truncations able to efficiently interact 
with E2. 
(A) Models based upon the truncation analysis data and the consensus topology prediction 
presented in Chapter 3. The positions of the C-terminal truncations used in Chapter 3 (red 
boxes) and the predicted start of the first TMD (green boxes) are noted. The putative TMDs are 
coloured for comparison; first TMD (red), second TMD (green) and third (blue). (B) JFH-1 NS2 
amino acid sequence. Hydrophilic residues (red) within the predicted TMDs (underlined) are 
highlighted. 
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with E2, membranes were not required for the perpetuation of the interaction as the lysis 
conditions of 1% Triton X-100 should solubilise the majority of membranes, suggesting the 
formation of a stable protein-protein interaction rather than independent co-localisation to a 
membrane compartment. 
5.3.4 Oligomerisation of the NS2 trans-membrane domain 
Bimolecular cleavage of NS2/3 precursors led to the hypothesis that NS2 molecules may 
interact to facilitate autocleavage (Grakoui, 1993b; Lorenz et al., 2006b; Reed et al., 1995).  
Evidence of NS2 dimerisation has been presented by blue native (BN)-PAGE analysis of cell 
lysates (Lorenz et al., 2006b; Stapleford & Lindenbach, 2011) and crystallisation of the isolated 
catalytic domain as a dimer (Lorenz et al., 2006b). Cleavage of the NS2/3 junction is essential 
for genome replication (Jones et al., 2007). Mutation of three residues predicted to be at the 
dimer interface, based on the crystal structure, did not affect replication but severely reduced 
infectious virus production, although biochemical confirmation of a concomitant disruption of 
NS2 dimerisation was not provided (Dentzer et al., 2009). This suggested that dimerisation 
could be more important for assembly than NS2/3 cleavage and may be consistent with 
observations from mixing experiments using two differently cleavage-defective precursors that 
showed bi-molecular cleavage to be very inefficient (Grakoui, 1993b; Lorenz et al., 2006b; 
Reed et al., 1995).  
Co-IP of FLAG-tagged full-length NS2 by eGFP-NS2 (Figure 5.9) was consistent with the 
previous biochemical evidence indicative of NS2 dimerisation (Lorenz et al., 2006b). However, 
observations that the catalytic domain was capable of dimerisation were not reproduced here 
as eGFP (93-217) was not able to co-IP either NS2-FLAG or (93-217) FLAG (Figure 5.9B). 
Conversely, the trans-membrane domain was able to co-IP the corresponding FLAG-tagged 
catalytic domain fusion (Figure 5.9B). The reason for this apparent discrepancy was not 
immediately clear as both this study and Lorenz et al., (Lorenz et al., 2006b) used co-IP of 
differentially tagged-NS2 expressed in cells to assess oligomerisation. Although the crystal 
structure of the catalytic domain included residues 93-217 of NS2, subsequent co-IP 
experiments utilised differentially tagged NS2/3 consisted of residues 19–217 of NS2 and 1–
181 of NS3 (Lorenz et al., 2006b). Therefore it is possible that the oligomerisation observed for 
the catalytic domain was enhanced by the homogeneity and concentration of the purified NS2 
catalytic domain and that NS2 oligomerisation is primarily coordinated by the N-terminal 
residues (19-92). The co-IP of tNS2-FLAG by eGFP-NS2 (Figure 5.9) is consistent with this 
hypothesis as the truncation point of this peptide appears to be in the vicinity of residue 25 
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(Figure 4.8). The NS2 truncation sets described in Chapter 4 represent the ideal tools to 
investigate this more thoroughly. 
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5.4 Conclusions  
Co-immunoprecipitation studies presented here reveal that NS2 oligomerises via its trans-
membrane domain and this region is also responsible for interacting with E2. Consistent with 
previous findings regarding the NS2:NS3 and NS2:p7 interactions; the NS2:E2 interaction also 
appears to be genotype independent. 
Truncation analysis suggested that NS2 forms multiple interactions with E2 via the putative 
second and third TMDs, and to a lesser extent the putative first TMD, but that the catalytic 
domain is dispensable. By comparing with membrane-targeting data presented in the previous 
chapter, it is proposed that the NS2:E2 interaction is dependent upon membrane targeting of 
NS2 and the two proteins are likely to form intra-membrane contacts. The ultimate membrane 
topology of NS2 does not appear to be pivotal for the NS2:E2 interaction. 
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The data presented here demonstrate that NS2 assuming a three TMD topology. C-terminal 
truncation analysis demonstrated that aa 1-52 are capable of forming one TMD, aa 1-70 form 
two TMDs and aa 1-87 form three TMDs (Figure 3.17 Model E). Analysing protein topology 
using C-terminal truncations introduces the possibility of disruption to long-range intra-
molecular interactions which are required for achieving the native topology. Therefore it is 
possible that in full-length NS2 aa 1-52 do form two TMDs but that stabilising interactions with 
upstream residues (aa 53-70) are required in order to achieve this topology. However, the 
ability of residues 25-50, expressed with no additional NS2 sequence, to partially target to and 
insert into membranes (Figure 4.15) is suggestive that an absence of long-range interactions 
was not responsible for the phenotype of the S7 fusion (aa 1-52 of NS2 fused to SEAP). Taken 
together the truncation and membrane dissociation data suggest that residues 1-52 contain all 
of the first TMD and a significant portion of the second TMD of NS2, but not all of it. This led to 
the description of a refined model, Model F, of NS2 topology shown in (Figure 6.1). Although 
this model has been designed in part by experimental observations, the exact positions of the 
TMDs remain to be precisely mapped. As all the experiments carried out here were done using 
JFH-1 protein sequence this model represents a platform for confirmation of these findings 
within the full-length system and a more detailed mapping of NS2 topology.  
The extent to which NS2 topology is required for the role of NS2 in virus production is not 
clear. C-terminal truncation analysis of NS2 is not a valid approach to explore this in full-length 
virus as deletion of the protease domain (aa 94-217) in the context of a bi-cistronic virus, in 
which NS2 and NS3 were separated by a second IRES, was lethal to the virus (Jirasko et al., 
2008; Jones et al., 2007). Indeed, more recently it has been shown that deletions of aa 10- 62 
or aa 32-96 in a bi-cistronic virus were also lethal to virus production. Investigation of NS2 
topology by means of epitope or reporter-enzyme insertion in a bi-cistronic JFH-1 virus would 
also provide a means of validating that protein function was altered by introduction of the 
epitope/reporter. 
Experiments presented in Chapter 4 verified in vitro data describing the presence of multiple 
membrane-targeting within NS2, including one within the protease domain (Yamaga & Ou, 
2002). However, it is possible that some of the truncations recovered in the membrane 
fraction during the membrane-targeting experiments were forming aggregates rather than 
direct associations with membranes. Although it was not feasible to do so initially with such a 
large panel of fusions, re-examination of those constructs targeting to membranes by 
membrane flotation analysis would circumvent this problem. Co-immunoprecipitation studies  
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Figure 6.1 NS2 topology model. 
NS2 is shown modelled on to a lipid bi-layer. The N terminus is shown oriented to the ER 
lumen. The catalytic domain is shown oriented to the cytosol and in peripheral association 
with the membrane in accordance with membrane-targeting data. The predicted boundaries 
of the TMDs are noted (green boxes). 
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showed that NS2 and E2 expressed from separate DNA molecules were able to stably interact. 
As membrane association of NS2 was implicated in the NS2:E2 interaction, the membrane-
targeting of those fusions able to interact with E2 by membrane flotation should be confirmed. 
Co-expression of eGFP-NS2 and core-p7 in vitro in the presence and absence of microsomal 
membranes could also help to clarify the requirement of membranes for formation of the 
NS2:E2 interaction. 
Although time constraints and an inability to detect p7 in these systems prevented the 
investigation of the role of p7 in mediating the NS2:E2 interaction, repetition of the 
experiments described in chapter 5 with a core-E2, rather than core-p7, expression construct 
would provide a simple means of testing this. Mutation of the p7 basic loop was found to 
abrogate the NS2:E2 interaction leading to speculation that p7 ion channel function is 
specifically required for the interaction. However, as mutation of the basic loop may also alter 
p7 topology (Ma et al., 2011) and its ability to insert into membranes (StGelais et al., 2007); 
treatment of cells co-transfected with eGFP-NS2 and core-p7 with the drug rimantidine, which 
blocks p7 ion channel function (Griffin, 2010; Griffin et al., 2008; Luik et al., 2009), presents a 
specific means of investigating p7 ion channel function in relation to the NS2:E2 interaction. 
It is not clear whether the formation of physical interactions between NS2 and other viral 
proteins are required for the role of NS2 in virion morphogenesis. If the NS2:E2 interaction is 
found to be required for this function, the co-IP system described here provides a tool for the 
testing of compounds that disrupt the NS2:E2 interaction. As genotype 2a NS2 was able to 
efficiently interact with E2 from both genotype 2a and 1b, it is reasonable to assume that 
compounds that disrupt the NS2:E2 interaction may be cross-genotypic. Chemical disruption of 
NS2 dimerisation would also help to elucidate the role of dimerisation in cleavage of the NS2/3 
junction and virion morphogenesis.  
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Appendix 1. Oligonucleotides used for cloning. 
Primer Sequence 5’-3’ Purpose 
Wt SEAP XhoI f NNNNCTCGAGGCGGCCATGGCCATCATCCCAGTTGAGGAGGAG
AACC       
SEAP reporter 
controls 
Wt SEAP ApaI r  NNNNGGGCCCTTATGTCTGCTCGAAGCGGCCGGC SEAP reporter 
controls 
Wt LacZ XhoI f  
 
NNNNCTCGAGGCGGCCATGGCCACCATGATTACGGATTCACTGG β-gal reporter 
controls 
Wt LacZ ApaI r  NNNNGGGCCCTTATTTTTGACACCAGACCAACTGG β-gal reporter 
controls 
SPp7 HindIII f 
 
NNNNAAGCTTGCGGCCATGGCCAGAGTCTGCGCCTGCTTGTGG C-terminal 
truncations 
Furin-LacZ XhoI f 
 
NNNNCTCGAGGGCGGAAGCAGGGGTCGACGCGGCGGAAGCAC
CATGATTACGGATTCACTGG 
β-gal reporter 
fusions 
Furin-SEAP XhoI f NNNNCTCGAGGGCGGAAGCAGGGGTCGACGCGGCGGAAGCAT
CATCCCAGTTGAGGAGGAGAACC 
SEAP reporter 
fusions 
SEAP (no linker) 
XhoI f 
NNNNCTCGAGATCATCCCAGTTGAGGAGGAGAACC SEAP control 
fusions 
NS2 aa 217 XhoI r  NNNNCTCGAGAAGGAGCTTCCACCCCTTGG C-terminal 
truncations 
NS2 aa 120 XhoI r  NNNNCTCGAGCGCGAGCTGCTTCACCAAAGC C-terminal 
truncations 
NS2 aa 110 XhoI r  NNNNCTCGAGTATCAGAGCGTGAGCTCTGACG C-terminal 
truncations 
NS2 aa 95 XhoI r  NNNNCTCGAGGGCCCTTAAGAGGTAAGCAGG C-terminal 
truncations 
NS2 aa 87 XhoI r  NNNNCTCGAGAAGCAACGCCAAAAGCCATTTGG C-terminal 
truncations 
NS2 aa 70 XhoI r  NNNNCTCGAGTATAGTGACGGCCCACGCGATGC C-terminal 
truncations 
NS2 aa 52 XhoI r  NNNNCTCGAGTACCCACTCCTGAATCATGGC C-terminal 
truncations 
NS2 aa 40 XhoI r  NNNNCTCGAGGAGATAGCACAACCACCACAGACACTGG C-terminal 
truncations 
NS2 aa 27 XhoI r  NNNNCTCGAGCTTATACCCCGGGGTGAGTGTGAAGAGG C-terminal 
truncations 
P7 XhoI r  NNNNCTCGAGGGCATAAGCCTGCCGGGGCAGTGCC C-terminal 
truncations 
QC furin mutation f GAGGGCGGAAGCGCGGGTCGACGCG Generation of 
S12 and S13 
QC furin mutation r CGCGTCGACCCGCGCTTCCGCCCTC Generation of 
S12 and S13 
QC signal peptidase 
mutation f 
CGGCAGGCTTATCCCCTCGAGGGCG Generation of 
S11 and S13 
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Primer Sequence 5’-3’ Purpose 
QC signal peptidase 
mutation r 
CGCCCTCGAGGGGATAAGCCTGCCG Generation of 
S11 and S13 
P7 aa 62 XhoI r NNNNCTCGAGATAAGCCTGCCGGGGCAGTGCC Generation of 
delta 63 (S10 
derivative) 
Signal peptide oligo 
f  
AGCTTGCGGCCATGGCCCTGCTGCTGCTGCTGCTGCTGGGCCTG
AGGCTACAGCTCTCCCTGGGCC 
Generation of 
SP-β-gal 
Signal peptide oligo 
r  
TCGAGGCCCAGGGAGAGCTGTAGCCTCAGGCCCAGCAGCAGCA
GCAGCAGCAGGGCCATGGCCGCA 
Generation of 
SP-β-gal 
BK40(XhoI-mfur)F
 Forward: 
5'  
CTCGAGGGCGGAAGCGCGGGTCGACGCG  
NS2 aa 1 EcoRI f  GAATTCGCGGCCATGTATGACGCACCTGTGCACGG NS2-eGFP 
fusions 
NS2 aa 25 EcoRI f  GAATTCGCGGCCATGGGGTATAAGACCCTCCTCG NS2-eGFP 
fusions 
NS2 aa 51 EcoRI f  GAATTCGCGGCCATGTGGGTACCACCCATGCAGG NS2-eGFP 
fusions 
NS2 aa 93 EcoRI f  GAATTCGCGGCCATGTTAAGGGCCGCTTTGACAC NS2-eGFP 
fusions 
NS2 aa 24 BamHI r GGATCCCGGGGTGAGTGTGAAGAGG NS2-eGFP 
fusions 
NS2 aa 50 BamHI r GGATCCCTCCTGAATCATGGCTTCC NS2-eGFP 
fusions 
NS2 aa 92 BamHI r  GGATCCCCGAGGTAAGCAGGCCCAAGC NS2-eGFP 
fusions 
NS2 aa 217 BamHI r GGATCCAAGGAGCTTCCACCCCTTGG NS2-eGFP 
fusions 
SEAP (no linker) 
XhoI f 
NNNNCTCGAGATCATCCCAGTTGAGGAGGAGAACC SEAP control 
fusions 
NS2 aa 1 XhoI f   NNNNCTCGAGCTATGACGCACCTGTGCACG eGFP-NS2 
fusions 
NS2 aa 25 XhoI f NNNNCTCGAGCGGGTATAAGACCCTCCTCG eGFP-NS2 
fusions 
NS2 aa 51 XhoI f NNNNCTCGAGCTGGGTACCACCCATGCAGG eGFP-NS2 
fusions 
NS2 aa 93 XhoI f  NNNNCTCGAGCTTAAGGGCCGCTTTGACAC eGFP-NS2 
fusions 
NS2 aa 24 EcoRI r NNNNGAATTCTTACGGGGTGAGTGTGAAGAGG eGFP-NS2 
fusions 
NS2 aa 50 EcoRI r  NNNNGAATTCTTACTCCTGAATCATGGCTTCC eGFP-NS2 
fusions 
NS2 aa 92 EcoRI r NNNNGAATTCTTAGAGGTAAGCAGGCCCAAGC eGFP-NS2 
fusions 
  
Chapter 8: Appendices 
 
222 
 
Primer Sequence 5’-3’ Purpose 
NS2 aa 217 EcoRI r  NNNNGAATTCTTAAAGGAGCTTCCACCCCTTGG eGFP-NS2 
fusions 
Flag-tag oligo f P-GATCCAGGCGGAAGCGGCGGAAGCGACTACAAAGACG 
ATGACGACAAGTAACCGC 
NS2-FLAG 
fusions 
Flag-tag oligo r  
 
P-GGTTACTTGTCGTCATCGTCTTTGTAGTCGCTTCCGCCGC 
TTCCGCCTG 
NS2-FLAG 
fusions 
NS2 delta aa 25-50 
f 
ACCCTCTTCACACTCACCCCGTGGGTACCACCCATGCAGG NS2 deletion 
fusions 
NS2 delta aa 25-50 
r  
CCTGCATGGGTGGTACCCACGGGGTGAGTGTGAAGAGGGT NS2 deletion 
fusions 
NS2 delta aa 25-92 
f  
ACCCTCTTCACACTCACCCCGTTAAGGGCCGCTTTGACAC NS2 deletion 
fusions 
NS2 delta aa 25-92 
r  
GTGTCAAAGCGGCCCTTAACGGGGTGAGTGTGAAGAGGGT NS2 deletion 
fusions 
NS2 delta aa 51-92 
f  
GGGAAGCCATGATTCAGGAGTTAAGGGCCGCTTTGACAC NS2 deletion 
fusions 
NS2 delta aa 51-92 
r  
GTGTCAAAGCGGCCCTTAACTCCTGAATCATGGCTTCCC NS2 deletion 
fusions 
QC peGFP-N1 ATG f CACCGGTCGCCACCGCGGTGAGCAAGGGCG peGFP-N1 QC 
control 
mutant 
QC peGFP-N1 ATG r CGCCCTTGCTCACCGCGGTGGCGACCGGTG peGFP-N1 QC 
control 
mutant 
QC peGFP-C2 stop f  CGGACTCAGATCTCGAGCTAAAGCTTCGAATTCTGCAGTC peGFP-C2 
STOP control 
mutant 
QC peGFP-C2 stop r  GACTGCAGAATTCGAAGCTTTAGCTCGAGATCTGAGTCCG peGFP-C2 
STOP control 
mutant 
SEAP r NNNNTGGCGGCTGTCTGTGCAGGCTGC 
 
Sequencing 
Primer 
Lac Z f1 
 
NNNNGCCACTCGCTTTAATGATG Sequencing 
Primer 
Lac Z f2 NNNNGGCCACCGATATTATTTGC Sequencing 
Primer 
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Appendix 2. Amino acid nomenclature and hydropathy scoring. 
 
Amino acid names and three and single letter abbreviations. Hydropathy scores for each 
residue are those assigned by Kyte-Doolittle (Kyte & Doolittle, 1982). 
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Appendix 3. Prediction of N-linked glycosylation sites (N-X-S/T).  
Sequences were analysed using the NetNGlyc 1.0 Server. 
β-Galactosidase amino acid sequence: 
MTMITDSLAVVLQRRDWENPGVTQLNRLAAHPPFASWRNSEEARTDRPSQQLRSLNGEWRFAWF
PAPEAVPESWLECDLPEADTVVVPSNWQMHGYDAPIYTN
103
VTYPITVNPPFVPTEN
119
PTGCY
SLTFNVDESWLQEGQTRIIFDGVNSAFHLWCNGRWVGYGQDSRLPSEFDLSAFLRAGENRLAVM
VLRWSDGSYLEDQDMWRMSGIFRDVSLLHKPTTQISDFHVATRFNDDFSRAVLEAEVQMCGELR
DYLRVTVSLWQGETQVASGTAPFGGEIIDERGGYADRVTLRLNVENPKLWSAEIPNLYRAVVEL
HTADGTLIEAEACDVGFREVRIENGLLLLNGKPLLIRGVNRHEHHPLHGQVMDEQTMVQDILLM
KQNNFNAVRCSHYPNHPLWYTLCDRYGLYVVDEANIETHGMVPMNRLTDDPRWLPAMSERVTRM
VQRDRNHPSVIIWSLGN
461
ESGHGANHDALYRWIKSVDPSRPVQYEGGGADTTATDIICPMYAR
VDEDQPFPAVPKWSIKKWLSLPGETRPLILCEYAHAMGNSLGGFAKYWQAFRQYPRLQGGFVWD
WVDQSLIKYDENGNPWSAYGGDFGDTPNDRQFCMNGLVFADRTPHPALTEAKHQQQFFQFRLSG
QTIEVTSEYLFRHSDNELLHWMVALDGKPLASGEVPLDVAPQGKQLIELPELPQPESAGQLWLT
VRVVQPNATAWSEAGHISAWQQWRLAEN
726
LSVTLPAASHAIPHLTTSEMDFCIELGNKRWQFN
RQSGFLSQMWIGDKKQLLTPLRDQFTRAPLDNDIGVSEATRIDPNAWVERWKAAGHYQAEAALL
QCTADTLADAVLITTAHAWQHQGKTLFISRKTYRIDGSGQMAITVDVEVASDTPHPARIGLNCQ
LAQVAERVNWLGLGPQENYPDRLTAACFDRWDLPLSDMYTPYVFPSENGLRCGTRELNYGPHQW
RGDFQFNISRYSQQQLMETSHRHLLHAEEGTWLNIDGFHMGIGGDDSWSPSVSAEFQLSAGRYH
YQLVWCQK 
Probablility of N-glycosylation: 
N103 - 0.8114, N119 - 0.6079, N461 - 0.5674, N726 - 0.7344 
SEAP amino acid sequence: 
IIPVEEENPDFWNREAAEALGAAKKLQPAQTAAKNLIIFLGDGMGVSTVTAARILKGQKKDKLG
PEIPLAMDRFPYVALSKTYNVDKHVPDSGATATAYLCGVKGNFQTIGLSAAARFNQCN
122
TTRG
NEVISVMNRAKKAGKSVGVVTTTRVQHASPAGTYAHTVNRNWYSDADVPASARQEGCQDIATQL
ISNMDIDVILGGGRKYMFRMGTPDPEYPDDYSQGGTRLDGKNLVQEWLAKRQGARYVWN
249
RTE
LMQASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTEAALRLLSRNPRGFFLFVEGGRID
HGHHESRAYRALTETIMFDDAIERAGQLTSEEDTLSLVTADHSHVFSFGGYPLRGSSIFGLAPG
KARDRKAYTVLLYGNGPGYVLKDGARPDVTESESGSPEYRQQSAVPLDEETHAGEDVAVFARGP
QAHLVHGVQEQTFIAHVMAFAACLEPYTACDLAPPAGTTDAAHPG 
Probablility of N-glycosylation: 
N122 - 0.5276, N249 - 0.5333      
Only N249 is thought to be N-glycosylated in humans (Endo et al., 1988; Le Du et al., 2001).  
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Appendix 4. NS2-eGFP truncations produce ‘cleaved’ fusion products. 
 
COS7 cells were transfected with a selection of NS2-eGFP truncations (lacking the .QC 
mutation of the eGFP initiation site). Lysates were collected 48 h post-transfection and 
analysed by SDS PAGE and immuno-blotting. Membranes were probed with anti-GFP antibody 
(A) and antiserum raised against the NS2 catalytic domain (aa 94-217) (B). Oligomerisation of 
(1-24), (25-50) and (1-50) was not seen in any subsequent experiments. The observation here 
was thought to be caused by non-specific aggregation in the absence of sufficient reducing 
agent. Molecular weight markers are shown to the left and lanes are marked below. 
